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Cancer is the leading cause of death in U.S. women under 85.  It is becoming 
increasingly clear that individual treatments will not cure cancer and that combination 
approaches may be more effective.  Our goal was to further understand the molecular 
mechanisms of α-TEA's anticancer effects, and to explore its potential in combination 
with two other agents, MSC/MSA and t-RES.  Data support the efficacy of α-TEA as a 
chemopreventive and chemotherapeutic agent in human breast cancer cells.  We first 
determined that α-TEA, t-RES, and MSC/MSA inhibit cell proliferation, induce 
differentiation, and synergize when used in combination to induce apoptosis.  Treatment 
enhanced cell death was seen in other cancer cell lines and no cell killing was seen in 
HMECs. Next, the ability of these agents to reduce tumor burden, induce apoptosis, and 
prevent proliferation of MDA-MB-435-F-L cells was investigated in vivo.  α-TEA and 
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low doses of t-RES reduce tumor burden in athymic nude mice but combinations of the 
three compounds were not as effective as α-TEA or t-RES alone.  The three treatments 
significantly reduced visible and micrometastatic tumor foci.  We showed that the 
efficacy of t-RES administered at low (10 mg/kg bw) and high (100 mg/kg bw) 
concentrations was diet-related.  Our third aim was to determine if these compounds 
could effectively inhibit the formation of DMBA and MNU-induced lesions in the 
MMOC and rat mammary carcinogenesis models.  Each compound inhibited cancer 
lesions in these models but α-TEA and t-RES were better than MSA, and a combination 
of α-TEA and t-RES was best.  Next, we examined apoptotic and survival signaling 
events that could lead to synergy after α-TEA and t-RES treatment.   Pre-treatment 
sensitized the cancer cells to cell membrane receptor-mediated apoptosis.  α-TEA and co-
treatment induced cell death was caspases-dependent while that for t-RES was not.  Next, 
decreases in prosurvival survivin and c-FLIP proteins were shown to be significant to 
treatment induced apoptosis.   Based on the results reported here, we propose a signaling 
model where the synergy between α-TEA and t-RES is due to a combination of apoptosis 
and caspase-independent cell death (CICD). 
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Chapter 1:  Introduction and Literature Review 
INTRODUCTION AND CANCER STATISTICS 
In the last 50 years there have been numerous advances in medicine and the 
understanding of human diseases and disorders.  Epidemiological data shows significant 
decreases in the United States for death rates from cardiovascular, cerebrovascular, and 
infectious diseases.  Despite the many advances that have been made in the understanding 
of cancer progression and targeted drug development, cancer incidence and cure rates 
have remained relatively unchanged [1-2].  Among U. S. women under the age of 85, 
cancer is the most common cause of death, followed closely by cardiovascular disease.  
Specifically, it is estimated that breast cancer specifically will have the highest incidence 
of reported new cases in 2006 (31%) and will be responsible for approximately 15 
percent of cancer deaths in women [1].  
The cause of all diseases can be classified into one of three categories: diet, 
environment, or genetics.  It is estimated that 75-85% of all chronic illnesses and diseases 
are directly linked to lifestyle choices and not genetics [2], and while it is difficult to 
change some environmental factors and nearly impossible to change genetic factors, it is 
relatively easy to change diet and therefore reduce the risk of many diseases by a large 
factor.  In recent years there has been a scientific evaluation of many natural and 
biologically active compounds found in the human diet, many of which have their roots 
in traditional medicines from around the world.  Many of these natural agents have little 
toxicity and a high potential for use against human disease.  With this in mind, we 
evaluated the anti-tumor effects of three natural-based compounds, α-tocopherol ether 
analog (α-TEA), trans-resveratrol (t-RES), and methylseleninic acid (MSA), against 
human breast cancer cells and examined their potential in human therapy. 
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CELL DEATH 
Schleiden and Schwann first introduced the concept of a cell to the scientific 
community in 1839.  Soon after this initial report was the identification of cell death by 
Carl Vogt in 1842.  Since that time, cell death has continually been studied in order to 
understand the conditions that lead to cellular demise and the mechanisms by which it 
occurs [3-4].  Cell death and cell division are essential parts of the normal development 
and maintenance of multi-cellular organisms [4-5].  Disruption of either process can lead 
to disturbed embryogenesis, neurodegenerative diseases or cancer [5].   
Cells are constantly exposed to external and internal signals, some of which are 
pro-survival and some of which are anti-survival.  For this reason, the balance between 
life and death is highly regulated in the cell so that cell fate depends on how these signals 
are interpreted.  Melino et al [6] describe 11 types of cell death currently known.  While 
there is some overlap between characteristics of the different types, there are also unique 
characteristics and circumstances under which they occur.  In our evaluation of α-TEA, t-




Apoptosis is a highly regulated form of programmed cell death (PCD) that’s name 
is derived from the Greek term for “dropping off” of petals or leaves from a healthy 
plant.  First recognized in 1842 by Vogt, it has since become recognized as one of many 
types of cell death and is referred to as Type 1 PCD [4].  Characteristics include cell 
shrinkage, DNA fragmentation, chromatin condensation, and controlled blebbing of the 
nucleus and cytosolic cellular fractions into apoptotic bodies [4-5, 7-10], which are 
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engulfed by phagocytic cells in vivo [5, 7-9].  Often, apoptosis is associated with the 
activation of a group of cysteine proteases known as caspases and there is an absence of 
lysosomal involvement [4, 7-8, 11].   
 
FIGURE 1.1:  CHARACTERISTICS OF DIFFERENT TYPES OF CELL DEATH.  




For a cell to undergo apoptosis, precise signaling pathways must be activated 
either intrinsically or extrinsically.  In addition to the intermediate proteins in the 
signaling pathways, there are groups of proteins that can promote or block apoptotic 
pathways, justly named anti-apoptotic and pro-apoptotic proteins.  Some cancer 
therapeutic agents act to induce or sensitize cells to apoptosis by down-regulating anti-
apoptotic proteins and/or by upregulating pro-apoptotic proteins.   
Apoptosis begins when either an extracellular ligand binds to a death receptor on 
the cell surface or intracellulary via DNA damage [5, 9-15].  There are six known death 
receptors, including Fas(CD95), TNFR1, DR3(TRAMP), DR4(TRAIL-R1), 
DR5(TRAIL-R2), and DR6 [11] with ligands FasL (Fas), TNFα (TNFR1), TRAIL(DR4 
and DR5) and TWEAK(DR3) [4, 9, 11-15].   Binding of the ligand induces 
homotrimerization of the receptor and recruitment of FADD and pro-caspase-8 to the 
cytosolic part of the receptor to form the DISC, or death inducing signaling complex.  
Once formed, the DISC cleaves pro-caspase-8 to active caspase-8, which then cleaves 
and activates substrates in either the mitochondrial independent (type I) or dependent 
pathways (type II), both of which lead to apoptosis.  In the mitochondrial independent 
pathway (type I), caspase-8 directly activates caspase-3.  A slower activation of caspase-3 
is accomplished via the mitochondrial dependent pathway (type II).  In this pathway, 
caspase-8 cleaves Bid to tBid, which can then bind to and inhibit anti-apoptotic Bcl-2, 
allowing Bax to form pores in the mitochondria and release cytochrome c from the 
intermembrane space [4, 9, 11-15].   Once released, cytochrome c associates with apaf-1 
and pro-caspase-9 to form the apoptosome [4-5, 9, 11-15].  Apoptosome formation 
activates caspase-9, leading to activation of caspase-3 [4, 9, 11-15], which in turn 
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activates many proteins responsible for the morphological and chemical changes that lead 
to apoptotic cell death [12-15].   
Bcl-2 Family 
The Bcl-2 family is a group of proteins that influence the permeability of the 
mitochondria and can be classified as pro-apoptotic or anti-apoptotic.  Regardless of the 
type, all contain at least one Bcl-2 homology domain (BH) [4-5, 10].  The pro-apoptotic 
bcl-2 family members include Bax, Bak, Bok, Bid, Bad, Puma, Bmf, Bim, Bik, Noxa, 
and Hrk/DP5.  Upon apoptotic signals, the activation of Bax and Bak results in 
mitochondrial permeability. The anti-apoptotic bcl-2 family members include Bcl-2, Bcl-
XL, Bcl-w, and Mcl-1 [4, 10].  Bcl-2 and Bcl-XL form heterodimers with Bax-like 
proteins to inhibit mitochondrial permeabilization.  Since these two classes have 
opposing functions they are often in competition and can inhibit each other through direct 
binding [5, 10].  
Mitochondrial  Proteins 
Upon permeabilization of the mitochondria, there are several proteins released 
from the mitochondria in addition to cytochrome c.  Two pro-apoptotic proteins, 
apoptosis-inducing factor (AIF) and endonuclease G (endo G), work to enhance DNA 
condensation and degradation by working with caspase-activated DNase CAD/DFF40 [4-
5, 10-11].  Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP 
binding protein with low pI) and Omi/HtrA2 (high temperature requirement protein A2) 
are two other proteins released from the intermembrane space of the mitochondria and act 
to inhibit the activity of anti-apoptotic XIAP (see below) [4, 10-11].  Additionally, 




FIGURE 1.2:  MODEL OF SIGNALING EVENTS LEADING TO APOPTOSIS.  
Adapted from [14]. 
 
Inhibitors of Apoptosis Proteins  
Some cancer therapeutic agents can act to induce or sensitize cells to apoptosis by 
down-regulating inhibitor of apoptosis proteins (IAPs).  This family of proteins includes 
cIAP1, cIAP2, livin, XIAP (X-linked inhibitor of apoptosis) and survivin, most of which 
are expressed at high levels in tumor cells.  IAPs exert their anti-apoptotic activity by 
binding to the active form of caspases-3 and -9 [4, 11, 16].  To counteract the activity of 
IAPs, Smac/DIABLO and Omi/HtrA2 can bind to and inhibit their activity [4]. Cellular 
FLICE-inhibitory protein (c-FLIP), though not an IAP, is another anti-apoptotic protein 
that functions by competing with pro-caspase-8 for binding to FADD.  c-FLIP is able to 
bind to FADD because it shares high sequence homology to caspase-8, however  it 
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cannot signal as caspase-8 because it lacks a proteolytic domain required for downstream 
signaling [12, 15].  Several studies have shown that degradation of anti-apoptotic proteins 
can increase apoptosis [15].  Survivin, the smallest member of the IAP family, is down 
regulated by t-RES [11, 17] and α-TEA [18] in some cell types, and α-TEA can also 
down-regulate c-FLIP [18].  
Autophagocytosis  
Description 
In contrast to apoptosis, is type II PCD, or autophagocytosis.  It derives its name 
from the Greek word autophagy or “self eating.”  Characteristics primarily include the 
formation of autophagic vacuoles (AV), dilation of the endoplasmic reticulum (ER), and 
the enlargement of the Golgi [4-5, 7, 9, 19-20].  Once formed, autophagic vacuoles fuse 
with lysosomes to sequester cytoplasmic contents such as mitochondria and degrade them 
via lysosomal hydrolases [4-5, 7, 19-22].  Unlike apoptosis, autophagy depends on an 
intact cytoskeleton [8].  While the signaling events for autophagy are known in yeast, 
many of the mammalian homologs are yet to be found, so the exact signaling pathways 
are unknown [19, 21-23].  The general pathway begins with a signaling event that leads 
to the formation of a double membrane structure called an autophagosome, which fuses 
with cellular lysosomes to form an autolysosome, or autophagic vacuole (AV) [9, 19, 21-
22, 24].  Often in autophagocytosis, caspases are not activated and DNA fragmentation 
does not occur.  
Signaling Proteins 
Autophagocytosis can be induced both by nutrient starvation or DNA damage, the 
former as a means of cellular survival and the latter a means to death [10].  It is thought 
to primarily be controlled by phosphoinositide 3-kinase (PI3K)/Akt, which is the 
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mammalian target of rapamycin (mTOR) [7, 10, 21].  Another protein that has been 
identified is beclin-1, the mammalian homolog to the yeast Atg6 protein that is involved 
in the early steps of autophagic vesicle formation and whose action can be inhibited by 
bcl-2 [7, 10, 21, 25-26].  In addition to its role in autophagy, beclin-1 has also been 
shown to be a haplo-insufficient tumor suppressor gene, which supports the model of 
autophagy as a suppressor of tumorigenesis [7, 18].  It is mono-allelically deleted in 40-
75% of sporadic human breast and ovarian cancers, is frequently expressed at low levels 
in human breast epithelial carcinoma cell lines, and ubiquitously expressed at high levels 
in normal breast epithelial cells [27]. 
Another autophagy gene is microtubule-associated protein light-chain 3 (MAP-
LC3), which is the mammalian homolog to Apg8p/Aut7p.  MAP-LC3 is recruited to the 
pre-autophagosome membranes [19, 21, 24, 28] where it remains associated with the 
inner and outer phagosomal membrane [24].  MAP-LC3 can be proteolytically cleaved to 
smaller derivatives (LC3-I and LC3-II) that are found localized in either the cytosol 
(LC3-1) or the autophagosome membranes (LC3-2) [22].   The amount of LC3-II in cells 
is often used to estimate the abundance of autophagosomes in cells [19, 21-22]. 
LAMP-1 and LAMP-2 are structurally similar, highly N-glycosylated lysosomal 
proteins.  Each of these transmembrane proteins is critical for transport to lysosomes in 
cells.  Both LAMP-1 and LAMP-2 are ubiquitously expressed in cells and have been 
shown to be localized in late endosomes and lysosomes [29-30], and to serve as a 
receptor for the import and degradation of cytosolic proteins in the lysosome during 
autophagy [30].  This role is confirmed by studies that have shown that LAMP-2 
deficient cells can block autophagy [24]. 
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FIGURE 1.3:  FORMATION OF AUTOPHAGIC VACUOLES.  Adapted from [22, 24]. 
 
VITAMIN E 
Vitamin E is a fat-soluble vitamin that serves as an antioxidant and is widespread 
in the human diet.  It can be found in a variety of vegetable sources but is most abundant 
in vegetable oils and products made from vegetable oils.  Wheat germ oil [~13 mg/Tb], 
sunflower oil [~6 mg/Tb], cottonseed oil [~5 mg/Tb], and safflower oil [~5 mg/Tb] 
contain some of the highest concentrations of RRR-α-tocopherol.  Another form of 
vitamin E, tocotrienols, is highly concentrated in palm oil [~6 mg/Tb] and wheat germ oil 
[~3 mg/Tb] [32, 70].   
The recommended dietary allowance (RDA) for adult males and females is 15 mg 
RRR-α-tocopherol/ day (22.4 IU) [32].  Because vitamin E is so prevalent in the human 
diet, it is rare for humans to be deficient.  When it does occur, prolonged deficiency can 
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lead to neuromuscular dysfunction in the spinal cord and retina, loss of muscle 
coordination and reflexes, and impaired vision and speech, all of which can be corrected 
with vitamin E supplementation [33, 70].   Most cases of vitamin E deficiency occur in 
premature infants or as the result of genetic mutations in vitamin E binding proteins.  
Erthyrocyte hemolysis in premature infants occurs because the fetus has not yet reached 
the stage of development where the mother transfers vitamin E to the child, an event, 
which usually occurs in the last weeks of gestation [33-34, 70].  The most common 
genetic cause of vitamin E deficiency is Ataxia with vitamin E deficiency (AVED), 
which is an uncommon autosomal recessive neurodegenerative disease caused by 
mutations in α-tocopherol transfer protein (α-TTP) [34-35].  This mutation, along with 
others in proteins like apolipoprotein B (apoB), inhibits the proper uptake and 
metabolism of vitamin E [33-34, 70].  Symptoms include loss of deep tendon reflexes, 
cerebral ataxia, dysarthria, and mental retardation.  Skeletal myopathy and retinitis 
retardation can also occur [33-34].  Supplementation with vitamin E can prevent the onset 
of both erythrocyte hemolysis or AVED before damage develops [33-35, 70].   
In contrast to pathologies of vitamin E deficiency, there are also consequences to 
ingesting too much.  The tolerable upper intake limit for vitamin E is 1000 mg (1492.5 
IU) [32].  In these rare cases, extremely high doses can interfere with the role of vitamin 
K in blood clotting and can enhance the effects of anti-blood clotting drugs, leading to 
hemorrhaging [70].   
Discovery 
Evans and Bishop first discovered Vitamin E in 1922 when rats fed a semi-
purified diet containing all the then known vitamins failed to reproduce [34-36].  They 
found that by feeding lettuce to the rats, resorption of the fetus was prevented, which 
suggested a missing nutrient in the diet of the rats [35-36].  Over the next few years, 
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deficiency of this unknown nutrient was shown to cause sterility in rats [31, 33, 36], 
nutritional encephalomalacia in chicks, and muscular dystrophy in guinea pigs, rabbits, 
and ducklings [36].  In 1936, Evans finally isolated the nutrient from wheat germ oil and 
named it tocopherol, from the Greek phrases “tokos” and “phorein” meaning “to bring 
forth offspring” [31, 35-36].  In 1938, the structural formula was published and the α, β, 
γ, and δ prefixes were given to distinguish the different molecules of the tocopherol 
family.  In 1964, a second family of vitamin E was identified and named “tocotrienols” 
[36].  There is no clear relationship in humans between maternal vitamin E status and 
reproductive ability, but as a result of its discovery, vitamin E is now supplemented to 
farm animals [33].  
Structure 
Vitamin E is a general term often used to refer to both natural and synthetic 
vitamin E compounds.  The 8 naturally occurring compounds can be evenly divided 
between tocopherols and tocotrienols [34, 36-37].  Tocotrienols differ from tocopherols 
through an unsaturated phytyl tail at chiral carbons 3’, 7’, and 11’ [33, 36, 38]. 
Tocopherols and tocotrienols can be further distinguished within and between each other 
by the presence of methyl groups attached to the chroman head of the structure.  
Molecules with methyl groups at the 5, 7, and 8 positions are referred to as α; those with 
methyls at 5 and 8 or 7 and 8 are referred to as  β and δ respectively.  Molecules with a 
single methyl at the 8 position are referred to as γ [36, 38].  At room temperature, RRR-
α-tocopherol is a lipophilic viscous oil [36]. 
Synthetic Vitamin E is a mixture of 8 stereoisomers of α-tocopherol, or molecules 
that contain the same number and types of atoms but which are arranged differently 
spatially.  Sold commercially as dl-α-tocopherol or all-rac[emic]- α-tocopherol, only 
12.5% is authentic RRR-α-tocopherol and 87.5% are stereoisomers that have no known 
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biological activity since liver hepatocytes selectively incorporate RRR-α-tocopherol over 

















Cells are exposed to free radicals from endogenous and exogenous sources.  
Many biological re-dox reactions within cells can generate them as well as external 
drugs, pollutants, heavy metals, heat, UV, visible light, and other forms of ionizing 
radiation.  Reactant species can cause reversible or irreversible damage to DNA, proteins, 
carbohydrates, and lipids, which can result in diseases such as cancer, arthritis, ageing, 
and heart disease.  In many cases, the reactions that create free radicals are chain-
reactions and a single reactive species can produce and propagate large numbers of free 
radical species to target many molecules and structures in the cell [36].  The primary role 
of Vitamin E is to serve as an antioxidant against free radical damage, thus protecting 
lipids and cell membranes from oxidation destruction from free radicals and singlet 
oxygen [31, 34, 36-37].  Its most notable role is to prevent oxidation of polyunsaturated 
fatty acids (PUFAs) [31, 36-37].  A second function is to stabilize membrane structures 
by forming complexes with destabilizing molecules, which prevents the disturbance of 
the amphipathic balance within the structure [36]. 
Once a lipid peroxyl radical (LO2•) is formed, it attacks target lipids (L) by 
removing a hydrogen atom from the target lipid to form a lipid hydroperoxide (LOOH) 
and a carbon-centered lipid radical (L•).  A chain reaction then begins where the carbon-
centered lipid radical (L•) can react with oxygen (O2) to generate another lipid peroxyl 
radical (LO2•) which can go on to further damage more lipids. RRR-α-tocopherol (TOH) 
acts to scavenge lipid peroxyl radicals (LO2•) before they are able to attack their target 
lipid substrates in a re-dox reaction that yields α-tocopheroxyloxyl radical (TO•) and a 
lipid hydroperoxide (LOOH).  This newly formed radical is fairly stable due to the 
delocalization of the unpaired electron around the chroman head, which renders it 
relatively unreactive.  RRR-α-Tocopherol is also very efficient because it can be 
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regenerated from the tocopheroxyl radical to α-tocopherol by vitamins A, C, and 
coenzyme Q.  The reaction with coenzyme Q is a two-step process where the 
tocopheroxyl radical (TO•) first reacts with reduced coenzyme-Q (QH2) to form RRR-α-
tocopherol (TOH) and semi-reduced ubisemiquinone (QH•).  In a second step, a second 
tocopheroxyl radical (TO•) reacts with semi-reduced ubisemiquinone (QH•) to yield α-
tocopherol (TOH) and coenzyme Q (Q).  In vitro studies have shown that α-tocopherol 
can scavenge peroxyl radicals faster than peroxyl radicals can react with lipid substrates 
making them ideal for this purpose. Tocopherols have also been shown to react with 
other reactive species including singlet oxygen, alkoxyl radicals, peroxynitrite, nitrogen 
dioxide, ozone, and superoxide [36]. 
 15
 
FIGURE 1.5:  VITAMIN E AS AN ANTIOXIDANT.  Adapted from [36].  LO2•, lipid 
peroxyl radical; L, target lipid; LOOH, lipid hydroperoxide; L•, carbon-centered lipid 




The bioavailability differs for the different forms of vitamin E.  γ-tocopherol is 
the most abundant form found in human diets but its plasma concentration is 1/10 that of 
α-tocopherol, the most abundant form in plasma [33].  All forms of vitamin E are 
absorbed by intestinal enterocytes and are secreted to the liver via the portal vein in 
chylomicrons [33-34, 36, 38].  In addition to α-tocopherol, triglycerides, phospholipids, 
cholesterol and apoliproteins can be found in the chylomicrons, which are made by the 
Golgi of the enterocytes.  Once made they are stored as secretory granula until they are 
exocytosed into the lymphatic compartment where they make their way to the blood 
stream via the ductus thoracicus.  In the bloodstream, HDLs exchange apoliproteins with 
the chylomicrons, which triggers the formation of remnants, a prerequisite for uptake by 
liver parenchyma by the endothelial lipoprotein lipase (LPL) [35].   
Once the remnants arrive at the liver, the apoliproteins act as ligands to induce 
receptor-mediated endocytosis where they then fuse with lysosomes of the cell [35]. 
RRR-α-tocopherol is preferentially transported from the hepatic lysosomes to very low-
density lipoproteins (VLDLs) by α-TTP and excreted into the bloodstream for transport 
to tissues [33, 35-36, 38].  Once in the blood, the plasma phospholipids transfer protein 
(PLTP) catalyses the exchange of α-tocopherol between HDL and LDL [35].  The 
binding affinity of α-TTP is α=β>γ>δ.  LDL structures typically carry 6-12 molecules of 
α-tocopherol (0.5 mol/LDL).  The structure of a LDL is that of a phospholipids 
monolayer with a core of neutral lipid including cholesterol esters with α-tocopherol 
positioned within the phospholipids monolayer [36].  
 α-TTP is a small protein that specifically selects α-tocopherol with a side chain 
linked to the chroman head in the R configuration at position 2 for incorporation into 
VLDL [33-34].  It is primarily expressed in the liver and its expression can be 
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upregulated by the presence of dietary tocopherols.  In addition to being found in the 
liver, low concentrations have also been found in the brain, spleen, lung, and kidney [33].  
Other forms of vitamin E that are not taken up are excreted in the bile or urine as 
carboxyethyl hydroxychromans (CEHCs) [33-35].    
Transport of vitamin E occurs via binding to lipoproteins and intracellular 
transport may occur through binding to tocopherol-associated proteins (TAP).   Several 
TAP proteins have been identified.  One 46-kDa TAP may be responsible for intracellular 
transport by acting as a chaperone to move vitamin E between membranes compartments 
containing tocopherol-metabolizing enzymes.  Another TAP is 15-kDa and may be 
responsible for intracellular distribution, and a third 75-kDa TAP is known to facilitate 
the exchange of α-tocopherol between HDL and LDL [33].  It is theorized that tissue 
specific retention and biological effects may be due to a cytosolic vitamin E binding to 
TAPs or supernatant protein factor (SPF) [38].   
In humans, normal RRR-α-tocopherol plasma concentrations are around 25 
µmol/L and it is difficult to increase this more than 2-3 fold, irrespective of amount or 
duration of supplement.  This is due to the fact that RRR-α-tocopherol is absorbed at a 
constant rate and not due to limited absorption.  Another limiting factor is that newly 
absorbed α-tocopherol replaces older α-tocopherol in plasma lipoproteins [33]. Studies 
have shown that TAP can selectively bind to RRR-α-tocopherol and that its presence can 




FIGURE 1.6:  ABSORPTION OF VITAMIN E.  Adapted from [35]. 
 
Metabolism 
Vitamin E is highly metabolized by CYP3A prior to excretion.  CYP3A is a 
cytochrome P450 enzyme with specificity for a wide range of substrates including 
steroids, antibiotics, and other pharmacological agents. The initial steps in the 
metabolism of RRR-α-tocopherol consist of two successive ω-oxidations 
(hydroxylations) on the phytyl tail by cytochrome P450 (CYP)-dependent hydroxylases. 
This is followed by several β-oxidation steps that result in two intermediates, α-2-[6’-
carboxy-4’-methylhexyl]hydroxychroman (α-CMHHC) and α-2-[4’-carboxy-4’-
methylbutyl]hydroxychroman (α-CMBHC) [33].  The final product of metabolism is α-
2-[2’-carboxyethyl]hydroxychroman (α-CEHC) [33, 35].  Similar metabolism is seen for 
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β-, δ-, and γ- forms of vitamin E and synthetic dl-α-tocopherol is excreted at a 3-4 times 
higher rate than natural α-tocopherol [33]. 
 




Both natural RRR-α-tocopherol and synthetic vitamin E can be purchased as 
more stable acetate or succinate derivatives.  Normally the hydroxyl moiety at the C-6 
position is prone to oxidation when exposed to air.  Since this hydroxyl moiety is 
responsible for the antioxidant effect of vitamin E, it must be removed in order to restore 
potency.  In addition to these acetate and succinate forms, our lab has developed a non-
hydrolyzable ether derivative referred to as α-tocopherol ether analog (α-TEA) [37]. 
Vitamin E Succinate 
RRR-α-tocopherol succinate (vitamin E succinate, VES) is a commercially 
available derivative of vitamin E.  It is effective against several cancer cell lines in vitro, 
including breast.  It has previously been shown by our lab that VES induces apoptosis by 
restoring Fas/FasL signaling in cells.  Unfortunately, it has also been shown that an intact 
molecule is necessary for activity in vivo, and since the succinate moiety is linked via an 
ester linkage, esterases in vivo can cleave and inactivate the molecule [37-38]. 
Alpha-tocopherol ether analog 
α-TEA was developed with the hope of finding a clinically useful vitamin E-
based chemotherapeutic agent that could be administered in a clinically relevant manner.  
It is a non-hydrolysable ether analog of RRR-α-tocopherol referred to as called RRR-α-
tocopheryloxyacetic acid or RRR-α-tocopherol ether-linked acetic acid analog (α-TEA).  
The chemical name is 2,5,7,8-tetramethyl-2R-(4R, 8R-12-trimethyltridecyl)chroman-6-
yloxyacetic acid [38].  α-TEA differs from RRR-α-tocopherol by an ether linked aecetic 
acid moiety at the phenolic oxygen at carbon 6 of the chroman head.  Unlike VES, the 
ether linkage is unhydrolyzable and the molecule remains stable in vivo.  For this reason, 
α-TEA is not known to have antioxidant properties [37-38]. 
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α-TEA is capable of inducing human ovarian (A2780/cp-70), cervical (ME-180), 
breast (MCF-7, MDA-MB-231, MDA-MB-435), endometrial (RL-952), prostate 
(LNCaP, PC-3, DU-145), lung (A-549), colon (HT-29, DLD-1) and lymphoid (Raji, 
Ramos, Jurkat) cells to undergo apoptosis [39].  Also, α-TEA does not induce apoptosis 
in normal human mammary epithelial cells or normal PrEC human prostate epithelial 
cells [38].  Previous studies within our lab have also shown α-TEA to be effective at 
reducing tumor burden and metastasis in vivo [40-44]. 
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FIGURE 1.8:  STRUCTURAL ISOMERS AND ANALOGS OF RRR-α-




Trans-resveratrol (3,5,4’-trihydroxy-trans-stilbene; t-RES) was first isolated in 
1940 from the roots of white hellebore (Veratrum grandiflorum O. Leos), and later in 
1963 from the roots of Polygonum cuspidatum, a plant used in traditional Chinese and 
Japanese medicine [45].  It is a naturally occurring phytoalexin that has since been found 
in a variety of foods such as grapes, wine, berries, and peanuts [45-53, 57]. t-RES is 
considered a promising chemotherapeutic agent based on its ability to inhibit free radical 
formation [46-48], and to induce cellular differentiation [46], autophagocytosis in human 
ovarian cancer cells [54], and apoptosis in human promyelocytic leukemia cells [46-47], 
human colon cancer cells [47-48], and human breast cancer cells [47, 49, 55] in vitro.  t-
RES has also been shown to have antitumor effects in vivo against the development of 
7,12-dimethylbenz(a)anthracene (DMBA) induced hyperplasic and atypical preneoplasic 
lesions in the mouse mammary organ culture model (MMOC) [46-47, 52, 56], N-methyl-
N-nitrosourea (NMU) induced mammary lesions in rats, and tumorigenesis in a two-stage 
mouse skin cancer model [46-48, 50, 52].  It has also been shown to reduce tumor growth 
and metastases in syngeneic mouse tumor models [57].  In addition to its anticancer 
effects, this pleotrophic compound has been shown to prevent or slow the progression of 
cardiovascular disease, ischemic injuries, enhance stress resistance, and extend the 
lifespan of various species including yeast and vertebrates [45], all without toxicity [45-
48, 50, 52].   In vivo studies have shown such promise that there are now several Phase-I 
clinical trials for oral administration of t-RES to humans with the purpose of preventing 
cancer, HIV-1, and treating colon cancer [45]. 
Biosynthesis and Structure 
Resveratrol and flavonoids are made in plants via a common synthetic pathway.  
The pathway begins when phenylalanine is converted to hydroxy-cinnamoic acid. 
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Depending on the number of cinnamoyl-radicals combined, chalcone synthase can form 
flavonoids (three required) or pinosylvin synthase can form resveratrol (two required).  In 
plants, resveratrol functions both as an antioxidant and a free radical scavenger to protect 
plants against fungus and other types of stress [58]. 
Resveratrol is a polyphenolic derivative of plant stilbenes.  Its structure is an 
alkene with two phenyl groups on either carbon.  Resveratrol can exist as one of two 
structural isomers, cis-(Z) or trans-(E).  Due to the instability of the cis conformation 
caused by steric hindrance, most resveratrol is found in the trans conformation, though 
isomerisation can occur due to heat or UV irradiation.  The structure of resveratrol 
contains three hydroxyl groups positioned on the phenyl groups at carbon 3, 5, and 4’ 





FIGURE 1.9:  STRUCTURE OF trans-RESVERATROL.  Adapted from [58]. 
 
Metabolism 
Promising results have been seen in vitro over a wide range of concentrations (32 
nM-100 µM) and in vivo ranging from 100 ng-1500 mg/kg bodyweight.  Such large 
ranges question the bioavailability of t-RES and whether in vivo concentrations are large 
 25
enough to exert many of the effects seen in vitro.   Pharmacokinetic studies have shown 
that the parental t-RES structure has a short half-life (8-14 min) and is extensively 
metabolized by cytochrome P450 enzymes in the liver [45].  When t-RES is administered 
intravenous to humans, the parental structure is primarily converted to sulphate 
conjugates within 30 min.  Glucuronide conjugates can also be detected in the serum and 
up to four metabolites have been reported in urine.  The most abundant urine metabolites 
are trans-resveratrol-3-O-glucuronide and trans-resveratrol-3-sulfate, followed by trans-
resveratrol-4’-O-glucuronide and trans-resveratrol-4’-sulfate [59].  The serum half-life 
for t-RES metabolites is 9.2 h, which suggests that the efficacy of t-RES may actually 
arise from metabolites that retain biological activity [60].  It is clear from the many in 
vivo studies that t-RES has a high efficacy so further studies are needed to determine 
whether the metabolites retain activity and are responsible for the high efficacy of t-RES 
[45]. 
FIGURE 1.10:  METABOLISM OF trans-RESVERATROL.  Adapted from [58-59]. 
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SELENIUM 
Selenium is an essential nutrient for humans that can be found in cereal grains, 
meats, and seafood and is required for more than 13 human enzymes and proteins, in the 
form of L-selenocysteine [61].  Dietary supplementation of selenium beyond the 
recommended dietary allowance of 55 µg/day for women and 70 µg/day for men, at up to 
200 µg/day, reduces the incidence of lung, colorectal, and prostate cancer in humans [61-
64].  Se-(Methyl)selenocysteine (MSC) has been shown to be an effective suppressor of 
chemically induced mammary carcinogenesis in rats [61, 63-68].  Unfortunately it is not 
a good agent for use for in vitro studies because it requires conversion to methylselenol 
by β-lyase in the liver and kidney [63, 68].  Methylseleninic acid (MSA) is a better agent 
for in vitro studies because it easily undergoes reduction to methylselenol once taken up 
by the cells [62-63, 68] and has been shown to induce apoptosis in murine and human 
mammary cells [63-64, 68].  Also, MSC and MSA have been shown to have equal 
chemopreventive efficacy in vivo and are thus considered interchangeable [63, 68]. 
FIGURE 1.11:  STRUCTURES OF MSA AND MSC.  Adapted from [62, 69]. 
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Function 
Selenium is an essential trace mineral that is required for human health and is 
usually found in amino acids selenocysteine and selenomethionine.  In humans it 
functions as a cofactor for reduction of antioxidant enzymes like glutathione peroxidase, 
which works together with vitamin E to prevent free radical formation, and thioredoxin 
reductase.  Dietary sources include cereals, many meats, fish, and eggs [31].   
Selenium toxicity, also called selenosis, generally occurs at daily intakes of 
greater than 1 mg per day but symptoms can be seen with doses as low as 400 µg per day.  
It causes a variety of symptoms including garlic odor on the breath, vomiting, diarrhea, 
hair loss, skin lesions, fatigue, irritability and nervous systems disorders.  Extreme cases 
can lead to pulmonary edema, liver cirrhosis, and death [31].  
Selenium deficiency is relatively rare in developed countries.  Most cases occur 
when people have severely compromised intestinal function or where they rely on food 
grown in selenium-deficient soil.  Deficiency can cause a predisposition to two types of 
heart disease called Keshan disease and Kashin-Beck disease.  Keshan disease is 
characterized by an enlarged heart and myocardial necrosis.  Kashin-Beck disease is 
characterized by atrophy, degeneration and necrosis of cartilage tissue.  Both of these 
diseases are common to certain provinces of China where there are selenium-poor soils 
but symptoms can be reduced by taking selenium supplements.  In other geographical 
locations with selenium-poor soil, selenium deficiency is associated with certain types of 
cancer, goiter, cretinism, and recurrent miscarriage [31].  
Metabolism 
Different forms of selenium can be metabolized in vivo in several ways depending 
on the structure.  Ip et al [71-72] have previously shown that structures that can undergo 
conversion to a monomethylated form have the highest in vivo tumor efficacy.  This is 
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mainly due to their point of entry into the selenium metabolic pathway. Entry of a 
selenium compound at a point below the hydrogen selenide pool produces large amounts 
of monomethylated metabolites that bypass the conventional assimilatory pathway for 
incorporation into selenoproteins and selenocysteine [62].  Se-methylselenocysteine is 
metabolized in vivo by β-lyase enzyme to methylselenol.  This enzyme can be found in 
several tissues including liver, mammary gland, and intestine [72].  Likewise, 
methylselininic acid can also easily converted to methylselenol in cells either by 
enzymatic reduction through NADPH-linked reductases like glutathione reductase or 
nonenzymatic reduction through excess thiol [69].  




The main cell line in our studies, MDA-MB-435-F-L, is a derivative of the 
parental MDA-MB-435 human breast carcinoma cell line first derived by Dr. Janet Price 
(MD Anderson, Houston, TX).  Dr. LuZhe Sun (University of Texas Health Science 
Center, San Antonio, TX) derived this highly metastatic variant from a mouse lung 
metastasis after the parental MDA-MB-435 cell line was injected into the flank of an 
athymic nu/nu mouse.  In addition to selecting for a highly metastatic variant, Dr. Sun’s 
lab has stably transfected the cell line with green fluorescent protein (GFP) to allow for 
fluorescent detection of these cells within animal tissue [73].   
XENOGRAFT NUDE MOUSE MODEL 
Often what occurs in vitro does not mimic what occurs in vivo.  Many times there 
are unforeseen interactions between drugs and systems in the body that are difficult if not 
impossible to predict.  One method that is commonly used to test the efficacy of novel 
chemotherapy agents on human cancer cells is with an immunodeficient mouse model. 
There are three main types of immunodeficient mice commonly used: T lymphocyte 
deficient mice, T and B lymphocyte deficient mice, and T, B, and NK cell deficient mice 
[74-78].  T lymphocyte deficient mice have a spontaneous autosomal recessive Foxn1 
(forkhead N1) gene mutation, which causes abnormal thymus development and no body 
hair.  Normal and malignant tissues from xenograft and allograft donors are able to grow 
well in this model due to the deficient T cell function [74-75].  T and B lymphocyte 
deficient mice, also known as severe combined immuno-deficient (SCID) mice, lack both 
T and B cell function.  This is due to a spontaneous Prkdc (protein kinase, DNA 
activated, catalytic polypeptide gene) mutation that causes defects in V(D)J 
recombination and allows mice to more easily accept foreign tissue transplants [76-77].  
T, B, and NK cell deficient mice carry three separate gene mutations that result in T, B, 
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and NK cell deficiencies [78].  Besides the obvious advantage that human cells and 
tissues can be transplanted into these animal models, their lack of body hair allows for 
easy identification of growing tumors.  
CHEMOPREVENTION 
The definition of chemoprevention is the intervention in the tumorigenic process 
by a natural or synthetic compound.  Specifically, it is an agent that can block the early 
stages of initiation, pre-malignant development, and/or arrest malignant cell progression 
[38].  Most chemically induced mammary chemoprevention animal models use either 
DMBA or MNU to induce lesions.  There are several common features to DMBA and 
MNU induced lesions including organ specificity, reliable induction of mammary tumors, 
few metastases, and the examination of tumor initiation and promotion/progression.  One 
major difference between MNU and DMBA is that MNU is a direct acting carcinogen 
and thus does not require metabolic activation, whereas DMBA is a proximate 
carcinogen that requires metabolic activation.    Another difference is that MNU induces 
more aggressive carcinomas than DMBA, so that a higher proportion of MNU induced 
lesions are malignant compared to those induced by DMBA [79].   In our studies, DMBA 
was used to induce lesions in the mouse mammary organ culture (MMOC) model and 
MNU was used to induce lesions in the rat carcinogenesis model. 
Mouse Mammary Organ Culture Model  
The MMOC model is an ex vivo chemoprevention model that can be used to 
examine the effects of compounds on the very early stages of chemically induced lesion 
formation.  Studies have shown that there is a high correlation between agents that show 
chemopreventive activity in this model with those that show activity in the two-stage skin 
carcinogenesis and the chemically induced rodent mammary carcinogenesis model.   The 
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model can be adapted to target lesions to be either alveolar or ductal in origin and both 
methods consist of three main phases: pre-treatment, growth, and regression.  In the 
pretreatment phase, female balb/c mice are treated with 1 µg 17β-estradiol (E) and 1 mg 
progesterone (Pg) daily for nine days in order to stimulate growth of the mammary 
glands.  During the growth phase, animals are sacrificed and the glands are cultured in 
media containing different constituents depending on the desired type of lesion.  These 
additions to the media induce mammary gland differentiation so that at the end of the 10-
day phase, the glands morphologically resemble the gland of a pregnant animal, complete 
with lobulo-alveolar structures.  Chemopreventive agents to be tested are given in the 
media starting at day 1 of the growth phase and continue throughout the growth phase.  
On the third day, 2 µg/ml DMBA is added to the growth media for 24 h and then replaced 
with fresh growth media.  During the regression phase, the glands revert back to that of 
an involuted mammary gland.  Glands that contain DMBA lesions do not fully regress at 
the location of the lesion and can be quantitated after the glands have been mounted and 
stained with alum carmine [80-82].  
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FIGURE 1.13:  TIMELINE OF MOUSE MAMMARY ORGAN CULTURE MODEL.  
Adapted from [81].  I = insulin, P = prolactin , A = aldosterone, H = hydrocortisone, E = 
17β-estradiol, Pg = progesterone  
 
Rat Carcinogenesis Model  
Most work on early lesion formation is done in mouse models despite that mouse 
models predominantly form alveolar lesions.  MNU induced rat carcinogenesis models 
are another commonly used method to study chemically induced mammary gland lesions 
because the tumors in these animals typically show similar estrogen responsiveness and 
chromosomal abnormalities to that seen in humans, and therefore serve as a better model 
for human disease.  Similar to human pathology, MNU-induced rat models show an 80% 
incidence of intraductal hyperplasia, 45% incidence of ductal carcinoma in situ (DCIS), 
and greater than 95% incidence of adenocarcinomas [83].  Recently, a short-term 
carcinogenesis model has been developed by Thompson et al [79, 83, 86] that allows for 
the rapid induction of premalignant and malignant stages of mammary carcinogenesis.  
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The main difference between this model and the conventional model is the age at which 
the rats are injected (21 d versus 50 d) which allows that the experiment be completed in 
35 d compared to 6 months in the conventional model [79, 83-86].  In either model, the 
mammary glands are removed and mounted on glass slides at sacrifice.  Lesions are 
quantitated and classified as adenocarcinoma (AC), ductal carcinoma in situ (DCIS), 
intraductal proliferation (IDP), or within normal limits [79, 83-86].  The short-term 
carcinogenesis model has several advantages over the conventional model in addition to a 
shorter latency to carcinoma occurrence.  This model also shows a lower frequency of 
ovarian hormone-dependent tumors [86], and the relative simplicity of the gland in the 
younger rats allows for easier detection of IDP and DCIS in the gland [79].  
Histological classification of the rat whole mount lesions is based on 
classification criteria published by Russo et al [115].  Lesions are classified as intraductal 
proliferation (IDP), ductal carcinoma in situ (DCIS), adenocarcinoma (AC), or “within 
normal limits.”  The criteria for diagnosing hyperplasia is primarily based on an increase 
in the epithelial cells lining the acini and ducts, which can range from 3-4 four cells thick 
in mild subtypes or completely full in florid hyperplasias.  The individual cells that make 
up IDPs are not distinguishable and the nuclei are generally round to oval, haphazardly 
arranged, and lack nucleoli [86].  DCIS have at least one expanded ductal structure that is 
completely replaced by neoplastic cells that have uniform, monotonous, round, 
hyperchromatic and non-overlapping nuclei, and retain an intact ductal basement 
membrane.  DCIS can be further classified as cribiform or comedo carcinoma in situ. 
Lesions that have only a single duct replaced are labeled atypical ductal hyperplasia 
(ADH).  ACs are defined as the earliest breach of the ductal basement membrane and 
tend to invade as a broad front of several cells with clusters of neoplastic acini and like 
DCIS can be subdivided into cribiform and comedo [86].  
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Figure 1.14:  Mammary Gland While Mount.  Adapted from [79].  A, fixed and stained 
mammary gland whole mount preparation showing premalignant and malignant 
mammary gland lesions.  B, Subgross morphology of lesions identified in panel A.  C, 
histology of lesions shown in Panel B. 
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SUMMARY 
More than 90% of all cancer deaths can be attributed to distal secondary lesions 
[87].  These metastases arise from aggressive tumor cells that have escaped and survived 
earlier attempts at treatment, most likely due to the heterogeneity of cells within a tumor.  
As we continue to understand more about the nature of tumor cells and their signaling 
mechanisms, it becomes increasingly clear that treatment with a single agent or method 
will not eliminate all of the cells of a tumor, and that perhaps a cocktail of treatments 
would be more effective.  Based on this hypothesis, and the ability to induce cell death 
via different mechanisms with little to no toxicity to normal cells, α-TEA, t-RES, and 
MSC/MSA were chosen to investigate the combined effects of these compounds on a 
highly metastatic human breast cancer cell line.   
This dissertation focuses on studies of α-TEA, t-RES, and MSC/MSA, alone and 
together, as inhibitors of human breast cancer cells using both in vitro and in vivo 
methods.  The aim of this chapter was to introduce methods of cancer cell death, 
specifically apoptosis and autophagocytosis, as well as to provide background 
information on the function and metabolism of α-TEA, t-RES, and MSC/MSA. Various 
animal models and the main cell line used in the investigations presented in this 
dissertation were also reviewed.  Chapter 2 will focus on the initial studies that 
characterized how α-TEA, t-RES, and MSC/MSA synergize to inhibit proliferation and 
induce apoptosis in various breast and prostate cancer cell lines.  Chapter 3 will build on 
these findings and show how a combination of the three agents used together is just as 
effective as α-TEA used alone to treat tumor cells in a murine xenograft model, but can 
inhibit more metastases than individual treatments.  This chapter will also show that the 
diet that animals are fed is important to the overall tumor growth in the studies.  Chapter 
4 will focus on the use of α-TEA, t-RES, and MSA as chemopreventive agents and show 
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that α-TEA and t-RES together without MSA is the most effective combination for 
preventing DMBA-induced lesions in the mouse mammary organ culture model.  Chapter 
5 will report on studies designed to characterize the molecular signaling events that 
account for the synergistic ability of α-TEA and t-RES to induce cell death when used in 
combination, and will explore the role of apoptosis and autophagocytosis signaling 
proteins. 
Taken together, these studies suggest that α-TEA, in combination with other pro-
cell death agents such as t-RES and MSC/MSA, can reduce human breast cancer growth 
in vitro and in vivo more effectively than any of the agents alone.  These studies add 
insight into the complex mechanisms that regulate cell death in human breast cancer cells 
and provide a basis for future breast cancer treatment and prevention regimens. 
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Chapter 2: RRR-α-tocopherol ether analog, α-TEA, methylseleninic 
acid (MSA), and trans-resveratrol (t-RES) in combination 
synergistically inhibit human breast cancer 
ABSTRACT   
Alpha-tocopherol ether analog (α-TEA) is a novel form of vitamin E that is 
effective at killing cancer cells but not normal cells. α-TEA alone and together with 
methylseleninic acid (MSA) and trans-resveratrol (t-RES) were investigated for ability to 
induce apoptosis, DNA synthesis arrest, and cellular differentiation, and inhibit colony 
formation in human MDA-MB-435-F-L breast cancer cells in culture.  The three agents 
alone were effective in inhibiting cell growth by apoptosis, DNA synthesis arrest, cellular 
differentiation, and reducing colony formation.   Combination treatments synergistically 
inhibited cell proliferation in the four different assays conducted, in comparison to 
individual treatments.   For induction of apoptosis, enhanced levels of apoptosis were 
also found using human breast (MDA-MB-231, MCF7, and T47D) and human prostate 
(LNCaP, PC-3, and DU-145) cancer cell lines, as well as in immortalized but non 
tumorigenic MCF10A cells. No apoptosis was seen in primary cultures of human 
mammary epithelial cells (HMECs).  Western immunoblotting confirmed that all three 
compounds individually and in combination induced poly(ADP-ribose) polymerase 
cleavage with more complete cleavage seen in the combination treatment.  In studies of 
DNA synthesis arrest, clonegenic, and cell differentiation assays, all three compounds 
produced dose-dependent responses individually and enhanced responses in combination.   
In summary, the combination of α-TEA, MSA, and t-RES is more effective than single 
treatments for inhibiting cell proliferation, and inducing differentiation and apoptosis of 
human cancer cells in culture. 
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INTRODUCTION  
Breast cancer is the most common cancer among US women and second only to 
lung cancer in deaths [1].  Despite intense studies, the incidence of breast cancer remains 
high.  Toxicity and resistance to standard drug treatments limit the effectiveness of 
chemotherapy so there remains an urgent need for alternative strategies for prevention 
and treatment of cancers, specifically combinations of nutrient-based agents with low 
toxicities that act in a synergistic manner to enhance treatment efficacy.    
α-TEA has been developed for potential use in chemoprevention and 
chemotherapy [38, 40].  α-TEA is capable of inducing human ovarian (A2780/cp-70), 
cervical (ME-180), breast (MCF-7, MDA-MB-231, MDA-MB-435), endometrial (RL-
952), prostate (LNCaP, PC-3, DU-145), lung (A-549), colon (HT-29, DLD-1) and 
lymphoid (Raji, Ramos, Jurkat) cells to undergo apoptosis [38-40]. α-TEA does not 
induce apoptosis in normal human mammary epithelial cells or normal PrEC human 
prostate epithelial cells [38-40, 42].  Previous studies have also shown α-TEA to be 
effective at reducing tumor burden and metastasis in vivo [40-44]. 
trans-Resveratrol (3,5,4’-trihydroxy-trans-stilbene; t-RES) is a naturally 
occurring phytoalexin that can be found in a variety of foods such as grapes, wine, 
berries, and peanuts [46-53].  This phytoalexin is considered a promising 
chemotherapeutic agent based on its ability to inhibit free radical formation [46-48, 53], 
and to induce cellular differentiation and apoptosis in human promyelocytic leukemia 
cells [47-48], human colon cancer cells [48-49], and human breast cancer cells [48, 50] in 
vitro.  t-RES has been shown to inhibit the development of 7,12-
dimethylbenz(a)anthracene-induced hyperplastic and atypical preneoplastic lesions in the 
mouse mammary organ culture model [47-48, 53].  It also inhibits N-methyl-N-
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nitrosourea induced mammary lesions in rats, and tumorigenesis in a two-stage mouse 
skin cancer model with no observed toxicity in vitro and in vivo [47, 49, 51, 53].   
Selenium is an essential nutrient for humans that can be found in cereal grains, 
meats, and seafood and is required for more than 13 human enzymes and proteins, in the 
form of L-selenocysteine [61].  Dietary supplementation of selenium beyond the 
recommended dietary allowance of 55 µg/day for females and males 14 years of age or 
greater at up to 200 µg/day reduces the incidence of lung, colorectal, and prostate cancer 
in humans [61, 63, 65, 67-68].  Se-(Methyl)selenocysteine (MSC) has been shown to be 
an effective suppressor of chemically induced mammary carcinogenesis in rats [62, 64-
68, 71].  Unfortunately MSC is not a good agent for use for in vitro studies because it 
requires conversion to methylselenol by the liver and kidney [62, 64, 66-68, 71].  
Methylseleninic acid (MSA) is a better agent for in vitro studies because it easily 
undergoes reduction to methylselenol once taken up by the cells [63, 67, 71] and has been 
shown to induce apoptosis in murine and human mammary cells [67-68, 71].  MSC and 
MSA have been shown to have equal chemo-preventative efficacy in vivo and are 
considered interchangeable [67, 71]. 
Based on promising anticancer actions of the novel vitamin E analog, α-TEA, and 
that of t-RES and MSA, the combined effects of these compounds on the highly 
metastatic human breast MDA-MB-435-F-L cell line were investigated.  In these studies 
the effects of α-TEA plus t-RES and MSA, alone and in combination on cell proliferation 
and the induction of apoptosis and differentiation were investigated.  Combination 
treatments synergistically inhibited tumor cell growth by analyses of apoptosis, and 
greatly inhibited DNA synthesis arrest,  colony formation, and cellular differentiation.  
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MATERIALS AND METHODS               
Chemicals and Reagents 
t-RES was purchased from Cayman Chemical Co. (Ann Arbor, MI), MSA was 
purchased from PharmaSe, Inc. (Lubbock, TX), and Vitamin E Succinate (VES) was 
purchased from Sigma-Aldrich (St. Louis, MO).  All reagents for morphological analyses 
of apoptosis were purchased from Boehringer Mannheim (Indianapolis, IN).  α-TEA was 
prepared and validated as previously described [40].   
Cell Lines and Culture Conditions 
MDA-MB-231, T47D, MCF10-A, LNCaP, PC-3, and DU-145 cell lines were 
obtained from the American Type Culture Collection (ATCC; Manassas, VA).  The 
MCF-7 cell line was provided by Dr. Suzanne Fuqua (University of Texas Health Science 
Center, San Antonio, TX).  HMECs are primary cultures of mammary cells derived from 
normal mammoplasty specimens and received from the cooperative human tissue 
network Southern Division (CHTN; Birmingham, AL).  MDA-MB-435-F-L cells were a 
kind gift from Dr. LuZhe Sun (University of Texas Health Science Center, San Antonio, 
TX).  These cells are derived from MDA-MB-435 cells and have been stably transfected 
with enhanced green fluorescence protein (GFP).  They are more metastatic than the 
parental MDA-MB-435 cell line having been injected into the flank of a nude mouse and 
recovered from a lung metastasis [73].   
MDA-MB-435-F-L, MDA-MB-231, MCF-7, T47D, MCF10A, HMECs, LNCaP, 
PC-3, and DU-145 cells were cultured as previously described [43, 88-89].  For apoptosis 
analysis, exponentially growing T47D, MCF10A, and HMEC cells were plated at 1.5 x 
105 cells/well in 12-well plates while MDA-MB-435-F-L, MDA-MB-231, and MCF-7 
cell lines were plated at 1.0 x 105 cells/well in 12-well plates (1 ml/well).    MDA-MB-
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435-F-L cells were plated at 1.67 x 105 cells/ml in T-25 flasks (10 ml per flask) for 
Western analysis, 1.0 x 105 cells/ml in 96-well plates (150 µl/well) for DNA synthesis 
arrest studies, and 1.5 x 105 cells/ml in 6-well plates (2 ml/well) for differentiation 
studies.  Cells were allowed to attach overnight and the following day growth media were 
replaced with experimental media containing treatments.  Stock solutions of t-RES and 
α-TEA were at 20 mg/ml in DMSO, and MSA was at 1 mg/ml in water.  All solutions 
were stored at –20°C and diluted in experimental media to the desired final 
concentration.  Vehicle controls consisted of 0.167 % DMSO, or 1.67 µl/ml media. 
Apoptosis Analysis Using Morphology of 4’, 6-Diamidino-2-Phenylindole 
Dihydrochloride (DAPI) Nuclear Stained Cells 
All cell lines were plated and treated with α-TEA at 10.25 or 20.5 µM, t-RES at 
44 or 88 µM, MSA at 5 or 10 µM, a combination of the above drugs, or vehicle.  
Treatments were for two or three days and then cells were collected and stained with 
DAPI as previously described [88].  Cells in each sample were counted a minimum of 3 
times, with •100–200 cells/count.  Cells where the nucleus contained clearly condensed 
chromatin or fragmented nuclei were scored as apoptotic. Apoptotic data are reported as 
percent apoptosis (number apoptotic/total number of cells counted).  Data are mean ± 
S.D. of three independent experiments.  
Western Immunoblot Detection of Poly(ADP-Ribose) Polymerase (PARP) cleavage   
MDA-MB-435-F-L cells were plated and treated with 20 µM α-TEA, 88 µM t-
RES, 10 µM MSA, a combination of the three at the same concentrations, or a vehicle 
and allowed to incubate for 6, 12, 24, or 48 h.  Cells were detached by scraping and both 
adherent and floating cells were pelleted by centrifugation for 5 minutes at 350 × g.  
Whole cell lysates were prepared and western immunoblotting performed as previously 
described [88] with the exception that 50 µg of protein were loaded in each well of a 10% 
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polyacrylamide gel.  Immunoblotting was performed using 1 µg of primary rabbit anti-
human PARP antibody [PARP (H-250), Santa Cruz Biotechnology, CA], and horseradish 
peroxidase-conjugated goat anti-rabbit immunoglobulin (Ig) was used as the secondary 
antibody (Jackson Immunoresearch Laboratory, West Grove, PA) at a 1:2000 dilution; 
detection was carried out with enhanced chemiluminescense (ECL, Pierce, Rockford, IL).  
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH, in house) was used to verify equal 
lane loading. 
DNA Synthesis Arrest Assay  
Detection of DNA synthesis arrest was measured by [3H]-thymidine incorporation 
as previously described [90].  MDA-MB-435-F-L cells were plated and treated with 
different amounts of α-TEA, MSA, or t-RES to establish a dose response for each 
compound.  After 24 hours, 0.5 µCi [3H]-thymidine was added to media and allowed to 
incubate for another 8.5 hours.  Cells were harvested and [3H]-thymidine uptake was 
measured with a Beckman LS5000TD liquid scintillation counter. Following 
establishment of a dose response, data were entered into CalcuSyn 2.0 (Biosource, 
Ferguson, MO), a software program designed to determine drug interactions and ED50.   
Next, cells were plated as previously described and followed by a variety of combination 
treatments based on the ED50 values on day 2.  Pulsing and harvesting was performed as 
described previously.  Data are mean ± S.D. of three independent experiments. 
Clonegenic Assay 
Inhibition of colony formation was performed as previously described with the 
exception that treatments were given for 3 instead of 10 days [41].  MDA-MB-435-F-L 
cells were plated at increasing cell numbers ranging from 5 x 102 to 1 x 105 cells/well in 
laminin (2 µg) coated 6-well plates and allowed to adhere overnight.  The following day, 
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growth media was removed and replaced with experimental media containing different 
amounts of α-TEA, MSA, or t-RES to establish a dose response for each compound.  On 
day 4, treatment media were replaced with fresh experimental media and the cells were 
allowed to grow for 9 days, after which the media was removed and the plates were 
stained for 30 minutes with 1% methylene blue.  Plates were examined and colonies 
greater than 100 cells were counted manually in wells containing 50 to 300 colonies.  
Surviving fractions were calculated as number of colonies present divided by number of 
cells seeded x plating efficiency.  The dose response data were entered into CalcuSyn and 
ED50 values were determined.  Cells were plated as described above and treated with a 
variety of combination treatments based on the ED50 values.  Plating efficiencies and 
surviving fractions were determined.  Data are the mean ± S.D. of three independent 
experiments. 
Differentiation with Oil Red O-Stain 
Samples were prepared as previously described [91-92].  Cells were plated on 
cover slips and treated for 12, 24, or 48 h with experimental media containing various 
treatments.  Cells were fixed in 4% paraformaldehyde overnight at 4˚C and washed three 
times with phosphate buffered saline (PBS) solution.  Cells were stained with an Oil Red 
O working solution (6:4, saturated Oil Red O: distilled water) for 10 min and then 
washed three times with PBS.  Cells were counterstained for 5 min with Mayer’s 
hematoxylin solution and washed until the background was clean.  Cover slips were 
mounted onto a glass slide and examined with a Zeiss microscope at 1000x.  Cells 
containing 10 or more Oil Red O-stained lipid droplets were scored positive.  Data are the 
mean ± S.D. of three independent experiments.  Data was analyzed using ANOVA 
followed by a Newman-Keuls post-hoc test. 
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 Statistical Analyses 
Statistical analyses were conducted using Prism software version 4.0 (Graphpad, 
San Diego, CA) and a level of p < 0.05 was considered statistically significant.  CalcuSyn 
2.0 was used to determine ED50 values and synergy values. 
RESULTS       
α-TEA, t-RES, and MSA in combination act synergistically to induce apoptosis in 
MDA-MB-435-F-L cells 
Prior to conducting combination studies, α-TEA, t-RES, and MSA at sub-optimal 
to optimal concentrations were analyzed for ability to induce apoptosis (Fig 1A).  Based 
on these data, sub-optimal dosages of α-TEA at 10 and 20 µM, t-RES at 44 and 88 µM, 
and MSA at 5 and 10 µM were chosen for combination treatments.  MDA-MB-435-F-L 
cells were treated with sub-optimal apoptotic levels of α-TEA, t-RES, and MSA, 
separately and in combination, for 2 (data not shown), and 3 days (Fig 1 A).  
Combination treatments for two days with each of the lower individual agents induced 
28% apoptosis and a combination with the higher individual treatments induced 47% 
apoptosis, however, levels of apoptosis at 2 days treatment were not significantly 
different from single treatments (data not shown).  Combination treatments for 3 days 
significantly enhanced apoptosis in comparison to single treatments.  The low 
combination treatment induced 41% and the higher induced 82% apoptosis, respectively 
(Fig 1A).   Analyses of the combination data using CalcuSyn software to determine a 
combination index value (CI) and synergy, showed the enhanced apoptosis to be 
synergistic at both concentrations of the three agents, CI for α-TEA (10 µM), t-RES (44 
µM) and MSA (5 µM) = 0.682. CI for α-TEA (20 µM), t-RES (88 µM) and MSA (10 
µM) = 0.465.  Synergistic relationship is defined as CI < 1. 
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Evidence of apoptosis induced by treatments was also confirmed using PARP 
cleavage (p84).  VES, a known inducer of apoptosis [88] was used as a positive control 
for PARP cleavage.  Combination treatments, in comparison to single treatments, cleave 
PARP at an earlier time point and more completely than individual treatments (Fig 1B). 
At 12 h, a p84 cleavage band was seen in the combination treatment.  At 24 h, α-TEA 
and the combination treatments both show PARP cleavage with the combination showing 
a 2.7-fold stronger cleavage band in comparison to the α-TEA band.  α-TEA, MSA, t-
RES, and the combination treatments all have cleavage bands at 48 h with the 
combination treatment showing a 5.9, 2.8, and 2.4 fold increase over individual 
treatments (Fig. 1B).   
α-TEA, t-RES, and MSA in combination act synergistically to induce apoptosis in 
breast and prostate cancer cells and immortalized but non-tumorigenic breast cells, 
but not normal mammary epithelial cells.     
To determine if the enhanced effect of the combination treatment was applicable 
to other cell lines, breast (MDA-MB-231, MCF-7, and T47D); prostate (PC-3, LnCaP, 
and DU-145), immortalized but non-tumorigenic MCF-10A cells,  and normal epithelial 
mammary cells (HMECs) were examined.   All cell lines were treated at the same 
concentrations of the three agents separately and in combination  and durations as used to 
treat MDA-MB-435-F-L cells in Fig 1A. Combination treatments for 2 and 3 days 
significantly enhanced apoptosis, in comparison to single treatments, in all tumorigenic 
cell lines and the immortalized cell line, but not HMECs (Table 1).  
α-TEA, t-RES, and MSA in combination act synergistically to enhance DNA 
synthesis arrest in MDA-MB-435-F-L cells 
Prior to conducting combination treatments, the EC50 values for α-TEA, t-RES, 
and MSA treatments alone for induction of DNA synthesis arrest were established.   
MDA-MB-435-F-L cells showed a dose-dependent arrest of DNA synthesis after 30 h of 
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single treatments with several levels of α-TEA, t-RES, and MSA (Fig 2).   ED50 values 
generated by CalcuSyn were 14.23, 19.8, and 1.16 µM for α-TEA, t-RES, and MSA 
respectively (Fig 2).   For combination studies, α-TEA, t-RES, and MSA treatments were 
made using either the ED50 or half of the ED50 concentrations derived from Fig 2A.  The 
combination treatments induced percent DNA synthesis arrest in the range of 53-92% 
(Table 2).  Two of the combination treatments significantly induced DNA synthesis arrest 
at 92 and 90% respectively. (Table 2, CI values of 0.93 and 0.95 respectively). One 
combination treatment additively enhanced DNA synthesis arrest (CI value of 1.04).  The 
most effective combination was 14.23 µM α-TEA + 19.8 µM t-RES + 1.16 µM MSA 
(Table 2, CI value of 0.93).   
α-TEA, t-RES, and MSA in combination act synergistically to inhibit colony 
formation in MDA-MB-435-F-L cells 
Prior to conducting combination treatments, the EC50 values for α-TEA, t-RES, 
and MSA treatments alone for inhibition of colony formation were established. Using 
CalcuSyn, ED50 values were calculated to be 4.73, 13.2, and 6.9 µM for α-TEA, t-RES, 
and MSA, respectively (Fig 3).  Using these values, combinations were made using either 
the ED50 concentration or concentrations half of the ED50.  The combination treatments 
induced percent cell death in the range of 62 to 92% (Table 3).  Three of the combination 
treatments synergistically inhibited colony formation (CI values of 0.54, 0.88, and 0.94, 
respectively).  One combination treatment additively inhibited colony formation (CI 
value of 1.03).  The most effective combination was 4.73 µM α-TEA + 13.2 µM t-RES + 
MSA at 3.45 µM (Table 3).  
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α-TEA, t-RES, and MSA in combination act synergistically to induce cellular 
differentiation in MDA-MB-435-F-L cells 
Incorporation of Oil Red O-stain was used to assess cell differentiation. MDA-
MB-435-F-L cells were treated with vehicle control, VES (40 µM), t-RES (88 µM), α-
TEA (20.5 µM), MSA (10 µM), or a combination of t-RES, α-TEA and MSA for 12, 24, 
and 48 h.  VES, a compound known to induce differentiation in MDA-MB-435 cells [91-
92] was used as a positive control.   All single treatments significantly induced cellular 
differentiation at the three time points in comparison to vehicle control (Fig 4).  
Combination treatments were significantly different from individual treatments at all time 
points (Fig 4).   
DISCUSSION       
In the studies reported here, we show that α-TEA alone and together with t-RES 
and MSA, can prevent the formation of colonies, inhibit DNA synthesis, increase cell 
death by apoptosis and induce cell differentiation in human MDA-MB-435 cells in 
culture.  These studies demonstrate that the administration of α-TEA together with t-RES 
and MSA induces synergistic levels of apoptosis, DNA synthesis arrest, inhibition of 
colony formation, and enhanced levels of cellular differentiation in comparison to 
individual treatments in MDA-MB-435-F-L human breast cancer cells.  Combination 
treatments enhanced apoptosis in a variety of epithelial prostate and breast cancer cell 
lines. These data show that the combination effects are not limited to a single cancer cell 
line, supporting broad-spectrum use in humans.   
Perhaps significant to the potential use of these compounds in human 
chemotherapy is not only the observation that individually these compounds do not 
induce apoptosis in normal human mammary epithelial cells, but neither do combination 
treatments.  These data suggest that these agents in combination selectively target 
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tumorigenic and not normal cells, suggesting potential synergistic anti-cancer potential in 
humans with perhaps limited to no toxicity when used as a chemotherapeutic treatment.  
To a lesser extent, combination treatments selectively target immortalized but non-
tumorigenic cells, suggesting potential use as a long-term chemoprevention regimen.   
Data in the literature using these three agents singly as anticancer agents is supportive of 
the data reported here.  α-TEA [39-40, 42] is nontoxic to normal human prostate 
epithelial cells in vitro [38-40, 42] and exhibits no visible signs of toxicity to mice in vivo 
[40-44].  t-RES does not have toxic effects in vitro or in vivo [46-53].  Although selenium 
toxicity can occur, the levels that were used here were below the threshold for toxicity 
and within the range of concentrations reported in the literature [63, 67, 71].  
Additionally, several forms of selenium are commonly used in long-term 
chemoprevention models [64-66, 68, 71], re-enforcing the relevance of its use.  
Combination treatments showed an enhanced ability to inhibit tumor cell growth 
at lower concentrations when compared to individual treatments.  Using DNA synthesis 
as an example, the most effective combination (14.23 µM α-TEA + 19.8 µM t-RES + 
1.16 µM MSA) inhibited DNA synthesis arrest by 92%.  In order to obtain similar results 
with individual agents, treatments would require 2.4 fold more α-TEA, 2.89 fold more t-
RES, or 6.5 fold more MSA than what was used in the combination treatment.    These 
combination treatments have the potential to maximize anticancer efficacy with reduced 
levels of potentially toxic agents. 
Unlike the DNA synthesis arrest data, MSA appears to play an inhibitory role in 
combination treatments when t-RES is at high concentrations.  For example, the 
combination of 4.73 µM α-TEA + 13.2 µM t-RES + 3.45 µM MSA had a much greater 
inhibition on colony formation than with the same concentration of α-TEA and t-RES but 
with twice as much MSA (92 vs. 70 % inhibition of colony formation).  By adding more 
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MSA to the combination, the effectiveness decreased by 24%.  This inhibitory effect is 
also reflected in the CI value (0.54 v 1.66, CI > 1 is antagonistic).  However, when t-RES 
is at low concentrations, MSA does not seem to affect the results.  For example, the 
combination of 4.73 µM α-TEA + 6.6 µM t-RES + 6.9 µM MSA is nearly identical to 
that with half as much MSA (74 vs. 75%).  Likewise, the combination of 2.36 µM α-
TEA + 6.6 µM t-RES + 6.9 µM MSA is very similar to that with half the MSA (67 vs. 
62%). 
Differentiation is another mechanism by which cancer therapeutic and 
chemopreventive agents can work.  The data for the individual treatments is consistent 
with that found in the literature.  Previous reports by our lab have shown that several 
forms of vitamin E, including α-TEA can induce cellular differentiation in human MDA-
MB-435 and MCF-7 breast cancer cell lines [91-92].  t-RES has been shown to induce 
differentiation in medulloblastoma cells and promyelocytic leukemia cells [47, 93].  
Results with the differentiation assay were similar to that for apoptosis (PARP cleavage) 
in that the combination showed both a quantitative and kinetic advantage over all the 
individual treatments. 
It seems highly plausible that these unique combinations of compounds could be 
extremely effective if used either as a chemotherapy or chemoprevention cocktail in vivo.  
If successful, this combination could be a very attractive alternative to traditional 
chemotherapy due both to the absence of toxicity and the effectiveness of treatment.  
However, the combination data point out a challenging problem, the need to obtain 
different levels of each agent in order to maximize anticancer efficacy.  Data show that 
α-TEA can be effectively paired with more traditional and toxic chemotherapeutic agents 
(celecoxib, 9-nitro-camptothecin, and cisplatin) to significantly reduce tumor burden, 
while using reduced levels of toxic chemotherapeutic agents [42-44].     
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Based on data reported in this paper, and the effectiveness of α-TEA in vivo, 
preclinical animal studies were conducted using α-TEA, t-RES and MSC separately and 
in combination. Unfortunately synergisms found in cell culture did not occur in the 
animal study.  MSC, t-RES, and α-TEA alone decreased tumor volume by  0.1, 23.5, and 
59.7%, respectively, and only a 52.6% decrease in the combination treatment (Chapter 
3).  One possible explanation is that MSC was inhibitory to the combination of t-RES and 
α-TEA, as was found in the colony assay.  The combination of MSC + α-TEA showed a 
51.4% reduction in tumor volume, which was less effective than α-TEA alone.  A group 
containing only t-RES + α-TEA was not present in this study that could have supported 
the theory that MSA inhibited the combination.  A second possible explanation is that 
synergistic combinations of the three agents were not obtained in vivo.   Thirdly, cell 
culture data may not be predictive of in vivo outcome.   
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Table 2.1.  Apoptosis induced in human breast cancer, immortalized, and normal 
mammary cells treated with α-TEA, MSA, and t-RESa 
 Breast Prostate 
Tumorigenic + + + - - + + + 
Immortalized - - - + - - - - 















































(µM)- 2 Day         
VEH 4 ± 1 3 ± 1 3 ± 1 5 ± 2 3 ± 1 4 ± 1 4 ± 1 4 ± 1 
α-TEA 20 17 ± 2 
(3) 
7 ± 2 
(4) 
4 ± 1 
(1.5) 
8 ± 2 
(3) 
2 ± 1 
 
12 ± 2 
(5.8) 
20 ± 3 
(1.5) 
10 ± 2 
(4.9) 
RES 88 7 ± 1 
(7.3) 
9 ± 3 
(3.1) 
3 ± 1 
(2) 
7 ± 2 
(3.4) 
2 ± 1 
 
14 ± 4 
(4.9) 
7 ± 2 
(4.3) 
12 ± 2 
(4.1) 
MSA 10 14 ± 2 
(3.6) 
7 ± 2 
(4) 
2 ± 1 
(3) 
5 ± 2 
(4.8) 
2 ± 1 
 
31 ± 6 
(2.2) 
6 ± 1 
(5) 
19 ± 3 
(2.6) 
α-TEA 20 
+ RES 88 
+ MSA 10 
51 ± 3 
* 
28 ± 2 
* 
6 ± 2 
* 
24 ± 5 
* 
2 ± 1 
 
69 ± 3 
* 
30 ± 2 
* 
49 ± 3 
* 
Treatment 
(µM)- 3 Day         
VEH 3 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1 3 ± 1 4 ± 1 5 ± 2 
α-TEA 20 51 ± 3 
(1.7) 
17 ± 2 
(2.7) 
5 ± 2 
(3.4) 
11 ± 3 
(2.9) 
3 ± 1 
 
15 ± 3 
(5.8) 
60 ± 5 
(1.2) 
9 ± 3 
(8.1) 
RES 88 13 ± 1 
(6.6) 
13 ± 2 
(3.5) 
4 ± 2 
(4.3) 
6 ± 8 
(5.3) 
3 ± 1 
 
15 ± 2 
(5.8) 
12 ± 1 
(6.2) 
16 ± 3 
(4.6) 
MSA 10 34 ± 3 
(2.5) 
20 ± 3 
(2.3) 
5 ± 1 
(3.4) 
4 ± 2 
(8) 
2 ± 1 
 
44 ± 5 
(2) 
7 ± 1 
(10.6) 
30 ± 3 
(2.4) 
α-TEA 20 
+ RES 88 
+ MSA 10 
86 ± 4 
* 
46 ± 4 
* 
17 ± 2 
* 
32 ± 8 
* 
2 ± 1 
 
87 ± 2 
* 
74 ± 4 
* 
73 ± 3 
* 
a:  Cells were treated with α-TEA, MSA, t-RES, or a combination, and analyzed after 48 
and 72 h treatment.  Treatments are given in µM concentrations.  Data reflect an average 
of three experiments +/- S.D.   Percentages have been rounded to the nearest integer. 
(#): Represents fold increase of combination over individual treatment 
* p<0.05 compared to the individual treatments for that cell line.  Data was analyzed 
using a one-way analysis of variance followed by a Tukey post-hoc test. 
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Table 2.2.  Combination Treatments with α-TEA, t-RES, and MSA Synergistically 














Increase  CI value 
14.23 19.8 1.16 2:2:2 92 1.8 0.93** 
14.23 19.8 0.58 2:2:1 90 1.8 0.95** 
7.11 19.8 1.16 1:2:2 80 1.6 1.18 
7.11 19.8 0.58 1:2:1 79 1.6 1.04* 
14.23 9.9 1.16 2:1:2 82 1.6 1.19 
14.23 9.9 0.58 2:1:1 73 1.5 1.32 
7.11 9.9 1.16 1:1:2 68 1.4 1.31 




 Data represent an average of three experiments.  The ED50 values were 14.23, 19.8, 
and 1.16 µM for α -TEA, t-RES, and MSA, respectively.  These values were 
designated as a 2:2:2 ratio.  Other ratios were made with respect to the ED50 values.  
% DNA Synthesis Arrest was rounded to the nearest integer. 
**:  Data represent synergistic effect 




Table 2.3.  Combination Treatments with α-TEA, t-RES, and MSA Synergistically 














4.73 13.2 6.9 2:2:2 30 70 1.4 1.66 
4.73 13.2 3.45 2:1:2 8 92 1.8 0.54** 
2.36 13.2 6.9 1:2:2 20 80 1.6 0.88** 
2.36 13.2 3.45 1:1:2 27 73 1.5 0.94** 
4.73 6.6 6.9 2:2:1 26 74 1.5 1.28 
4.73 6.6 3.45 2:1:1 25 75 1.5 1.03* 
2.36 6.6 6.9 1:2:1 33 67 1.3 1.20 




 Data are representative of three experiments.  The ED50 values were 4.73, 13.2, and 6.9 
µM for 〈-TEA, t-RES, and MSA, respectively.  These values were treated as a 2:2:2 
ratio.  Other ratios were made with respect to the ED50 values.   
**:  Data represent synergistic effect 
*:  Data represent additive effect 
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Figure 2.1.  α-TEA, t-RES, and MSA induce apoptosis.  A: MDA-MB-435-F-L cells 
were treated with various individual or combined treatments of α-TEA, t-RES, and MSA 
for 72 h.  Cells were collected, DAPI stained, and analyzed for apoptosis. Data are the 
mean ± S.D. of three independent experiments.  * (CI = 0.682) and ** (CI = 0.465) 
indicates synergy in comparison to vehicle and individual treatments.  B:  MDA-MB-
435-F-L cells were treated for 6, 12, 24, and 48 h with α-TEA, t-RES, and MSA, alone or 
in combination.  Western immunoblotting was performed to evaluate PARP cleavage 
(p84) in response to treatments.  GAPDH was used to verify lane loading and to perform 
densitometric analyses.  Numerical value represents fold increase of combination over 
respective individual treatment.  Data are representative of 3 or more experiments. 
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Figure 2.2.  Dose-dependent DNA synthesis arrest.  Uptake of  [3H]-thymidine was used 
as a measure of DNA synthesis arrest.  MDA-MB-435-F-L cells were treated for 30 h 
with various concentrations of α-TEA, t-RES, and MSA to determine a dose response for 
each compound to induce DNA synthesis arrest.  ED50 values were 14.23, 19.8 and 1.16 
µM for α-TEA, t-RES, and MSA, respectively (indicated by the dashed line).  Data are 
mean ± S.D. of three independent experiments.  
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Figure 2.3.  Dose-dependent inhibition of colony formation.  MDA-MB-435-F-L cells 
were seeded at varying concentrations per well in laminin-coated wells and treated with 
varying concentrations of α-TEA, t-RES, and MSA for 72 h.  Treatment media was 
replaced with fresh media and cells were allowed to grow for nine days.  Surviving 
fractions were calculated as number of colonies present divided by number of cells 
seeded x plating efficiency.  ED50 values were 4.73, 13.2 and 6.9 µM for α-TEA, t-RES, 
and MSA, respectively (indicated by the dashed line).  Data are mean ± S.D of three 
independent experiments.  
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Figure 4.  Cell differentiation by α-TEA, t-RES, and MSA.  MDA-MB-435-F-L cells 
were treated with VEH, VES (40 µM), t-RES (88 µM), α-TEA (20.5 µM), MSA (10 µM), 
or a combination of t-RES + MSA + α-TEA for 12, 24, and 48 h.  Cells were analyzed 
for expression of neutral oil droplets using Oil Red O-stain.  Results are expressed as 
mean percentage of Oil Red O-stained cells ± S.D. of three independent experiments.  * p 




Chapter 3: α-TEA, trans-resveratrol, and selenium, alone and together, 
reduce human MDA-MB-435 tumor burden and metastases in a human 
MDA-MB-435 breast cancer xenograft model 
ABSTRACT 
α-TEA, methylselenocysteine (MSC) and trans-resveratrol (t-RES) alone were 
shown to be effective in inducing human MDA-MB-435 breast cancer cells to undergo 
cell death by apoptosis. Combinations of the three agents significantly enhanced DNA 
synthesis arrest and apoptosis (Chapter 2).  Studies reported here investigated the ability 
of α-TEA, MSC, and t-RES (low dose, 10 mg/kg bw; and high dose, 100 mg/kg bw) 
alone and in combination to reduce tumor burden and inhibit lung and lymph node 
metastases using human MDA-MB-435-F-L breast cancer cells transplanted into nude 
mice.  Two animal studies were conducted.  In study #1 all treatments significantly 
reduced tumor burden, in comparison to control, with the exception of high dose t-RES.  
High dose t-RES alone and in combination enhanced tumor growth in comparison to 
control and other treatments.  MSC was less effective than α-TEA or low dose t-RES in 
reducing tumor burden, and α-TEA alone was as effective as combination treatments in 
reducing tumor burden.  Analyses of tumor sections show α-TEA alone and in a two-way 
combination with MSC, as well as in three-way combinations to significantly enhance 
TUNEL positive cells.  α-TEA and both doses of t-RES alone significantly reduced Ki-
67 positive cells.  Treatments had no effect on CD31 positive cells.   α-TEA alone and in 
combination with MSA significantly reduced the average number of visible lung 
metastases.  All treatments significantly reduced the total number of lung micrometastatic 
lesions, and with the exception of low dose t-RES, lymph node metastases.  Study #2 was 
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conducted to determine if the ability of high dose t-RES to enhance tumor growth was 
repeatable.  The tumor burden data was not repeatable in that both low and high dose t-
RES significantly reduced tumor burden.  Both doses of t-RES significantly reduced 
average number of visible lung metastases, as well as micrometastatic lung and lymph 
node lesions.  In summary, these data do not support the use of α-TEA with MSA or t-
RES over α-TEA alone in treatment of human breast cancer.  
INTRODUCTION 
Cancer is the most common cause of death for women under the age of 85 in the 
U.S.  It is estimated that breast cancer specifically will have the highest incidence of 
reported new cases in 2006 (32%) and will be responsible for about 15 percent of cancer 
deaths in women [1].  Without question, it is necessary to find ways to treat and prevent 
breast cancer, preferably via methods that involve little to no toxicity. 
A novel, non-hydrolyzable ether analog of RRR-α-tocopherol, 2,5,7,8-
tetramethyl-2R-(4R, 8R-12-trimethyltridecyl)chroman-6-yloxyacetic acid (called RRR-α-
tocopheryloxyacetic acid or RRR-α-tocopherol ether-linked acetic acid analog and 
abbreviated α-TEA) was synthesized based on a desire to develop a clinically useful 
vitamin E-based chemotherapeutic agent.  α-TEA is capable of inducing human ovarian 
(A2780/cp-70), cervical (ME-180), breast (MCF-7, MDA-MB-231, MDA-MB-435), 
endometrial (RL-952), prostate (LNCaP, PC-3, DU-145), lung (A-549), colon (HT-29, 
DLD-1) and lymphoid (Raji, Ramos, Jurkat) cells to undergo apoptosis [38].  α-TEA 
does not induce apoptosis in normal human mammary epithelial cells or normal PrEC 
human prostate epithelial cells [38-40, 42].   Preclinical animal studies show α-TEA to be 
effective at reducing tumor burden and metastasis [39-44]. 
trans-Resveratrol (3,5,4’-trihydroxy-trans-stilbene; t-RES) is a naturally 
occurring phytoalexin that can be found in a variety of foods such as red grapes, wine, 
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berries, medicinal plants and peanuts [46-53].  This antioxidant is considered a promising 
chemotherapeutic agent based on its ability to inhibit free radical formation [46-49], and 
to induce differentiation and apoptosis in promyelocytic leukemia cells [47-48], colon 
cancer cells [48-49], and breast cancer cells [48, 50] in vitro.  t-RES has been shown to 
inhibit the development of 7,12-dimethylbenz(a)anthracene (DMBA) induced 
hyperplastic and atypical preneoplastic lesions in the mouse mammary organ culture 
model, (MMOC) [47-48, 53] and N-methyl-N-nitrosourea (NMU) induced mammary 
lesions in rats with no observed toxicity in vitro and in vivo [47-49, 51, 53].   
Selenium is an essential nutrient for humans that can be found in cereal grains, 
meats, and seafood and is required for more than 13 human enzymes and proteins, in the 
form of L-selenocysteine [61].  Dietary supplementation of selenium beyond the 
recommended dietary allowance of 55 µg/day for women and 70 µg/day for men, at up to 
200 µg/day reduces the incidence of lung, colorectal, and prostate cancer in humans [61, 
63-65, 68].  One particularly active form, Se-(Methyl)selenocysteine (MSC), has been 
shown to be an effective suppressor of chemically induced mammary carcinogenesis in 
rats [62, 64-68, 71].  In vivo, MSC is converted to methylselenol by β-lyase in the kidney 
and liver [64, 71].   
Due to the chemotherapeutic actions of α-TEA, t-RES and MSC, alone, and cell 
culture data showing that a combination of these three agents synergistically enhanced 
apoptosis in human MDA-MB-435 breast cancer cells, preclinical animal studies were 
conducted to evaluate the combination effects of the three agents in the highly metastatic 
human breast MDA-MB-435-F-L cell line growing in immune compromised nude mice.  
Study #1 evaluated the three agents separately and in combination for ability to inhibit 
human MDA-MB-435 breast cancer tumor growth and metastases.  An unexpected 
finding from Study #1 was that high dose t-RES (100 mg/kg/bw) enhanced tumor growth.   
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Study #2 was conducted, using two doses of t-RES, to determine if high-dose t-RES 
enhanced tumor growth found in Study #1 was repeatable.   
MATERIALS AND METHODS 
Chemicals and Reagents 
Se-(methyl)selenocysteine hydrochloride (MSC) was purchased from Sigma 
Chemical Co. (St. Louis, MO).  trans-Resveratrol (t-RES) was purchased from Cayman 
Chemical Co. (Ann Arbor, MI).  Neobee oil was purchased from Stepan (Anaheim, CA).  
α-TEA was synthesized, purified, and characterized in house. For scaled-up production, 
α-TEA was prepared as previously described [40].   
Cell Lines and Culture Conditions 
MDA-MB-435-F-L (a kind gift from Dr. LuZhe Sun, University of Texas Health 
Science Center, San Antonio, TX) cells are an estrogen-receptor-negative human breast 
cancer cell line. MDA-MB-435-F-L cells are MDA-MB-435 cells that have been stably 
transfected with enhanced green fluorescent protein (GFP) by Dr. LuZhe Sun.  These 
cells were then injected into the flank of a nude mouse and removed from a metastasis to 
the lung.  Prior to use in the nude mouse studies, cells were sent to the University of 
Missouri Research Animal Diagnostic and Investigative Laboratory (RADIL; Columbia, 
MO) and were certified to be pathogen free.  
MDA-MB-435-F-L cells were cultured in McCoys’s 5A medium (Life 
Technologies, Inc., Grand Island, NY) supplemented with 10% FBS plus 100 µg/ml 
streptomycin, 100 IU/ml penicillin, 1X (v/v) nonessential amino acids, 1X (v/v) MEM 
vitamins, 1.5 mM sodium pyruvate, and 50 µg/ml gentamycin (Sigma). Cell lines were 
routinely examined to verify absence of mycoplasma contamination. 
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Nude Mice 
Female NU/NU homozygous mice (approximate 23 g in weight) were purchased 
from Charles River Laboratories (Wilmington, MA) at 6 weeks of age and were allowed 
to acclimate for one week.  Animals were housed in the Transgenic Suite at the Animal 
Resource Center at the University of Texas at Austin at 74 ± 2°F with 30-70% humidity 
and a 12 hour alternating light-dark cycle.  Animals were housed 5/cage and given water 
and diet ad libitum.  The diets for study # 1 and #2 were Teklad 2018 and Teklad 7012, 
respectively.   Guidelines for the humane treatment of animals were followed as approved 
by the University of Texas Institutional Animal Care and Use Committee. 
Tumor Cell Inoculation and Treatment Groups 
MDA-MB-435-F-L cells were harvested by trypsinization, centrifuged, and 
resuspended in McCoy’s media containing no supplements and at a density of 1 x 
10
6
/100µl.  Mice were injected subcutaneously in the inguinal area at a point equal 
distance between the 4th and 5th nipples in the right side using a 23-gauge needle. 
Study 1:  Twenty-one days after tumor inoculation, 80 mice were assigned (10 per 
group) to one of the following eight groups: control, α-TEA, MSC, low t-RES (10 mg/kg 
bw), high t-RES (100 mg/kg bw), α-TEA+MSC, low combination (α-TEA + MSC + low 
t-RES), or high combination (α-TEA + MSC + high t-RES).  Study 2: mice were 
assigned 18 days post inoculation as described above to one of three groups: control, low 
t-RES (10 mg/kg bw), or high t-RES (100 mg/kg bw).  The average tumor volumes for all 
groups were closely matched and the average tumor volume was 18.94 and 21.07 mm3 in 
studies 1 and 2, respectively.  Animals in groups receiving α-TEA were given α-TEA 
formulated in liposomes and delivered via aerosol, depositing approximately 36 µg/α-
TEA into the respiratory tract/mouse daily; those receiving MSC were gavaged daily at 3 
ppm MSC dissolved in sterile filtered milli-Q water, and those receiving t-RES were 
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gavaged daily with either 10 or 100 mg/kg bw dissolved in 6.5% EtOH and 93.5% 
Neobee oil.  The control group was given aerosolized liposome, sterile-filtered milli-Q 
water, and the t-RES solvent.  Treatments were given 7 days per week and tumors were 
palpated using calipers every other day.  Tumor volumes were calculated using the 
formula: volume (mm3) = [width (mm)2 x 1ength (mm)]/2 [94].  Body weights were 
determined weekly. 
Preparation of MSC for Delivery by Gavage 
It was determined that each mouse would be gavaged a volume of 100 µl daily 
and receive 3 ppm MSC [66-67].  This was determined to be equal to 12 µg MSC based 
on an estimate that an average mouse eats four grams of food per day.  A stock solution 
was made by dissolving MSC in sterile filtered milli-Q water at a concentration of 120 
µg/ml.  The solution was aliquoted into sterile eppendorf tubes and stored at –20°C until 
needed.  Control treatments consisted of sterile filtered milli-Q water.  Prior to delivery, 
aliquots were brought to room temperature 
Preparation of t-RES for Delivery by Gavage.   
It was determined that each mouse would receive 10 or 100 mg/kg bw [53].  
Treatments of t-RES were made weekly and amounts of t-RES were adjusted based on 
the weight of the animals.  t-RES was dissolved in 100% EtOH and then mixed with 
Neobee oil to give a final solution of 6.5% EtOH and 93.5% Neobee oil.  Control 
treatments consisted of 6.5% EtOH and 93.5% Neobee oil, as contained in the t-RES 
treatments [53].  Solutions were aliquoted into sterile eppendorf tubes and stored at –
20°C until needed.  Prior to delivery, aliquots were brought to room temperature.  
 64
Preparation of α-TEA Liposomes for Delivery by Aerosol.   
Preparations of α-TEA liposomes were made as previously described [40-44].  
An α-TEA/liposome ratio of 1:3 (w/w) was determined empirically to be optimal by 
methods previously described [96].  To prepare the α-TEA/lipid combination, the 
components were first brought to room temperature.  The lipid [1,2-dilauroyl-sn-glycero-
3-phosphocholine (DLPC); Avanti Polar-Lipids, Inc., Alabaster, AL], at a concentration 
of 120 mg/ml, was dissolved in t-butanol (Fisher Scientific, Houston, TX) then sonicated 
to obtain a clear solution.  α -TEA at 40 mg/ml was also dissolved in tertiary-butanol and 
vortexed until all solids were dissolved.  The two solutions were then combined in equal 
amounts (v:v) to achieve the desired ratio of 1:3 α -TEA/liposome, mixed by vortexing, 
frozen at -80° C for 1-2 h, and lyophilized overnight to a dry powder prior to storing at -
20°C until needed.  Each treatment vial contained 75 mg α -TEA.  
Aerosol Delivery.   
Aerosol was administered to mice as previously described [40-44].  Briefly, an air 
compressor (Easy Air 15 Air Compressor; Precision Medical, Northapton, PA) producing 
a 10 L/min airflow was used with an Aero Tech II nebulizer (CIS-US, Inc. Bedford, MA) 
to generate aerosol.  The particle size of α-TEA liposome aerosol discharged from the 
AeroTech II nebulizer was determined by the Anderson Cascade Impactor to be 2.01-µm 
mass median aerodynamic diameter (NMAD), with a geometric standard deviation of 
2.04.  About 30% of such particles when inhaled will deposit in the respiratory tract of 
the mouse and the remaining 70% will be exhaled [96].  Prior to nebulization, the α-
TEA/lipid powder (75 mg/vial) was brought up to room temperature then reconstituted by 
adding 3.75 ml sterile filtered milli-Q water to achieve the final desired concentration of 
20 mg/ml α-TEA.  The mixture was allowed to swell at room temperature for 30 min 
with periodic inversion and vortexing, and then transferred to the reservoir of a nebulizer.  
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Mice were placed in clear plastic cages (7 x 11 x 5 in.) with a sealed top in a safety hood.  
Aerosol entered the cage via a 1 cm (i.d.) accordion tube at one end and discharged at the 
opposite end, using a one-way pressure release valve.  Animals were exposed to aerosol 
until all α-TEA/liposome was aerosolized (approximately 20 min).   
Aerosol Characteristics of α-TEA Incorporated into Liposomes.   
HPLC analyses were conducted on α-TEA liposomes recovered from aerosol in 
the All Glass Impinger (Ace Glass Co., Vineland, NJ).  The delivered dosage = 
concentration (µg/L) x mouse minute volume (1-min/kg) x duration of delivery (min) x 
estimated deposited fraction (30%; [96]).  Based on this formula, we estimate that 36 µg 
of α-TEA was deposited in the respiratory tract of each mouse each day.  Thus, for the 
43-day treatment period, we estimate that each mouse received 1548 µg of α-TEA from 
liposomal delivery.  For this same period, animals in the MSC group received 516 µg 
MSC (12 µg/day), and those in the t-RES group, were given 9.23 and 92.3 mg t-RES for 
the low and high dose groups, respectively. 
Lung and Lymph Node Metastases.   
Metastatic lesions in the five lung lobes were counted visually at time of sacrifice.  
Fluorescent green micro-metastatic cancer cell colonies in the left lung lobe and lymph 
nodes were counted using a Nikon fluorescence microscope (TE-200) with a 20X 
objective (200X magnification) as previously described [40-44].  Prior to counting, lungs 
were flattened and both sides (top and bottom) were counted.  Lymph nodes were 
flattened and one side was counted.  Fluorescent lesions were separated into four sizes:  
<20 µm, 20-50 µm, 50-100 µm, and >100 µm.  The size of a MDA-MB-435-F-L cell is 
10-20 µm in diameter so it is thought that the <20 µm group represents single cells and 
larger groups involve larger and larger clusters of cells. 
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H&E Staining of Tumor Tissue.   
Tumors were fixed with 10% neutral buffered formalin, and embedded in paraffin 
according to standard histological procedures.  H&E stained 5 µm thick sections were 
used to examine tumor morphology. 
Terminal Deoxynucleotidyl Transferase-mediated Nick End Labeling (TUNEL) 
Assay for Detection of Apoptosis in Vivo.   
Deparaffinized sections (5 µm) of tumor tissue were processed as previously 
described [40] using reagents supplied in the ApopTag In Situ Apoptosis Detection Kit 
(Intergen, Purchase, NY) according to the manufacture’s instructions.  Nuclei that stained 
brown were scored as positive for apoptosis and those that stained blue were scored as 
negative.  At least sixteen 400X microscopic fields were scored per tumor.  Data are 
presented as the mean ± S. E. number of apoptotic cells counted (n = 4).   
Ki-67 Staining for Detection of Proliferation in Vivo.   
Deparaffinized sections (5µm) of tumor tissue were processed as previously 
described [40].  Briefly, endogenous peroxidase activity was blocked using a 3% H2O2 
solution for 10 min followed by washing with PBS.  Ten-percent rabbit serum in PBS 
was applied to sections in order to clock non-specific antibody binding.  Sections were 
incubated with Ki-67 antibody (1:200) dilution overnight at 4°C.  After primary antibody 
incubation, slides were incubated with biotinylated rabbit-anti-rat IgG (Vector 
Laboratories, Burlingame, CA) at a 1:200 dilution for 30 min at room temperature.  
Sections were then incubated with avidin-biotin complex (ABC-HRP, Vector 
Laboratories) for 30 min at room temperature.  Immunoreactivity was visualized via 
incubation with Di-aminobenzidine Dihydrochloride (DAB).  Slides were lightly 
counterstained with hematoxylin. Nuclei that stained brown were scored as positive for 
apoptosis and those that stained blue were scored as negative.  At least sixteen 400X 
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microscopic fields were scored per tumor.  Data are presented as the mean ± S. E. 
number of apoptotic cells counted (n= 4). 
CD31 Staining for Determination of Blood Vessel Formation in Vivo. 
 Deparaffinized sections (5µm) of tumor tissue were processed as previously 
described [40, 43] to detect the intratumoral microvessel density based on the “hot spot” 
method [97].  Areas of highest microvascularization were found by scanning tumor 
sections at low magnification (200X) with a light microscope.  Areas with the greatest 
density staining were selected and microvessel counts were made using a 400X field.  
Ten fields were counted for each tumor section.  Data are presented as mean ± S. E. 
(n=4). 
Statistical Analyses.   
Animal numbers for experiments were determined to be adequate based on power 
calculations.  Tumor growth was evaluated by transforming volumes using a logarithmic 
transform (base 10) and analyzed using a nested two-factor ANOVA using SPSS (SPSS, 
Inc., Chicago, IL).  Statistical significance for macroscopic and microscopic metastases, 
TUNEL, Ki-67 and CD31 were determined using a two-tailed Mann-Whitney rank test in 
Prism software version 4.0 (Graphpad, San Diego, CA).   A level of p < 0.05 was 
considered statistically significant. 
RESULTS 
Treatment Effects on Tumor Growth.   
Study 1. All treatment groups significantly reduced tumor burden in comparison 
to control  (P < 0.001 for all) with the exception of high-dose t-RES and combination 
treatment with high-dose t-RES.  Tumor volume of mice receiving the combination of α-
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TEA + MSC + high dose t-RES were slightly larger than tumor volume of control (Fig 
1).   Average tumor volumes of the MSC and α-TEA groups, compared to the control 
group at sacrifice, were reduced 0.13 and 59.7%, respectively (Fig. 1).  The low t-RES 
and the low combination groups reduced average tumor volumes 23.5 and 52.6%, 
respectively (Fig. 1).  Average tumor volumes were enhanced 15.1 and 108.2% by the 
high combination, and high t-RES groups, respectively, and reduced 51.4% by α-TEA + 
MSC treatment (Fig 1).  Study 2. This animal study, utilizing low and high dose t-RES, 
was conducted to determine if the unexpected finding that high-dose t-RES to enhance 
tumor burden was repeatable.   Both doses of t-RES significantly reduced tumor volume 
in comparison to control (low-dose t-RES, P< 0.0001; and high-dose t-RES, P < 0.0001; 
Fig 2).    Average tumor volumes at the low- and high-dose t-RES, in comparison to 
control, at sacrifice were reduced 25.6 and 42 %, respectively (Fig 2).  No differences in 
mean body weight among any of the groups for study 1 and study 2 were observed (data 
not shown). 
Treatment Effects on Visible Lung Metastases.   
Study 1. At sacrifice, all lung lobes were examined for visible metastasis.  The 
average number of visible lung tumors was significantly reduced by treatments with α-
TEA (P <0.0147) and α-TEA + MSC (P < 0.0185) (Table 1).  Study 2. The average 
number of visible lung tumors were significantly reduced by both low- and high-dose t-
RES (low dose, P < 0.0119; high-dose, P < 0.0013), respectively Table 1).  Percent 
inhibition of multiplicity was reduced 45 and 67 percent in low t-RES and high t-RES 
groups, respectively (Table 1).  
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Treatment Effects on Apoptosis, Cell Proliferation, and Blood Vessel Density.   
TUNEL assay was used to detect apoptosis, Ki-67 assay to detect cell 
proliferation, and CD31 to detect an increase in blood vessel density as an indicator of 
angiogenesis in tumor tissue sections from control and treatment groups.    α-TEA, α-
TEA + MSC,  α-TEA + MSC + low-dose t-RES, and α-TEA + MSC + high-dose t-RES  
significantly enhanced apoptosis in comparison to control (P < 0.0286 for all; Fig. 3A). 
The average number of Ki-67 positive nuclei was significantly reduced by treatments 
with α-TEA, low-dose t-RES, and high-dose t-RES (P < 0.0286 for all treatments).  
Combination treatments did not significantly reduce Ki-67 positive cells (Fig 3B).   
Blood vessel density was not significantly different among control and treatment groups 
(Fig 3C).    
Treatment Effects on Lung and Lymph Node micrometastatic lesions. 
Study 1.  Total number of lung micrometastatic lesions were significantly reduced 
in all treatment groups with the exception of low-levels of t-RES [α-TEA, P < 0.023; 
MSC P < 0.0052, high t-RES P < 0.0185,  α-TEA + MSC P < 0.0011, α-TEA + MSC + 
low-t-RES P < 0.0355, and α-TEA+ MSC + high t-RES P < 0.0003, respectively (Table 
2)].  Likewise, the total number of axillary and brachial lymph node metastatic lesions 
were significantly reduced in all treatment groups with the exception of low-level t-RES 
treatment [α-TEA, P <0.0066; MSC P <0.0023, high t-RES P <0.003, α-TEA + MSC P 
<0.0019, α-TEA + MSC + low-t-RES P < 0.0002, and α-TEA+ MSC + high t-RES P < 
0.0002, respectively (Table 2)].  Study 2.  Lung micrometastatic lesions were 
significantly reduced by both low-and high-dose t-RES treatments in comparison to 
control.  (low-t-RES, P < 0.0094; high-t-RES, P < 0.0266).  Likewise, lymph node 
micrometastatic lesions were significantly reduced by both treatments (low and high t-
RES, P < 0.0001). 
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DISCUSSION 
The focus of our lab has been on the development of α-TEA as a stand alone as 
well as companion drug for treatment and prevention of cancers.  Rationale for 
conducting preclinical animal studies using combinations of α-TEA, MSC, and t-RES 
came from encouraging data from cell culture studies showing that combinations of these 
three compounds induced apoptosis in human MDA-MB-435 breast cancer cells in a 
synergistic manner (Chapter 2).   Two animal studies were conducted.   In study #1, with 
the exception of high-dose t-RES and the combination containing high-dose t-RES, all 
treatments significantly reduced tumor burden.  Surprisingly, high-dose t-RES 
significantly enhanced tumor growth in comparison to control and all treatment groups.  
Synergisms obtained with combination treatments in cell culture were not obtained in 
these animal studies, α-TEA was more effective than both combination treatments in 
reducing tumor burden.  All treatments, except low-dose t-RES, were effective in 
reducing lung and lymph node metastases; however, there were no significant differences 
among single and combination treatment groups.  Although MSC was the less effective 
than α-TEA or low-dose t-RES in reducing tumor burden, MSC was equally effective in 
reducing metastases.   High-dose t-RES in a second animal study significantly reduced 
tumor burden rather than enhanced tumor growth.  
  The anticancer effects of individual treatments on tumor volume reported here 
are consistent with reports in the literature, with the exception of high-dose t-RES.  α-
TEA decreases tumor burden and metastases significantly from control in ovarian [44], 
breast [38, 40-43], and prostate cancer models (Jia, Manuscript in Preparation). t-RES 
reduces metastases [98], induces apoptosis [99] and reduces tumor burden in vivo [99]. 
Consistent with cell culture studies (Chapter 2), in vitro data show t-RES to inhibit cell 
proliferation [48-50, 52-53].  In study #2, high and low dose t-RES reduced tumor burden 
 71
in a manner consistent with the literature.  MSC has been shown to be an effective 
suppressor of chemically induced mammary carcinogenesis in rats [61, 63-68].  
The ability of high-dose t-RES to enhance tumor growth, with one exception, is 
not consistent with the literature.  Sato et al reported a similar differential response to t-
RES in prepubescent rats [100].  In their study, rats were given control, 10mg/kg bw or 
100 mg/kg bw t-RES for 5 consecutive days prior to an injection of 50mg/kg MNU.  
Control and treated mice were evaluated for tumor incidence and tumor volume for 33 
weeks.  Prior treatment with high-dose t-RES, in comparison to low-dose t-RES and 
control, significantly increased the incidence of mammary carcinomas greater than 1 cm 
in diameter [100].   The ability of high-dose t-RES to increase tumor growth reported in 
this paper, and the literature showing that pretreatment with high-dose t-RES prior to 
carcinogen treatment accelerates mammary cancer occurrence are not understood but 
have important implications that require further study.  
Inhibition of metastases is perhaps just as important as the effect an agent has on 
primary tumors since the majority of cancer deaths result from metastases [87].  The 
mechanisms whereby high-dose t-RES increases tumor growth, but reduces lung and 
lymph node metastases are also not understood.  Likewise, it is not understood how MSC 
was more effective in inhibiting metastasis than tumor burden.  Perhaps t-RES and MSC 
are more effective in inhibiting smaller tumors or are inhibiting tumor cell migration.  
Mechanistically, α-TEA alone and in combination with MSC or the three agents kill 
tumor cells by induction of apoptosis.  
Growth rates of tumors in control mice in study #2 were much slower than control 
tumors in study #1, even though the tumor sizes in the two studies were equal at the start 
of treatments.  Also, tumor sizes in studies #1 and 2 were smaller when compared to 
published data from our lab using the same MDA-MB-435-F-L cell line, mice from the 
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same source and age and housed in the same environment [43].  Control tumors in 
experiment 1 were 52% smaller (101 mm3) and those in experiment 2 were 60% smaller 
(84 mm3) after 31 days compared to those seen by Zhang et al (212 mm3) [43].  The only 
discernable difference between these studies was the diets.  Animals treated by Zhang et 
al were fed gamma-irradiated AIN-76A diet, those in experiment 1 an autoclavable 
Teklad 2018 diet, and those in experiment 2 were fed Teklad 7012 diet.  The general 
content of the three diets is very similar.  All three have similar percentages of protein 
(19, 19, and 20% for 7012, 2018, and AIN-76A, respectively) and fat (5, 4, and 5%, 
respectively).  The largest difference between these diets is the concentration of 
isoflavones, a class of phytoestrogens called isoflavonoids [101].   The 7012 diet has 
nearly twice as many isoflavones as the 2018 diet (400 ppm v 207 ppm), and both have 
more than the AIN-76A diet, which has undetectable levels of isoflavones because the 
protein source is casein [101-102].  Previous studies have shown that diets containing 
isoflavones can reduce mammary tumors in animal models [101-104], in some cases by 
as much as 40% [101-103].  This is consistent with the trend in our data showing smaller 
tumors with higher levels of isoflavones in the diet.  Many reports accredit the reduction 
in tumor volume to genistein and daidzein [87, 103], the main isoflavones in soy [102].  
Genistein has been shown to significantly reduce the latency, incidence, and tumor 
number in DMBA treated rats [102] and to inhibit the proliferation of human tumor cell 
lines in vitro [102].  There are also reports that genistein’s effect on mammary cancers is 
diet dependent [105].  In one study, animals fed the AIN-76A diet showed no protection 
from MNU-induced breast cancer, but those fed Teklad 4% diet (containing genistein) 
had 44-61% fewer lesions [105].  The levels of genistein and daidzein in rodent chow are 
in the same range for that found in human soy products like tofu and soy flour.  Species 
differences in uptake, distribution, and elimination could affect the potency, but 
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correlation from human epidemiology studies find that phytoestrogens, specifically from 
soy, can decrease human cancer risk [106], suggesting a similar relationship between 
tumor volume and phytoestrogen intake in rodents and humans.  The difference in 
isoflavone content might also account for the difference in t-RES tumor response.  These 
isoflavones could act as antagonists to t-RES, preventing the uptake and decreasing the 
bioavailability of t-RES or yield effects of their own that affect tumor growth in addition 
to those arising from t-RES administration. 
Another difference between studies 1 and 2 was that the 7012E diet in experiment 
2 was autoclaved, but not the 2018 diet in study #1.  Despite containing extra vitamins to 
account for nutrient loss during autoclaving, it has been shown that irradiated diets 
maintain higher levels of intact nutritional components when compared to autoclaved 
diets [107].  Susceptible targets of autoclave breakdown are essential fatty acids (EFAs), 
which are known to drive tumor growth [108-111].  If these were destroyed during 
autoclaving, then their absence could be responsible for the slower tumor growth rates in 
control and treatment mice in study  #2.   Irradiated diets do not increase temperature 
significantly (5˚c at 2.4 Mrad) nor do they significantly alter proteins, amino acids, or 
PUFAs [107], which may make them a more ideal choice for future animal studies. 
Upon analysis of the diets pre-autoclave using information provided by the 
manufacturer, both diets contained similar levels of EFA (7012 diet had 33.8 and 3.5 g/kg 
linoleic and linolenic acids, while the 2018 had 31.4 and 2.8 g/kg linoleic and linolenic 
acids [107]).  If EFA were destroyed in autoclaving, then perhaps there were more EFA 
in the 2018 diet.  Several studies have shown that linoleic acid can drive MDA-MB-435 
tumor growth, incidence and multiplicity [108, 110-111], metastases [108, 110-111] and 
tumor cell invasion in vitro in MDA-MB-435 and MDA-MB-231 cell lines [109].  In all 
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of these studies, irradiated diets were used to minimize the risk or nutrient deterioration 
[108-111].  
If differences in the results of in vivo studies can be diet-dependent, it is important 
to note that the nutritional value of any diet can change over time.  Nutritional values and 
sources for components will vary by plant source, species differences, geographical 
location grown, season grown, time of harvest, and method used to process the 
ingredients [101, 106, 112].  Differences in isoflavone content alone can vary greatly 
between varieties of soybeans (116-309 mg/g between species) and 46-195 mg/g within 
the same variety grown in different locations [101, 113].  Because these studies were 
performed far apart in time, actual diet samples were not taken and analyzed at the time 
of the study that could have allowed insight into the actual nutritional content of our 
diets.   
Further work into the mechanism of action for α-TEA alone and in combination 
with MSA and t-RES are needed.  Perhaps the knowledge gained from these studies can 
help to explain the apparent differences that we have seen in vitro and in vivo.  Future 
work will also investigate the effects of α-TEA in combination with t-RES, without 
MSC.  Another reason to look into the α-TEA and t-RES combination is that both 
compounds appear to be effective chemopreventive agents so one could hope that their 
combination would prove more beneficial than either of the two alone.   
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Table 3.1: α-TEA, MSC, and t-RES treatments alone or together reduce visible lung 
metastases 
 





















Control 8/10 4.4 ± 1.0 12/12 5.8 ± 0.9 
α-TEA 5/10 1.0 ± 0.4*   
MSC 6/10 1.3 ± 0.4*   
t-RES (low) 10/10 5.8 ± 0.8 12/12 3.2 ± 0.5* 
t-RES (high) 8/10 2.6 ± 0.8 8/12 1.9 ± 0.6* 
α-TEA + MSC  6/10 1.1 ± 0.4*   
α-TEA + MSC  
+ t-RES (low) 
6/10 2.6 ± 0.8   
α-TEA + MSC  
+ t-RES (high) 
6/10 1.9 ± 0.8   
 
* Designates significant difference from control. Study #1:Average # macroscopic lung 
tumor foci (α-TEA P <0.0147; MSC, P < 0.023; α-TEA + MSC, P <  0.0185.  Study #2: 
Average # macroscopic lung tumor foci t-RES low, P < 0.0119; t-RES high, P < 0.0013).   
a α-TEA was formulated into liposomes and delivered daily (7 days/week) by aerosol, 
MSC and t-RES were fed daily (7 days/week) by gavage 
b Macroscopic lesions in all lung lobes in control and treatment groups were counted 
visually at the time of sacrifice 
c Data are expressed as the average number of macroscopic lung tumor foci observed in 





Table 3.2: Comparison of Microscopic Metastatic Lesions After Treatment with α-TEA, 
MSA, and t-RES Separately and Together 
 









Total   (p value)
Control 56 41 12 4 113 
α -TEA 40* 22* 12 3 78*    (0.0232)
MSC 40 24* 8* 3 75*    (0.0052)
Low t-RES 32* 28 11 4 76 
High t-RES 42 24* 5* 2 73*    (0.0185)
α -TEA  
+ MSC 
32* 21* 7 2 62*    (0.0011)
Low 
Combination 






29* 20* 7* 1* 58*    (0.0003)
Control 9 7 0 0 16 
α -TEA 5* 4* 0* 0 9*      (0.0066)
MSC 5* 3* 0 0 8*      (0.0023)
Low t-RES 7 5 0 0 13 
High t-RES 3* 3* 0 0 7*      (0.0003)
α -TEA  
+ MSC 
5* 3* 0 0 8*      (0.0019)
Low 
Combination 








4* 3* 0 0 7*      (0.0002)
Lungs and lymph nodes removed at sacrifice were evaluated under fluorescent 
microscopy for microscopic metastases.  Metastases were grouped into four size 






Table 3.3.   Comparison of Microscopic Metastatic Lesions After Treatment with t-RES 









Total    (p value) 
Control 101 40 6 3 151 
Low t-RES 53 20* 5 2 80*     (0.0094) 
Lung 
Microscopic 
Metastases High t-RES 48* 22 7 2 78*     (0.0226) 
Control 24 13 5 1 43 






High t-RES 8* 3* 1* 0 11*     (0.0001) 
Lungs and lymph nodes removed at sacrifice were evaluated under fluorescent 
microscopy for microscopic metastases.  Metastases were grouped into four size 
classifications.  Values were rounded to the nearest integer.  * indicates significance (p < 
0.05) 
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Figure 3.1.  Study 1:  MDA-MB-435-F-L Tumor Volume.  Athymic nu/nu mice were 
injected with 1 x 106 MDA-MB-435 GFP FL cells.  Following establishment of tumors, 
treatments were given daily for 43 days.   = control,  = MSC, = α-TEA, ✕ = low t-
RES,  = low combination,  = high t-RES,  = high combination,  = α-TEA + 
MSC.  Statistical analyses compared treatment groups to the control group in SPSS. 
Volumes reflect mean tumor volume +/- S.E. * p < 0.05 was considered significant.  
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Figure 3.2.  Study 2:  MDA-MB-435-F-L Tumor Volume. Athymic nu/nu mice were 
injected with 1 x 106 MDA-MB-435 GFP FL cells.  Following establishment of tumors, 
treatments were given daily for 43 days.  = control, ✕ = low t-RES,  = high t-RES. 
Statistical analyses compared treatment groups to the control group in SPSS.  Volumes 
reflect mean tumor volume +/- S.E. * p < 0.05 was considered significant. 
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Figure 3.3  Study 1: Effects of α-TEA, MSA, t-RES on MDA-MB-435-F-L tumors. 
Immunohistochemistry for increased apoptosis, reduced cell proliferation and reduced 
blood vessel density was performed on 5 µm sections of tumors taken from animals in all 
groups (n = 4).  A and B, The number of positive nuclei were scored in 16 separate 
microscopic fields (x400) of each slide/tumor.  The data are depicted as mean +/- S.E. of 
number of TUNEL and Ki-67 positive nuclei per field.  C.  The number of CD31 positive 
staining blood vessels was scored for each slide/tumor using the ‘hotspot’ method for 10 
separate microscopic fields. * designates a significant increase in positive cells compared 
to control (p < 0.05). 
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Chapter 4: α-TEA, methylselininic acid, and trans-resveratrol: potential 
chemopreventive agents when given in combination  
ABSTRACT 
Epidemiological studies suggest that diet can account for as much as 30% of 
cancers.  Since diet is a relatively easy risk to reduce in humans and because tumors take 
years to develop, there are many opportunities for intervention in this process.  Here we 
evaluate the effectiveness of several natural compounds, α-TEA, MSA and t-RES, to 
inhibit the formation of DMBA-induced lesions in the MMOC model and to prevent 
MNU-induced lesions in a rat mammary carcinogenesis model.  In the MMOC model, α-
TEA, MSA and t-RES were each effective at inhibiting the incidence and multiplicity of 
alveolar lesions and the multiplicity of ductal lesions.  Four combinations of co-
treatments were also made and analyzed for increased efficacy over individual 
treatments.  A combination of α-TEA + t-RES was most effective against alveolar and 
ductal lesions.  Based on these results, α-TEA + t-RES were combined in the MNU-
induced rat mammary carcinogenesis model.  Treatments lasted for 39 days at which time 
there were 45, 55 and 65% fewer tumors in the α-TEA, t-RES and Co-tx groups 
compared to the control.  Even though a statistical difference was not seen between Co-
tx, α-TEA and t-RES, the co-treatment group had 36% fewer tumors than α-TEA and 
22% fewer than t-RES.  Weight loss was also looked at in this study as a measure of 
toxicity.  Neither α-TEA nor t-RES caused significant weight loss, nor did α-TEA cause 
significant loss in tissue weight for spleen, heart, ovaries/uterus, lungs or kidneys.  




Cancer is a major public health problem in the U.S. and in developed countries.  
Currently, one in four deaths in the U.S. are due to cancer [1].   The precise number of 
cancer cases diagnosed each year in the U.S. is unknown since complete cancer 
registration has not been achieved [1].    However, based on data available, estimates are 
that 1.4 million new cases of invasive cancer will occur this year, of which over 214,000 
will be new cases of breast cancer [1].    Prevention of new cases of cancer is a major 
challenge, and the failure to reduce the trend in cancer incidence from year to year point 
to the urgent need for new agents with low toxicity that can be used by high risk 
individuals for several years to a life time.   
Chemoprevention can be defined as an intervention in the tumorigenic process by 
a natural or synthetic compound.  Specifically, it is an agent that can block the early 
stages of initiation, pre-malignant development, and/or arrest malignant cell progression 
[38].  Transgenic murine models and chemically induced cancers in mice and rats serve 
as useful models for studying potential chemoprevention agents.  Most chemically 
induced mammary chemoprevention animal models use either DMBA or MNU to induce 
lesions in vivo or in mouse mammary organ culture (MMOC).     
The MMOC model is an ex vivo chemoprevention model that can be used to 
screen potential preventive agents on the very early stages of chemically induced lesion 
formation [114].  Studies have shown that there is a high correlation between agents that 
show chemopreventive activity in this model with those that show activity in the two-
stage skin carcinogenesis and the chemically induced rodent mammary carcinogenesis 
model [114].  MMOC can be adapted to target lesions to be either alveolar or ductal in 
origin and both methods consist of three main phases: pre-treatment, growth, and 
regression [80-82, 114].   
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A short-term rat carcinogenesis model has been developed by Thompson et al 
[79, 83, 86] that allows for rapid induction of premalignant and malignant stages of 
mammary carcinogenesis using 50 mg/kg bw MNU [79, 83].  The main difference 
between this model and the conventional rat model is the age at which the rats are 
injected (21 d versus 50 d), which allows for the experiment to be completed in 35 d 
compared to 6 months in the conventional model [79, 83].  In this short-term model, 
greater than 90% of animals injected with MNU have a spectrum of premalignant and 
malignant lesions greater than 1 mm2 in their abdominal-inguinal mammary glands 35 d 
post-carcinogen [79].  
Histological classification of the rat whole mount lesions is based on 
classification criteria published by Russo et al [115].  Lesions are classified as intraductal 
proliferation (IDP), ductal carcinoma in situ (DCIS), adenocarcinoma (AC), or “within 
normal limits.”  In rats, IDPs are equivalent to ductal hyperplasias in human breast 
carcinogenesis.  The criteria for diagnosing hyperplasia is primarily based on an increase 
in the epithelial cells lining the acini and ducts, which can be further categorized as mild, 
moderate, or florid.  Mild hyperplasias are generally three to four cells thick while 
moderate lesions have four or more cells with an occasional bridge across the lumen.  
Florid hyperplasias have ducts, which are packed with cells and lumen that are 
identifiable but displaced.  The individual cells that make up IDPs are not distinguishable 
and the nuclei are generally round to oval, haphazardly arranged, and lack nucleoli [86].    
To meet the criteria of a DCIS at least one expanded ductal structure must be 
completely replaced by neoplastic cells that have uniform, monotonous, round, 
hyperchromatic and non-overlapping nuclei, and retain an intact ductal basement 
membrane.    The two main DCIS subtypes are cribiform and comedo carcinoma in situ.  
In the cribiform subtype there is at least one expanded ductal lumen that has been 
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completely replaced by a monotonous population of cells with round, hyperchromatic, 
and non-overlapping nuclei with no remnants of the primary lumen.  Comedo subtypes 
are centrally necrotic and have a high-grade anaplastic nuclei and nucleoli.  Lesions that 
have only a single duct replaced are labeled atypical ductal hyperplasia (ADH) [].  ACs 
are defined as the earliest breach of the ductal basement membrane and tend to invade as 
a broad front of several cells with clusters of neoplastic acini.  Like DCIS, there are two 
main subtypes observed in the rat model, cribiform and comedo [86].  
trans-Resveratrol (3,5,4’-trihydroxy-trans-stilbene; t-RES) is a naturally 
occurring antioxidant that can be found in a variety of foods such as grapes, wine, berries, 
and peanuts [46-53].  This phytoalexin is considered a promising chemopreventive agent 
based on its ability to inhibit the development of DMBA induced hyperplastic and 
atypical preneoplastic lesions in the mouse mammary organ culture model [47-48, 53], 
MNU induced mammary lesions in rats, and tumorigenesis in a two-stage mouse skin 
cancer model [47, 49, 51, 53].   
Selenium is an essential nutrient for humans that can be found in cereal grains, 
meats, and seafood and is required for more than 13 human enzymes and proteins, in the 
form of L-selenocysteine [61].  Dietary supplementation of selenium beyond the 
recommended dietary allowance of 55 µg/day for females and males 14 years of age or 
greater at up to 200 µg/day has been shown to reduce the incidence of lung, colorectal, 
and prostate cancer in humans [61, 63, 65, 67-68].  Methylseleninic acid (MSA), a form 
of selenium that easily undergoes reduction to methylselenol by cells [61, 63, 65, 67-68], 
has been shown to be an effective suppressor of chemically induced mammary 
carcinogenesis in rats [62, 64-68, 71]. 
α-TEA has been shown to be an effective chemotherapeutic agent, inhibiting 
human ovarian, cervical, breast, endometrial, prostate, lung, colon and lymphoid cells to 
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undergo apoptosis [38-40], and reducing tumor burden and metastases in breast, ovarian, 
and prostate cancer [39-44].  Furthermore, α-TEA does not induce apoptosis in normal 
human mammary epithelial cells or normal PrEC human prostate epithelial cells nor 
show overt toxicity in animal studies [38-40, 42], suggesting potential as a 
chemopreventive agent.  α-TEA has not been studied extensively as a preventative agent, 
but has been shown to prevent papilloma development in a UV-B mouse skin model 
(Best, Manuscript in Preparation).  
In the studies reported here, DMBA was used to induce lesions in the mouse 
mammary organ culture (MMOC) model and MNU was used to induce lesions in the rat 
carcinogenesis model.  In the MMOC model, α-TEA, t-RES and MSA, separately and in 
combination, were screened for ability to prevent DMBA-induced alveolar and ductal 
lesions.    In the NMU Sprague Dawley rat model, α-TEA and t-RES, separately and 
together, were evaluated for ability to prevent NMU-induced mammary lesions.   
MATERIALS AND METHODS                
Chemicals and Reagents 
α-TEA was prepared and characterized as previously described [40].  trans-
Resveratrol (t-RES) was purchased from Cayman Chemical Co. (Ann Arbor, MI).  
Neobee oil was purchased from Stepan (Anaheim, CA).  HPLC grade methanol, hexane, 
10 % neutral buffered formalin, 10% A/OT solution, xylene and ethanol were purchased 
from Fischer Scientific (Pittsburgh, PA).  Sodium dodecyl sulfate (SDS), RRR-δ-
tocopherol, estradiol-17β, progesterone, insulin, prolactin, aldosterone, hydrocortisone, 
DMBA, gum arabic, aluminum potassium sulfate, carmine, methyl salicylate, Scott’s 
water, and saline were purchased from Sigma (St. Louis, MO).  Waymouth’s MB 152/1 
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medium, and streptomycin and penicillin antibiotics were purchased from Gibco (Grand 
Island, NY).  
Mouse Mammary Organ Culture (MMOC) Model 
DMBA-induced mammary gland lesions were induced and analyzed according to 
procedures previously published [80-82].  Female balb/c mice were purchased from 
Charles River (Wilmington, MA) at 3-4 weeks of age and separated into groups of 10.  
Stock solutions of 1 µg/ml estradiol-17β, 1 mg/ml progesterone, 1 mg/ml aldosterone and 
1 mg/ml hydrocortisone were prepared in 100% ethanol.  Insulin was dissolved at 1 
mg/ml in 0.3 ml 0.001 N HCl and 0.7 ml saline and sterile filtered.  Prolactin was 
dissolved at 1 mg/ml in 0.25 ml 0.001N HCl and 0.75 ml medium and then sterile 
filtered.  DMBA was dissolved at 2 mg/ml in DMSO and used at 2 µg/ml final 
concentration (5 µl into 5 ml medium). Media for the glands was prepared using 
Waymouth’s media supplemented with 290 µg glutamine/ml media, and (0.5 ml insulin, 
0.5 ml prolactin, 0.1 ml estradiol-17β, 0.1 ml progesterone, and streptomycin (100 µg/ml) 
and penicillin (100 U/ml) per 100 ml media.  Mammary alveolar lesions and ductal 
lesions were induced as described below.  To use this model for chemoprevention 
studies, potential agents are added to the media during the growth phase.  Following a 
dose-response experiment, the following concentrations were chosen for combination 
studies: α-TEA at 1 µg/ml, MSA at 1 µg/ml, and t-RES at 2.5 µg/ml.  In order to test α-
TEA, MSA, and t-RES for their effectiveness at preventing these types of lesions, 
mammary glands were divided evenly into one of eight treatment groups: α-TEA, MSA, 




A working solution of 10 µg estradiol-17β and 10 mg progesterone per ml of 
suspension was prepared as previously described [81-82].  Estradiol was prepared at 5 
mg/ml in ethanol.  Progesterone was prepared by adding 1 g progesterone to 10 mg gum 
arabic into 10 ml physiological saline.  To this suspension, 90 ml saline and 0.2 ml 
estradiol-17β (5 mg/ml stock) were added to make the working solution above.  Mice 
were injected daily with 0.1 ml of the suspension in order to yield a final concentration of 
1 µg estradiol and 1 mg progesterone per mouse per day for 9 days. 
Mammary Gland Preparation 
Stencil silk (Nazdar, Elk Grove Village, IL) was cut into 7 mm squares, put into 
group labeled tissue culture dishes (Fischer Scientific) and autoclaved.  Dishes were then 
filled with 5 ml prepared Waymouth’s media containing the appropriate hormones for the 
protocol (see below).  Mice were sacrificed by CO2 asphyxiation and disinfected with 
70% ethanol.  Following incision, the thoracic mammary glands were removed and 
placed onto the floating silk rafts (five glands/dish).  Dishes were placed on a tray and 
placed into a controlled atmosphere chamber for 10 min at 10 psi, 95% O2 and 5% CO2.  
Following removal, dishes were transferred to an incubator kept at 37˚C.  Media was 
changed as required by the protocol 3 times per week and the chamber gassed after each 
change. 
Alveolar Lesion Induction (MAL) 
Mammary alveolar lesions (MAL) were induced according to previously 
published procedures [81-82].  Glands were incubated for 10 days in Waymouth’s media 
containing 5 µg/ml insulin, 5 µg/ml prolactin, 1 µg/ml aldosterone, and 1 µg/ml 
hydrocortisone (growth phase).  On day 3, DMBA (2 µg/ml) was added to the culture 
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dishes.  After 24 h, medium was replaced with fresh growth media and incubated for 6 
more days (changing media as needed).  After the 10 d growth phase, growth media was 
replaced with fresh media containing only insulin (5 µg/ml) and incubated for an 
additional 14 d, changing media 3 times/week (regression phase).  Glands were then 
fixed in 10% buffered formalin for whole mount preparation. 
Ductal Lesion Induction 
Mammary ductal lesions were induced according to previously published 
procedures [81-82] and identical to the procedures for MAL induction with one 
exception.  Glands were incubated for 10 days in Waymouth’s media containing 0.001 
µg/ml estradiol-17β and 1 µg/ml progesterone in place of aldosterone and hydrocortisone 
during the growth phase. 
MMOC whole mounts 
Whole mounts were prepared as described previously [81].  A working solution of 
alum carmine stain was prepared by suspending 1 g alum carmine and 2.5 g potassium 
sulfate into 500 ml water, then it was boiled for 20 min, and filtered.  Formalin fixed 
glands were washed in water for 5 min and then stained with alum carmine overnight.  
Glands were then washed in a series of increasing ethanol concentrations (50, 70, 95 and 
100%) for 15 min.  Glands were transferred to xylene for 72 h and then analyzed for 
lesions.  
Rat Chemoprevention Model 
Female Sprague-Dawley rats were purchased from Harlan (Madison, WI) at 21 
days of age.  Following injection (see below), rats were assigned to one of four treatment 
groups (30 rats/group): α-TEA, t-RES, α-TEA + t-RES, and a vehicle control.  Rats were 
treated daily for 39 days beginning on the day of MNU injection and weighed weekly.  
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Animals were housed at the Animal Resource Center at the University of Texas at Austin 
at 74 +/- 2˚F with 30-70% humidity and a 12-h alternating light-dark cycle. Rats were 
housed 3/cage and given water and AIN-76A (Dyets Inc., Bethlehem, PA) purified diet 
ad libitum.  Guidelines for the humane treatment of animals were followed as approved 
by the University of Texas Institutional Animal Care and Use Committee.   
MNU Preparation and Injection 
MNU was purchased from the Midwest Research Institute Chemical Carcinogen 
Reference Standard Repository (Kansas City, MO) and prepared according to the 
procedures published by Thompson et al [84].  Safety procedures and training for safe 
use of NMU and disposal of animal waste were provided by the U.T. Environmental 
Health and Safety Office, and were followed throughout the study. MNU was added into 
pre-weighed glass injection vials (Wheaton Inc, Wheaton, IL), sealed and re-weighed to 
determine weight of MNU inside of vials, and returned to ice.  After weighing, vials were 
kept over a desiccant at -80˚C, and wrapped in aluminum foil until use to prevent 
decomposition from light and moisture sensitivity.  Vials were carried to the animal room 
on ice and MNU was dissolved in acidified 0.9% NaCl solution (pH 4.0 using acetic 
acid) immediately prior to use and used within 20 minutes.  Saline was added to bring a 
final working solution of 1.4% w/v MNU.  To completely dissolve MNU, vials were 
heated under tap water and shaken vigorously one at a time as needed.  Rats were 
weighed and injected intraperitoneally (ip) along the ventral midline, halfway between 
the third and fourth pairs of nipples with 50 mg/kg body weight MNU using 26-guage 
3/8-inch-long needles. 
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Preparation of t-RES for Delivery by Gavage 
Based on the literature, it was determined that each rat would receive 10 mg/kg 
bw t-RES [53].  Treatments of t-RES were made weekly and amounts of t-RES were 
adjusted based on the weight of the animals.  The stock solution was based on the 
average weight of rats receiving the t-RES and t-RES control treatments.  t-RES was 
dissolved in 100% EtOH and then mixed with Neobee oil to give a final solution of 6.5% 
EtOH and 93.5% Neobee oil.  Control treatments consisted of 6.5% EtOH and 93.5% 
Neobee oil, as contained in the t-RES treatments [53].  Solutions were aliquoted into 
sterile eppendorf tubes and stored at –20°C until needed.  Prior to delivery, aliquots were 
brought to room temperature.  
Preparation of α-TEA Liposomes for Delivery by Aerosol 
Preparations of α-TEA liposomes were made as previously described [40-44].  
An α-TEA/liposome ratio of 1:3 (w/w) was determined empirically to be optimal by 
methods previously described [96].  To prepare the α -TEA/lipid combination, the 
components were first brought to room temperature.  The lipid [1,2-dilauroyl-sn-glycero-
3-phosphocholine (DLPC); Avanti Polar-Lipids, Inc., Alabaster, AL] at a concentration 
of 120 mg/ml was dissolved in tertiary butanol (t-butanol) from Fisher Scientific 
(Houston, TX) then sonicated to obtain a clear solution.  α -TEA at 40 mg/ml was also 
dissolved in tertiary-butanol and vortexed until all solids were dissolved.  The two 
solutions were then combined in equal amounts (v:v) to achieve the desired ratio of 1:3 α 
-TEA/liposome, mixed by vortexing, frozen at -80° C for 1-2 h, and lyophilized 
overnight to a dry powder prior to storing at -20°C until needed.   
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Aerosol Delivery 
Aerosol was administered to rats as previously described [40-44].  Briefly, an air 
compressor (Easy Air 15 Air Compressor; Precision Medical, Northapton, PA) producing 
a 10 L/min airflow was used with an Aero Tech II nebulizer (CIS-US, Inc. Bedford, MA) 
to generate aerosol.  The particle size of α-TEA liposome aerosol discharged from the 
AeroTech II nebulizer was determined by the Anderson Cascade Impactor to be 2.01 µm 
mass median aerodynamic diameter (NMAD), with a geometric standard deviation of 
2.04.  About 30% of such particles when inhaled will deposit in the respiratory tract of 
the rat and the remaining 70% will be exhaled [96]. Prior to nebulization, the α-
TEA/lipid powder (75 mg/vial) was brought up to room temperature then reconstituted by 
adding 3.75 ml sterile filtered milli-Q water to achieve the final desired concentration of 
20 mg/ml α-TEA.  The mixture was allowed to swell at room temperature for 30 min 
with periodic inversion and vortexing, and then transferred to the reservoir of a nebulizer.  
Rats were placed in clear plastic cages (6.5 x 26.1 x 15.6 in) with a sealed top in a safety 
hood.  Aerosol entered the cage via a 1 cm (i.d.) accordion tube at one end and 
discharged at the opposite end, using a one-way pressure release valve.  Animals were 
exposed to aerosol until all α-TEA/liposome was aerosolized (approximately 20 min).   
Aerosol Characteristics of α-TEA Incorporated into Liposomes 
HPLC analyses were conducted on α-TEA liposomes recovered from aerosol in 
the All Glass Impinger (Ace Glass Co., Vineland, NJ).  The delivered dosage = 
concentration (µg/L) x rat minute volume (1-min/kg) x duration of delivery (min) x 
estimated deposited fraction (30%; [96]). Based on this formula, we estimate that 1327 
µg/kg bw of α-TEA was deposited in the respiratory tract of each rat each day.  Thus, for 
the 39 day treatment period, we estimate that each rat received 5.02 mg α-TEA.  For this 
same period, animals treated with t-RES were given 37.8 mg t-RES.   
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Rat Mammary Gland Whole Mounts 
Mammary glands were removed and processed as previously described [83, 85-
86].  At necropsy, 40 rats were killed by C02 inhalation each day (10 from each group) at 
41, 42, and 43 days post-carcinogen.  Rats were skinned and the skin was examined 
under translucent light.  Both the cervical-thoracic and abdominal-inguinal mammary 
glands were evaluated for visual lesions and then the abdominal-inguinal mammary 
glands were carefully excised and spread onto clean 50 x 70 mm pre-labeled microscope 
slides.  These whole mounts were processed and photographed as previously described 
[83, 86].  The whole mounts were fixed in 10% neutral buffered formalin for 12-18 h and 
then rinsed in distilled water for 15 min.  Whole mounts were then dehydrated with a 
series of ethanol washes, 1 h each (70, 95 and 100%), and then cleared in two changes of 
toluene for 1 h each.  The process was then reversed to rehydrate the glands to water 
followed by immersion in alum carmine stain for 5-7 d.  Once staining was complete, the 
whole mounts were dehydrated using ethanol as described above and cleared once in 
xylene for 2 h.  One at a time whole mounts were removed and placed in 4 x 6 in 4.5 ml 
clear heat seal pouches filled with 20 ml methyl salicylate and sealed.  The following day 
air bubbles were removed and then the mounts were photographed at a uniform 
magnification (2X).  Photographs were kept as a permanent record of the mammary 
glands to identify the location and gross morphology of the lesions.  Lesions were 
identified on the photograph using a scanned image of the photograph overlaid with a 
sheet of transparent 18 X 24 cm graph paper (each square is 2 X 2 mm to the cm) where a 
2 mm2 lesion on the photograph is analogous to a 1 mm2 lesion (lower size limit for 
histological analyses) and removed.  Dissected lesions were individually placed into 
tissue processing cassettes and processed through three changes of toluene to remove 
residual methyl salicylate and two changes of molten paraffin.  The embedded lesions 
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were then rough cut to expose the surface of the lesion and then overlaid with a 
surfactant, 10% A/OT solution for 30 min to soften the tissue and reduce ‘Venetian blind’ 
effect during microtomy.  Four-micron sections were cut and placed onto glass 
microscope slides pre-coated with homogenized rat tail collagen.  Sections were heat 
immobilized in an 80˚C oven for 2 h and allowed to cool.  Sections were then stained 
using a standard H&E protocol with the following exceptions: sections were destained 
using a 0.1% Li2CO3 solution prior to staining with modified Harris hematoxylin and then 
blued with Scotts water in lieu of 0.25% ammonia water in order to prevent detachment 
of the tissue sections.  All removed lesions were histologically classified according to 
published criteria for the rat [115]. 
Lipid Extraction from Serum Samples 
Lipid extraction was performed using previously published procedures [39-116] 
with slight modifications on serum removed from rats treated with α-TEA or untreated to 
measure the concentration of α-TEA in serum.  Fifty µl of internal standard, RRR-δ-
tocopherol (10 mg/ml in ethanol) were added to each sample in disposable 5-ml 
centrifuge tubes (Sarstedt Inc, Newton, NC).  Serum was resuspended in 0.1 M SDS as 
described previously [39, 116-117] and two ml of ethanol were added to each vial and 
mixed by vortexing.  Lipids were extracted using 1 ml of hexane, followed by vortexing 
for 60 s, centrifugation for 5 min at 1000 X g, and organic layer removed.  Extraction was 
repeated twice for each sample and the hexane extracts combined and evaporated under 
nitrogen.  Samples were resuspended in 200 µl of methanol before HPLC analyses.  
Stock standard solutions were prepared fresh prior to use by dissolving 10 mg of 
standards in 10 ml of methanol. 
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HPLC Analyses of α-TEA Concentration in Rat Serum 
α-TEA levels were measured by an internal standard method using reverse-phase 
HPLC with fluorometric detection as previously described [39, 116].  Forty µl of each 
sample in methanol were injected into a Waters 717 HPLC equipped with an 
autosampler.  The mobile phase consisted of 96% HPLC grade methanol, 4% water, and 
0.001% glacial acetic acid.  Samples were separated on a Waters spherisorb ODS-2 5u 
(250 X 4.6-mm) column (Alltech, Deerfield, IL).  Excitation and emission wavelengths 
of 210 and 300 nm, respectively, and a flow-rate of 1.5 ml/min were used for all 
determinations.  Quantitation of the separated compounds was performed based on the 
internal standard method using RRR-δ-tocopherol as the internal standard and 
Millennium-32 chromatography manager software for data analyses (Waters Corp., 
Milford, MA).  To prevent possible degradation of α-TEA, samples were run within one 
week of being resuspended in methanol. 
Rat tissue collection 
Six female rats were cared for and fed as described above, four were treated for 
39 consecutive days with aerosolized α-TEA and two served as controls.  Following the 
final treatment, food was withdrawn and animals were sacrificed 18 h later.  Animals 
were anesthetized with diethyl ether and tissues were removed for weighing. 
Statistical Analyses 
Animal numbers for experiments were determined to be adequate based on power 
calculations. Statistical test were performed using Prism software version 4.0 (Graphpad, 
San Diego, CA). Tissue weights and animal weights were compared using a two-tailed t-
test.  Palpable tumors were compared using a one-way analysis of variance followed by a 
Neuman-Keul’s post-hoc test.  A level of p < 0.05 was considered statistically significant. 
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RESULTS 
α-TEA, MSA and t-RES inhibit DMBA-induced alveolar lesions in the MMOC. 
  After the regression phase of the MMOC, mammary glands were removed from 
mice and analyzed for alveolar lesions.  α-TEA, t-RES, and MSA were each effective at 
inhibiting lesions individually showing a 63, 63, and 38 percent inhibition of incidence 
compared to control glands (Table 1).  Each of the compounds was also able to inhibit the 
number of lesions per gland showing a 64, 79, and 29 percent inhibition of multiplicity 
compared to the control glands.  Four combinations of co-treatments were also made and 
analyzed including α-TEA + t-RES, α-TEA + MSA, t-RES + MSA, and α-TEA + t-RES 
+ MSA.  The most effective combination was α-TEA + t-RES which showed a 75% 
inhibition of incidence and a 79% inhibition of multiplicity compared to control and was 
more effective than α-TEA or t-RES alone.  This combination was 19% more effective 
than either treatment alone in terms of incidence and 23% more effective than α-TEA 
alone and the same as t-RES alone in terms of multiplicity.  The least effective 
combination was α-TEA + t-RES + MSA which showed a 38% inhibition of incidence 
and a 32% inhibition of multiplicity, values that were less effective than α-TEA and t-
RES alone but very similar to MSA alone.  This combination was 40% less effective than 
α-TEA and t-RES alone in terms of incidence, and the same as MSA alone.  It was also 
50 and 59% less effective than α-TEA and t-RES in terms of multiplicity, and was 10% 
more effective than MSA alone.  Combinations of α-TEA+ MSA and t-RES + MSA both 
showed a 63% inhibition of incidence which is the same as α-TEA or t-RES alone but 
more effective than MSA alone, and a 54 and 64% inhibition of multiplicity, which is 
less effective than α-TEA or t-RES alone but more effective than MSA alone (Table 1). 
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α-TEA, MSA and t-RES inhibit DMBA-induced ductal lesions in the MMOC.   
After the hormone treated regression phase of the MMOC, mammary glands were 
removed from mice and analyzed for ductal lesions.  α-TEA, t-RES and MSA were each 
able to inhibit the number of lesions per gland showing a 61, 65, and 49 percent 
inhibition of multiplicity compared to the control glands (Table 2).  Four combinations of 
co-treatments were also made and analyzed including α-TEA + t-RES, α-TEA+ MSA, t-
RES + MSA, and α-TEA + t-RES + MSA.  The most effective combination was α-TEA 
+ t-RES which showed a 73% inhibition of multiplicity compared to control and was 
more effective than α-TEA or t-RES alone.  This combination was 20% more effective 
than α-TEA alone and 12% more effective than t-RES alone.  The least effective 
combination was α-TEA + MSA which showed only a 34% inhibition of multiplicity, 
which was less effective than α-TEA or MSA alone.  This combination was 44% less 
effective than α-TEA alone and 31% less for MSA alone.  A combination of t-RES + 
MSA showed 38% inhibition of multiplicity which was less effective than either t-RES or 
MSA alone.  The combination containing all three agents showed a 55% inhibition of 
multiplicity, which was less effective than α-TEA or t-RES alone but more effective than 
MSA alone.  
 Rats treated with α-TEA and t-RES maintain weight.   
Animals were fed AIN-76A lab chow ad libitum over the course of the study and 
were weighed weekly starting on day 1 and on the last day (Fig 1).  There was no 
observed weight loss in any of the treatment groups and no statistical difference between 
control and treatments.   
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α-TEA does not cause a loss in tissue organ weight. 
Spleen, heart, ovary/uterus, lungs, and kidneys were removed from two rats that 
were untreated or 4 rats treated with α-TEA for 39 days.  Tissues were weighed and no 
statistical difference in tissue weights was seen between control and α-TEA treated 
tissues (Fig 2). 
α-TEA and t-RES reduce palpable tumors in MNU-injected rats.   
Twenty-one day old rats were i.p. injected with 50 mg/kg bw MNU to induce 
mammary gland tumors.  Animals were palpated every other day beginning at day 31 of 
treatment for their presence of palpable tumors (Fig 3).  At each of the days observed, 
control animals had more palpable tumors than α-TEA, t-RES, or co-treated groups.   
Control animals had an incidence rate of 20, 30, 47, 57 and 67% for 31, 33, 35, 37, and 
39 post-carcinogen, respectively. α -TEA animals had an incidence rate of 0, 13, 23, 30 
and 37% for 31, 33, 35, 37, and 39 post-carcinogen, respectively. t-RES animals had an 
incidence rate of 7, 10, 23, 23 and 30% for 31, 33, 35, 37, and 39 post-carcinogen, 
respectively. Co-treated animals had an incidence rate of 7, 7, 10, 17 and 23% for 31, 33, 
35, 37, and 39 post-carcinogen, respectively, which made it the most effective treatment.  
Starting at day 35, the difference between the control and co-treated animals was 
statistically significant and beginning at day 37 all three treatment groups were 
statistically significant from control. 
Analyses of NMU-induced lesions using rat mammary gland whole mounts 
At this time, data analyses are still in progress for mammary whole gland mounts. 
Serum levels of α-TEA 
 Lipid fractions were extracted from serum collected from control and α-TEA 
treated rats and analyzed by HPLC.  Delta-tocopherol and α-TEA standards were run at 
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the same time as samples to identify sample peaks.  Analyses of samples did not show 
detectable levels of α-TEA in samples from α-TEA treated animals (data not shown). 
Blood Chemistry Profile 
Rat serum was also used for a full serum chemistry profile (Fig 4).  Creatine and 
BUN were as indicators of renal toxicity.  ALT, ALK, total bilirubin, albumin, and total 
protein were used as indicators of hepatic toxicity.  No statistical difference was seen 
between control and α-TEA treated serum for any of these assays.  Additional assays that 
were performed included: cholesterol, triglyceride, glucose, globulin, calcium, 
phosphorous, sodium, potassium, chloride, C02, anion gap, and osmolarity.  Statistical 
differences were seen in phosphorous (p < 0.0372) and C02 (p < 0.0047) assays. 
DISCUSSION 
The ideal chemopreventive agent would either restore normal growth to 
preneoplastic or cancerous cell populations or selectively kill these cells.  Characteristics 
of an ideal chemopreventive agent would include selectivity for transformed cells, good 
bioavailability, and more than one mechanism of action to avoid cross-talk and 
redundancy in signaling pathways.  Epidemiology studies suggest that dietary intake can 
account for as many as 30% of cancers.  This reflects that there are a number of dietary 
components that can induce cancer, but there are also an increasing number of 
compounds in nutrients being discovered that may be protective.  Because the 
carcinogenic process involves many steps over a long time period, there are many 
opportunities for intervention in the process by dietary constituents or nutrient-based 
agents.  There are also an increasing number of reports that show combinations of two or 
more chemopreventive agents to be highly effective at doses where single administration 
is less effective or where single administration has no effect.  One example of this in 
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humans is the ongoing chemoprevention trial (SELECT) using selenium and vitamin E 
individually and in combination to prevent prostate cancer [42].  For these reasons, we 
have chosen three compounds that show potential as chemopreventive agents, α-TEA, t-
RES and MSA [12-14, 16, 18, 21-27, 29-33].  There are five main in vitro models used to 
predict in vivo efficacy for mammary models: MMOC, human lung tumor A427 cell 
assay, JBC epidermal cell assay, human foreskin epithelial (HFE) cell assay, and rat 
tracheal epithelial (RTE) cell transformation assay.  If the results from these assays are 
positive, then 83% of the time there is a similar positive result in vivo, and a positive in at 
least one assay is an accurate predictor at least 70% of the time.  Of these, the MMOC 
model has the highest positive predictive value to predict success of a chemopreventive 
agent for mammary cancer in vivo.  It has the highest sensitivity; the highest specificity, 
the highest positive and negative predictive value, and the highest overall accuracy in 
predicting positive efficacy of chemopreventive agents in mammary models. (A positive 
result in the MMOC is defined when an agent can inhibit 60-100% of lesions at nontoxic 
doses [3].    
In studies presented here, α-TEA, t-RES, and MSA were evaluated in the MMOC 
to predict which agents would be best to use in the in vivo rat mammary carcinogenesis 
model. Data show that α-TEA and t-RES are effective at inhibiting both the incidence 
and multiplicity of DMBA-induced alveolar lesions and the multiplicity of DBMA-
induced ductal lesions.  MSA also reduced the incidence and multiplicity of these lesions 
but to a smaller degree, less than the 60% considered to be the cutoff as a positive 
predictor of in vivo efficacy.  
Results for α-TEA in the MMOC model are consistent for those previously seen 
for other forms of vitamin E, vitamin E acetate and Vitamin E succinate, both of which 
have shown positive results in the MMOC [3].  Results for t-RES alone is also consistent 
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with studies showing t-RES to be effective in a dose-dependent manner when used alone 
with IC50 values ranging from 3.0-3.2 µM [12, 18].  Though MSA has not previously 
been tested in the MMOC model, predictions were that it would be effective since MSC 
reduces tumorigenesis by as much as 54% in rat mammary carcinogenesis models [21, 
23-25, 27] and because studies have shown MSA and MSC to be interchangeable in vivo 
[22-24].   
Interestingly the most effective combination to inhibit alveolar lesions was α-
TEA + t-RES and not the combination with all three compounds.  This combination 
produced a 75% inhibition of incidence and a 79% inhibition of multiplicity, better than 
α-TEA alone and equal to t-RES alone in terms of inhibition of multiplicity.  The 
addition of MSA to the combination cut both inhibition rates by approximately half (75% 
vs 38% and 79% vs 32%).   Combinations of MSA + α-TEA were equally as effective as 
α-TEA alone in terms of inhibition of incidence (63%) and were slightly less than α-TEA 
alone to inhibit multiplicity (64% vs 54%).  Combinations of MSA + t-RES were also as 
effective as t-RES alone in terms of inhibition of incidence (63%) and were slightly less 
than t-RES alone to inhibit multiplicity (79% v 64%).  The results of the DMBA-induced 
ductal lesion assay showed similar results.  The most effective combination was again α-
TEA + t-RES without MSA (73%), which was more effective than α-TEA or t-RES 
alone.  In this assay the addition of MSA was not the least effective combination, but it 
did decrease the effectiveness to levels less than that seen for α-TEA and t-RES alone, 
negating the advantage given by the combination.  In this assay, α-TEA + MSA was the 
least effective combination (34%) but the combination of t-RES + MSA was slightly 
higher (38%).  Together, these results suggest that MSA is antagonistic when in the 
presence of α-TEA and t-RES together, and that it does not contribute to the combination 
effect when used with only one of the other agents.   
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The incidence of palpable tumors after t-RES treatment is consistent with 
previous studies reporting a delay to onset of MNU-induced tumors and a decrease in the 
total number of tumors in rats treated with 100 mg/kg bw t-RES compared to control 
animals in the traditional rat carcinogenesis model [18].  Starting at day 35, a statistical 
difference was seen between the control and co-treated animals and beginning at day 37 
reduced tumors in all three treatment groups were statistically significant from control.  
On day 39, there were 45, 55 and 65% fewer tumors in the α-TEA, t-RES and α-TEA + 
t-RES groups compared to the control.  Overall, the co-treated group was the most 
effective, followed by t-RES and then α-TEA.  Even though a statistical difference was 
not seen between the co-treated, α-TEA and t-RES groups, the co-treatment group had 
36% fewer tumors than α-TEA and 22% fewer than t-RES.  At this time the histological 
data from the rat carcinogenesis model is incomplete and analyses are currently in 
progress.   
Serum analyses of α-TEA and control treated animals were performed using 
HPLC.  Levels of α-TEA in rat serum were undetectable.  One possible explanation for 
this is that since the rats were fasted for overnight before euthanasia, the circulating α-
TEA may have been metabolized.  Previous studies have shown the presence of serum α-
TEA 24 h post-treatment to be approximately 4 µg/ml in unfasted mice (unpublished).  
Another possible explanation for the difference between this study and previous studies 
by our lab could be due to species differences in uptake and metabolism.  In support of 
the argument that these results are due to fasting is the triglyceride assay data.  Due to 
errors in the test, only one animal from each treatment was tested. α-TEA treated animals 
showed a decrease in triglyceride levels compared to control animals which is consistent 
with fasted status [43]. 
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Neither α-TEA nor t-RES caused weight loss in rats treated with individual 
treatments or combinations.  Also, animals treated with α-TEA did not appear to have 
any significant loss in tissue weight for spleen, heart, ovaries/uterus, lungs or kidneys.  
Additionally, serum profile analyses for total bilirubin, ALT, ALK, BUN, creatine, total 
protein, and albumin did not show a statistical difference between control and α-TEA 
treated animals indicating no renal or hepatic toxicity.  There was however a statistical 
difference between these two groups in phosphorous and C02 assays.  Animals treated 
with α-TEA showed a statistical increase in phosphorous levels.  Increased levels of 
inorganic phosphorous may be indicative of myeloma, Paget’s disease of bone, osseous 
metastases, and a variety of other conditions in addition to drug-related causes [43].  
Since these animals were i.p. injected with MNU and control animals were not, it is 
possible that the increase could be due to osseous metastases or perhaps some other 
MNU-related cause and not a direct result from α-TEA treatment.  α-TEA treated 
animals showed a decrease in C02 levels which could be indicative of metabolic acidosis 
or compensated respiratory alkalosis [43].  More probable is that the serum samples were 
not collected under anaerobic conditions, which could have allowed for interaction of 
blood and atmosphere and may have varied enough between animals to cause a statistical 
difference [43].  Further work will need to be done to determine if these differences 
between α-TEA and control treated animals are due to α-TEA treatment.  Overall, the 
anti-cancer efficacy of α-TEA and t-RES separately and together, and the lack of overt 




Figure 4.1.  Rat Weights Over Time.  Twenty-one day old rats were injected with 50 
mg/kg bw. MNU to induce mammary gland tumors.   Animals were fed AIN-76A lab 
chow ad libitum over the course of the study and were weighed weekly.  Graph shows 









Figure 4.2.  Tissue Weights from Rats Treated with α-TEA.  Spleen, heart, ovary/uterus, 
lungs, and kidneys were removed from rats that were untreated or treated with alpha-TEA 
for 39 days.  Graph shows tissue weights after removal.  There was no statistical 
difference between control and alpha-TEA treated tissues using a two-tailed unpaired t-
test.  (n=2 for control, n=4 for α-TEA treated) 
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Figure 4.3.  Palpable Tumors in Rat Carcinogenesis Model.  Twenty-one day old rats 
were i.p. injected with 50 mg/kg bw. MNU to induce mammary gland tumors.  
Treatments were initiated on day 1 and animals were palpated every other day beginning 
at day 31 of treatment for their presence or absence.  Graph shows the number of animals 
each day with palpable tumors.  Number of rats for control and treatment groups = 30.  * 








Figure 4.4  Blood Chemistry Profile.  Serum from fasted rats was analyzed using a full 
serum chemistry profile.  Statistical analyses was done using a two-tailed 
unpaired test.  (p < 0.05)  (n = 2 for control, n = 4 for α-TEA treated) 
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Table 4.1: Comparison of DMBA-induced alveolar lesions in the mouse mammary organ 
culture model (MMOC) 




























1 µg/ml 5 of 10 50 38 20 29 






2 of 10 20* 75 6 79 





3 of 10 30* 63 13 54 






3 of 10 30* 63 10 64 
8 α-TEA  






5 of 10 50 38 19 32 
Mammary glands were removed from mice and analyzed for lesions.  〈-TEA, MSA, t-
RES and combinations were scored for their ability to prevent lesion formation after 
treatment with DMBA. 
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Table 4.2: Comparison of DMBA-induced ductal  lesions in the mouse mammary organ 
culture model (MMOC) 

















1 µg/ml 41 49 


















8 α-TEA  






Mammary glands were removed from mice and analyzed for lesions.  〈-TEA, MSA, t-
RES and combinations were scored for their ability to prevent lesion formation after 






Chapter 5: α-TEA and trans-Resveratrol induce synergistic levels of 
apoptosis in human MDA-MB-435 breast cancer cells by caspase-
dependent and -independent mechanisms  
ABSTRACT 
Combinations of t-RES and α-TEA synergize to produce increased levels of cell 
death in MDA-MB-435-F-L human breast cancer cells in vitro.  Data reported here 
elucidates α-TEA and t-RES treatment, separately and in combination, mediated 
signaling events leading to cell death by apoptosis.  Pretreatment with t-RES and α-TEA 
alone and together sensitizes the cells to Fas and TRAIL mediated apoptosis.  Treatment 
with t-RES and α-TEA, separately and together, increases levels of DR5, TRAIL, and 
Fas, but decreases FasL.  α-TEA and α-TEA + t-RES induced cell death was dependent 
on activation of caspases-2, -3, -8, and -9 while that for t-RES was not.  Both t-RES and 
α-TEA decreased survivin and c-FLIP levels, and in combination decreased survivin and 
c-FLIP proteins to undetectable levels.  To further evaluate whether DR5, Fas, c-FLIP 
and survivin are important to α-TEA + t-RES synergy, levels of these proteins were 
knocked down using siRNA.  A significant decrease in apoptosis, in comparison to 
control siRNA treated cells, was seen in co-treated cells where Fas and DR5 were 
knocked down, and a statistical increase in apoptosis was seen in t-RES and α-TEA 
treated cells following knock down of survivin and c-FLIP. t-RES-induced cell death was 
also investigated.   Autophagocytosis was evaluated in the MDA-MB-435 cells in an 
effort to explain t-RES-induced cell death.  Using TEM, low levels of autophagic 
vacuoles (AV) were detected in cells treated with t-RES and the co-treatment but not in 
α-TEA treated cells.  We were unable to confirm autophagocytosis using western 
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immunoblotting or flow cytometry.  Based on the results reported here, we propose a 
signaling model where the synergy between α-TEA and t-RES is due to a combination of 
apoptosis and caspase-independent cell death (CICD). 
INTRODUCTION 
One specific type of cell death commonly studied in cancer is apoptosis, a highly 
regulated form of programmed cell death (PCD) commonly referred to as Type 1 PCD 
[4]. Apoptosis is initiated by the binding of ligands to one of several cell membrane death 
receptors, resulting in mitochondria-dependent or -independent mediated cell death. 
Apoptotic morphological characteristics include cell shrinkage, DNA fragmentation, 
chromatin condensation, blebbing of the nucleus and cytosolic cellular fractions into 
apoptotic bodies [4-5, 7-10], Type 1 PCD involves activation of caspases [4, 7-8, 11].  
Some cancer therapeutic agents sensitize cells to apoptosis by down-regulating inhibitor 
of apoptosis proteins (IAPs) such as cIAP1, cIAP2, livin, XIAP and survivin, which are 
usually expressed at high levels in tumor cells.  IAPs exert their anti-apoptotic activity by 
binding to the active form of caspases-3 and -9 [4, 11, 16].  To counteract the activity of 
IAPs, Smac/DIABLO and Omi/HtrA2 can bind to and inhibit their activity [8].  Cellular 
FLICE-inhibitory protein (c-FLIP), though not an IAP, is another anti-apoptotic protein 
that functions by competing with pro-caspase-8 for binding to FADD.  c-FLIP is able to 
bind to FADD because it shares high sequence homology to caspase-8, however  it 
cannot signal as caspase-8 because c-FLIP lacks a proteolytic domain required for 
downstream signaling [12, 15].  
In contrast to apoptosis, some therapeutic agents can induce cancer cells to 
undergo type II PCD, or commonly referred to as autophagocytosis.  Autophagocytic 
characteristics include the formation of autophagic vacuoles (AV), dilation of the 
endoplasmic reticulum (ER), and enlargement of the Golgi [4-5, 7, 9, 19-20].  Once 
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formed, AVs fuse with lysosomes to sequester cytoplasmic contents and degrade them 
via lysosomal hydrolases [4-5, 7, 19-22].  While the signaling events for autophagy are 
known in yeast, many of the mammalian homologs are yet to be found, so the exact 
signaling pathways are unknown [19, 21-23].  The general pathway begins with a 
signaling event that leads to the formation of a double membrane structure called an 
autophagosome, which fuses with cellular lysosomes to form an autolysosome [9, 19, 21-
22, 24].  Often in autophagocytosis, caspases are not activated and DNA fragmentation 
does not occur.  Three mammalian proteins are associated with autophagocytosis, beclin-
1, MAP-LC3, and LAMP-1.  Beclin-1 is involved in the early steps of autophagic vesicle 
formation and can be inhibited by bcl-2 [7, 10, 21, 25-26].  MAP-LC3 has been found to 
be recruited to the pre-autophagosome membranes [19, 21, 24, 28] where it remains 
associated with the inner and outer phagosomal membrane [24].  LAMP-1 is a highly N-
glycosylated lysosomal protein that is critical for transport to lysosomes in cells.  LAMP-
1 is ubiquitously expressed in cells and has been shown to be localized in late endosomes 
and lysosomes [29-30] and to serve as a receptor for the import and degradation of 
cytosolic proteins in the lysosome during autophagy [30].   
Caspase-independent cell death (CICD) is a third form of cell death that occurs 
under pro-apoptotic conditions but which proceeds without the activation of caspases [6, 
119].  There are generally low levels of chromatin condensation, DNA fragmentation, 
cellular blebbing, and loss of mitochondrial permeability [6, 119].  The exact signaling is 
poorly understood but it is thought that signaling begins by the binding of FasL to either 
Fas or TNFα receptors.  This binding leads to the recruitment of TRADD and RIP to the 
receptor. The chaperone protein Hsp90 can play an inhibitory role in this pathway by 
controlling RIP through the proteosome pathway [12].  RIP may activate cathepsins B 
and D via JNK, which may lead to the mitochondrial release of AIF, Omi/HtrA2 and 
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SMAC/DIABLO from the mitochondria [120].  Upon release, Omi/HtrA2 and 
SMAC/DIABLO can directly bind to and inhibit IAPs leading to apoptosis [10, 119].  
The release of AIF can lead to DNA fragmentation [10] and cytochrome c release [119].  
Another protein that may be involved and is released from the mitochondria is 
Endonuclease G (EndoG), which translocates into the nucleus and can induce DNA 
degradation [119]. 
trans-Resveratrol (3,5,4’-trihydroxy-trans-stilbene; t-RES) is a naturally 
occurring phytoalexin found in a variety of foods such as grapes and red wine [46-53].  t-
RES has previously been shown to induce cellular differentiation and apoptosis in human 
promyelocytic leukemia cells [47-48], human colon cancer cells [48-49], and human 
breast cancer cells [48, 50].  It is not toxic in vitro and in vivo which makes it attractive as 
a chemotherapeutic agent [47-49, 51, 53].   
α-TEA is a derivative of natural vitamin E, RRR-α-tocopherol, and is capable of 
inducing human ovarian (A2780/cp-70), cervical (ME-180), breast (MCF-7, MDA-MB-
231, MDA-MB-435), endometrial (RL-952), prostate (LNCaP, PC-3, DU-145), lung (A-
549), colon (HT-29, DLD-1) and lymphoid (Raji, Ramos, Jurkat) cells to undergo 
apoptosis [38, 40] and is nontoxic to normal epithelial cells [38-40, 42].   α-TEA induces 
apoptosis via the Fas [121] and DR5 receptor pathways [unpublished].  α-TEA and t-
RES in combination prevent chemically induced lesions in the MMOC model [Chapter 4] 
and can synergize with MSA to induce cell death in vitro [Chapter 2].   
Here we show that α-TEA + t-RES synergize in vitro to induce high levels of cell 
death in a highly aggressive human breast cancer cell line, MDA-MB-435-F-L.  α-TEA 
and  α-TEA + t-RES in combination, but not t-RES alone, sensitize the cells to both Fas 
and TRAIL induced apoptosis, involving caspases 8, 2, 9, and 3.   Both agents, alone and 
in combination, reduce pro-survival c-FLIP and survivin proteins.  Autophagy was 
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investigated in an effort to better understand how t-RES was inhibiting cell growth 
independent of caspases.  
MATERIALS AND METHODS 
Chemicals and Reagents 
α-TEA was prepared as previously described [40].  trans-Resveratrol (t-RES) was 
purchased from Cayman Chemical Co. (Ann Arbor, MI).  Acridine orange was purchased 
from Sigma Co. (St. Louis, MO). Caspase-3 inhibitor (Z-DEVD-FMK), caspase-9 
inhibitor (Z-LEHD-FMK), caspase-8 inhibitor (Z-IETD-FMK), and a pan caspase 
inhibitor (Z-VAD-FMK) were purchased from BioVision Research Products (Palo Alto, 
CA),  All reagents for the morphological analyses of apoptosis were purchased from 
Boehringer Mannheim (Indianapolis, IN). The following antibodies were used:  Fas (sc-
8009, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), FasL (sc-959, Santa Cruz), DR5 
(PX063A, Cell Sciences Inc., Canton, MA), TRAIL (sc-8440, Santa Cruz), pro- and 
cleaved caspase-8 (#9476, Cell Signaling Technology, Beverly, MA), pro- and cleaved 
caspase-9 (sc-8355, Santa Cruz), pro- and cleaved caspase-2 (clone 11B4, Axxora, San 
Diego, CA), pro- and cleaved caspase-3 (sc-7148, Santa Cruz), PARP (sc-7150, Santa 
Cruz), c-FLIP (sc-5276, Santa Cruz), survivin (sc-17799, Santa Cruz), beclin-1 (sc-
10086, Santa Cruz), MAP-LC3 (sc-16756, Santa Cruz), lamp-1 (sc-17768, Santa Cruz), 
GAPDH (made in-house),  antihuman Fas mouse monoclonal IgM antibody (clone CH-
11; Upstate Biotechnology, Inc., Lake Placid, NY), antihuman DR5 mouse monoclonal 
IgM antibody (Upstate Biotechnology), and irrelevant control antibody (mouse IgM, 
Sigma).   siRNA to Fas, DR5, c-FLIP, survivin, caspase-2 or silencer negative control 
were purchased from Ambion's Silencer Predesigned siRNA listing (Austin, TX).   The 
wild type survivin, Myc-tagged pcDNA3.plasmid, was a kind gift from Dr. J. Q. Chen 
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(College of Medicine, University of South Florida [122]).  The wild type HA-tagged c-
FLIPL expression construct was kindly provided by Dr. John C. Reed (The Burnham Inst. 
La Jolla, CA; [123]).  The empty pcDNA3 vector was purchased from Invitrogen 
(Carlsbad, CA).   
Cell Culture and Treatment 
MDA-MB-435-F-L cells, recovered from a metastatic tumor in the lung of a nude 
mouse and stably transfected with enhanced green fluorescence protein, were a kind gift 
from Dr. LuZhe Sun (University of Texas Health Science Center, San Antonio, TX. 
[73]).  MDA-MB-435-F-L cells were cultured as previously described [43]. Stock 
solutions of t-RES and α-TEA were at 20 mg/ml in DMSO.  All solutions were stored at 
–20°C and diluted in experimental media to the desired final concentration.  Vehicle 
controls consisted of 0.167 % DMSO, or 1.67 µl/ml media. 
Apoptosis Analysis Using Morphology of 4’, 6-Diamidino-2-Phenylindole 
Dihydrochloride (DAPI) Nuclear Stained Cells 
Cells were plated and treated with VEH, t-RES, α-TEA or a co-treatment at 
various concentrations.  Treatments were for three days and then cells were collected and 
stained with DAPI for determination of apoptosis as previously described [88, 124].  
Cells in each sample were counted a minimum of 3 times, with •100–200 cells/count.  
Cells where the nucleus contained clearly condensed chromatin or fragmented nuclei 
were scored as apoptotic. Apoptotic data are reported as percent apoptosis (number 
apoptotic/total number of cells counted).  Data are mean ± S.D. of three independent 
experiments.  
Western Immunoblot Analyses 
Whole cell lysates were prepared as described by Yu et al [88, 124] from cells 
treated for 6, 12, 24, and 48 hrs with vehicle or 88 µM t-RES and 20.5 µM α-TEA alone 
 116
and in combination. Cells were washed with PBS and lysed with lysis buffer (13 PBS, 
1% NP40, 0.5% sodium deoxyxholate, and 0.1% SDS) plus 1 µg/ml of aprotinin and 
leupeptin, 1 mM DTT, and 2 mM sodium orthovandate and incubated on ice for 30 min.  
Lysates were centrifuged at 15,000 x g for 15 min at 4˚C and protein concentrations 
determined with Bio-Rad Dye Binding protein assay.  Western immunoblot analyses, 
using 50 µg protein per lane, were conducted as previously described [41, 42]. Proteins 
were separated using 10, 12 or 15% SDS-page under reducing conditions. 
Immunoblotting was performed using the primary antibodies listed above and 
peroxidase-conjugated goat anti-rabbit, goat anti-mouse, rabbit-anti-goat, or goat anti-rat 
secondary antibodies (Jackson Immunoresearch Laboratory, West Grove, PA), followed 
by detection with ECL (Pierce, Rockford, IL).  Densitometry was performed using Scion 
Image Software (Scion Corporation, Frederick, MD). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, in house) was used to verify equal lane loading and for 
densitometric determinations. 
Fas and DR5 Death Receptor Sensitivity Assays 
MDA-MB-435-F-L ells were plated at 1.5 x 105 cells/ml overnight, followed by 
pretreatment for 6 h with VEH, 88 µM t-RES, 20.5 µM α-TEA alone and in combination, 
and vehicle.  Cells were washed in medium to remove treatments and then treated with 
0.5 µg/ml antihuman Fas mouse monoclonal IgM antibody, 5 ng/ml antihuman DR5 
mouse monoclonal IgM antibody, or 0.5 µg/ml irrelevant control antibody for 42 h, DAPI 
stained and analyzed for apoptosis.  
Caspase Inhibitors 
MDA-MB-435-F-L cells were plated at 1.5 X 105 cells/well in 12-well plates 
overnight. Next, cells were pretreated for 2 h with media containing the following 
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caspase inhibitors: caspase-3 inhibitor (Z-DEVD-FMK), caspase-9 inhibitor (Z-LEHD-
FMK), caspase-8 inhibitor (Z-IETD-FMK), a pan caspase inhibitor (Z-VAD-FMK) (each 
at 2 µM), or a vehicle control (0.1% DMSO).  Following pre-treatment, cells were treated 
with 88 µM t-RES, 20.5 µM α-TEA, alone and in combination or vehicle, for 48 h, and 
analyzed for apoptosis using DAPI staining [124]. 
Functional knock down of Fas, DR5, c-FLIP, survivin, and caspase-2. 
siRNA/siPORT NeoFX reagent complex was made by first mixing 3.6 µl siPORT 
NeoFX reagent with 0.2 ml serum-free media and incubated for 10 min with siRNA to 
Fas, DR5, c-FLIP, survivin, caspase-2, or silencer negative control.   siRNA was added to 
the siPORT NeoFX mixture so that the final concentration of siRNA in 0.6 ml was 30 
nM, and then incubated for 10 min.  During the preparation of the reagent complex, 
MDA-MB-435-F-L cells were collected by trypsinization and resuspended in serum free 
medium at 3.75 x 105 cells/ml.  Next, 0.2ml of the reagent mix plus 0.4 ml of the cell 
suspension were added to each well of a 12-well plate and allowed to incubate overnight.  
The following day the transfection media was replaced with normal culture media and 
cells were incubated for 24 h.  Cells were then treated with 88 µM t-RES and 20.5 µM α-
TEA), alone or in combination, and vehicle for 24 h.  The cells from vehicle and 
treatment groups were sub-divided into two groups, one group was analyzed for 
apoptosis using DAPI staining, and lysates from the other group were analyzed by 
western immunoblotting to confirm knockdown of Fas, DR5, survivin, c-FLIP, and 
caspase-2. 
Over-expression of wild-type survivin and c-FLIPL 
MDA-MB-435-F-L cells were plated at 1.5 X 105 cells/ml, and then transfected 
with plasmids encoding Myc-tagged wild-type survivin, HA-tagged wild-type c-FLIPL, or 
 118
vector control using published procedures [124].  DNA/LipofectAMINE/Plus reagent 
complex was made by mixing 0.7 µg of DNA/50 µl of serum-free medium with 4 µl of 
Plus (Invitrogen, Carlsbad, CA) reagent and incubated for 15 min.  This solution was 
then added to a second solution containing 2 µl of LipofectAMINE reagent/50 µl of 
serum-free medium and incubated for 15-min.  We generally obtain about 50% 
transfected cells using this method in MDA-MB-435 cells [124].  After 8 h transfection, 
the cells were incubated with culture media overnight. .  Next, the cells were treated with 
88 µM t-RES and 20.5 µM α-TEA, alone or in combination, or vehicle for 48 h.  The 
cells from vehicle and treatment groups were sub-divided into two groups, one group was 
analyzed for apoptosis using DAPI staining, and lysates from the other group were 
analyzed by western immunoblotting to confirm overexpression of survivin and c-FLIPL. 
Transmission electron microscopy 
Transmission electron microscope (TEM) analyses were used to determine if 
treatments, especially treatments with t-RES, were causing the cells to undergo cell death 
by autophagocytosis.  Cells were prepared according to the procedures of Opipari et al 
[43] and were evaluated at the Microscopy and Imaging Facility of the Institute for 
Cellular and Molecular Biology at The University of Texas at Austin.   MDA-MB-435-F-
L cells were treated with VEH, t-RES (88 µM), α-TEA (20.5 µM), or both.  Human 
cisplatin sensitive A2780 ovarian cancer cells treated with cisplatin or t-RES served as  
positive controls for apoptosis and autophagocytosis. Cells were treated for 24 h at the 
concentrations indicated and then floating cells were collected into 15 ml centrifuge tubes 
and pelleted at 1,500 g for 3 min.  Both floating and adherent cells were treated with the 
same reagents and combined after fixing.  Cells were rinsed twice in warm serum free 
media and then fixed for 30 min at 4°C with 2.5% glutaraldehyde in 0.1 M Sorensen’s 
buffer (pH 7.4).  Cells were rinsed twice in 0.1 M Sorensen’s buffer and then fixed for 15 
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min at 4°C in 1% osmium tetroxide in 0.1 M Sorensen’s buffer.  Samples were rinsed 
two more times with 0.1 M Sorensen’s buffer and then adherent cells were scraped and 
added to the cell suspension from that sample.  The new suspensions were rinsed with 
double distilled water to remove phosphate and then stained with 3% uranyl acetate in 
double distilled water for 15 min.  Cells were rinsed once in double distilled water and 
then dehydrated in a series of ethanol incubations, 5 min each in 50, 70, 90, and 100 % 
ethanol.  Samples were then infiltrated with Spurrs resin as follows:  3:1 (ethanol: resin) 
for 20 min, 1:1 (ethanol : resin) for 20 min, 3:1 (ethanol: resin) for 1 h, full strength resin 
for 1 h, fresh full strength resin for 1 h.  Samples were then allowed to polymerize at 
60°C for 24 h, after which they were given to the Microscopy facility for staining and 
sectioning.  For each sample, cells were quantitated according to the classifications of 
Opipari et al [54].  Cells that showed at least 3 autophagic vacuoles, no nuclear 
condensation, and intact plasma membrane were scored autophagic.  Cells that showed 
nuclear condensation and irregular plasma membranes were scored apoptotic.  All other 
cells were scored normal. 
Measurement of Red:Green Fluorescence Ratio in Acridine Orange-stained Cells  
Using Flow Cytometry 
The cytoplasm and nucleoli of acridine orange-stained cells fluoresce bright green 
and dim red while acidic compartments fluoresce bright red.  The intensity of the red 
fluorescence is therefore proportional to the degree of acidity and the volume of the 
cellular acidic compartment and so by measuring the change in mean red:green 
fluorescence ratio within different populations of cells, one can measure the change in the 
acidity or fractional volume of the acidic compartments.  MDA-MB-435 cells were 
plated at 1.5 x 105 cells/ml in T-25 flasks.  The following day cells were treated with 
VEH, t-RES (88 µM), α-TEA (20.5 µM), or both for 24 h.  MDA-MB-435 cells were 
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prepared for flow cytometry according to the procedures published by Paglin et al [29].  
A stock solution of 1 mg/ml acridine orange was made and cells were incubated for 17 
min at a working concentration of 1 µg/ml at 37˚C.  Adherent cells were removed from 
the plate using trypsin-EDTA and collected in phenol red-free growth medium.  Green 
(510-530 nm) and red (>650 nm) fluorescence emission from 10
4
 cells illuminated with 
blue (488 nm) excitation light was measured with a FACSCalibur flow cytometer 
(Becton Dickinson, San Jose, CA) using CellQuest software.  The mean red:green 
fluorescence was calculated using FlowJo software (TreeStar Inc., Ashland, OR).   MCF-
7 cells gamma-irradiated at 25˚C using a Cs-137 irradiator at a dose-rate of 243 cGy/min 
were used as a positive control 24 h after irradiation.  
Statistical Analyses 
 Statistical analyses were conducted using Prism software version 4.0 (Graphpad, 
San Diego, CA.) and a level of P < 0.05 was considered statistically significant.  
Apoptosis data were analyzed using one-way ANOVA followed by a Tukey's post-hoc 
test.  CalcuSyn 2.0 was use to determine synergy values.   
RESULTS 
α-TEA and t-RES,  alone and in combination induce apoptosis in MDA-MB-435-F-
L-GFP cells 
Separate treatments with t-RES at 44 and 88 µM and α-TEA at 10.3 and 20.5 µM 
significantly induced MDA-MB-435-F-L cells to undergo apoptosis in comparison to 
vehicle control (Fig 1A)  (P < 0.01; P < 0.001; P <0.05 ; and  P < 0.001; respectively).   
Likewise, treatments with t-RES at 44 and 88 µM in combination with α-TEA at 10.3 or 
20.5 µM significantly enhanced apoptosis in comparison to vehicle (P < 0.05; P< 0.001; 
P< 0.001, and P< 0.001, respectively). The combination data were entered into CalcuSyn 
to determine a combination index value (CI) and synergy.  The CI value was 0.742 for 
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the 88 µM t-RES + 20.5 µM α-TEA combination which indicates a synergistic 
relationship as defined as CI < 1. 
Pre-treatment with t-RES and α-TEA alone and together sensitize MDA-MB-435 
cancer cells to Fas and TRAIL mediated apoptosis.   
In an effort to better understand how separate and combination treatments with t-
RES and α-TEA induce apoptosis, Fas and TRAIL mediated apoptosis was investigated.  
Cells were pre-treated with VEH, t-RES, α-TEA and a co-treatment for 6 h and then 
replaced with Fas, or TRAIL activating antibodies, or irrelevant antibody control, 
cultured for 48 hrs and then analyzed for apoptosis.  Vehicle cells cultured with Fas or 
TRAIL activating antibodies did not undergo apoptosis, suggesting that MDA-MB-435 
cells were non-responsive to Fas or TRAIL induced apoptosis (Fig 1B).  However, pre-
treatment of the cells with t-RES, α-TEA alone and in combination, followed by treating 
with Fas or TRAIL activating antibodies significantly enhanced apoptosis over vehicle 
and irrelevant antibody controls (Fig 1B). These data show that pretreatment of MDA-
MB-435 cells with t-RES or α-TEA alone and in combination sensitize the cells to Fas 
and TRAIL induced apoptosis.  Levels of significance for Fas and TRAIL activating 
antibodies with the following pre-treatments were: t-RES, P< 0.01 and P< 0.01; α-TEA, 
P< 0.05 and P< 0.001; α-TEA + t-RES, P< 0.01 and P< 0.001, respectively.  
α-TEA alone and in combination with t-RES enhances DR5, TRAIL, and Fas 
protein levels.  
MDA-MB-435 cells were treated for 6, 12, 24 and 48 h with VEH, t-RES, α-TEA 
and co-treatment.  At 24 and 48 h, both α-TEA and co-treatment upregulated DR5 
protein levels by 2.4 and 2.3 fold and 4.2 and 4.2 fold, respectively (Fig 1C, top panel).  
TRAIL ligand was also upregulated beginning at 24 h in the co-treatment (1.5 fold) and 
by 1.8, 1.8 and 2.2 fold by t-RES, α-TEA and co-treatment, respectively at 48 h (Fig 1C, 
 122
second panel). t-RES and α-TEA treatments  enhanced Fas protein levels at 24 h (1.7 and 
1.8 fold, respectively) and by all treatments at 48 h (1.7, 1.2 and 1.2 fold) (Fig 1C, third 
panel).  In contrast, t-RES and combination treatments at 12 and 24 h decreased levels of 
FasL, 2.7 and 3.0 fold for 12 hours, and 12 and 10.5 fold at 24 hours, respectively.  α-
TEA reduced Fas L 1.5 fold at 24 hours, and all treatments decreased FasL at 48 hrs. (Fig 
1C, fourth panel).     
α-TEA alone and in combination, but not t-RES, induces caspase cleavage.    
Cells were treated with α-TEA and t-RES, alone and together, for 6, 12, 24 and 
48 h to evaluate the role of caspases in the induction of apoptosis.  t-RES alone did not 
activate caspases (Fig 2A).  Of the three key caspases normally involved in apoptotic 
signaling (caspases-3, -8, and-9), caspase-8 was the first to show cleavage.  Cleavage of 
caspase-8 was detected at 12 h in cells treated with α-TEA and co-treatment, with co-
treatment giving  a 1.7 fold increased caspase 8 cleavage fragment (Fig 2A, top panel).  
Both treatments showed caspase 8 cleavage at 24 and 48 h, with a 1.6 fold increase in 
cleavage fragment by α-TEA than the co-treatment at 24 h, and a 1.1 fold increase in the 
cleavage fragment by the co-treatment at 48 h (Fig 2A, top panel).  Caspase-9 cleavage 
was detected at 24 and 48 h in the α-TEA and co-treatment groups.  Treatment with t-
RES induced cleavage of caspase- 9 at 48 h treatment (Fig 2A, second panel).   Cleavage 
fragments for caspase-3 were detected at 24 and 48 h in the α-TEA and co-treatment 
cells.  At both time-points, in comparison to α-TEA treatment, co-treatment enhanced 
caspase-3 cleavage fragments 7.0 and 2.8 fold at 24 and 48 h treatment, respectively (Fig 
2A, third panel).  The disappearance of pro-caspase-2 was detected beginning at 6 h with 
the co-treatment (1.2 fold reduction in comparison to VEH). At each progressive time-
point, the co-treatment had less pro-caspase-2 than both VEH and the individual 
treatments, and at 48 h there was a 23.8, 11.1, and 8.6 fold decrease in caspase 2 
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compared to VEH, t-RES and α-TEA, respectively (Fig 2A, fourth panel).  Despite 
repeated efforts, a cleavage band was not found for caspase-2 at any time-point.   PARP 
cleavage by the co-treatment was detected at 12, 24 and 48 hours.  All treatments gave 
PARP cleavage at 24 and 48h, with co-treatment giving the greatest amount of PARP 
cleavage (Fig 2A, fifth panel). 
α-TEA and co-treatment induced apoptosis is caspase-dependent. 
As an alternate approach to the involvement of activated caspases in treatment 
induced apoptosis (data depicted in Fig 2A), cells were pre-treated with caspase-3, -8 and 
-9 specific inhibitors and a general pan-caspase inhibitor and levels of apoptosis 
quantified (Fig 2B).  Each of the four inhibitors significantly reduced apoptosis in α-TEA 
and co-treated cells, with the greatest reduction seen in the co-treatment  (Fig 2 B).  In the 
absence of an effective caspase-2 specific inhibitor, cells were transfected with caspase-2 
siRNA, followed by α-TEA and t-RES alone and together.  Following treatment, cells 
were subdivided into two groups with one group DAPI stained and assayed for apoptosis, 
and cell lysates assayed by western immunoblotting in the other group to verify 
effectiveness of siRNA.   Caspase 2 siRNA reduced levels of caspase-2 (Fig 2C) and 
significantly reduced levels of apoptosis induced by α-TEA and co-treatments (α-TEA, P 
< 0.01 and co-treatment, P < 0.05). (Fig 2D).  Although caspase 2 siRNA reduced the 
level of apoptosis induced by t-RES treatment, there was no significant difference from 
the negative siRNA control (Fig 2D).   
Apoptosis induced by t-RES is caspase-independent.  Despite inducing cleavage 
of caspase-9 after 48 h treatment (Fig 2A), it appears that apoptosis induced by t-RES is 
caspase-independent.  When cells were pre-treated with caspase-3, -8 and -9 specific 
inhibitors and a general pan-caspase inhibitor, there was not a statistical decrease in the 
percentage of apoptosis detected after t-RES treatment (Fig 2B).  Also, caspase 2 siRNA 
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reduced the levels of cellular caspase-2  (Fig 2C) but did not significantly reduce levels 
of apoptosis induced by t-RES (Fig 2D).  
t-RES and α-TEA alone and together down-regulate pro-survival c-FLIPL and 
survivin protein levels.   
t-RES and α-TEA alone and together decreased pro-survival c-FLIP and survivin 
protein levels, with the co-treatment showing the largest decrease of both proteins at each 
time point (Fig 3A).    At 12 h, there was a 2.1, 1.5 and 4.9 fold decrease in c-FLIP for t-
RES, α-TEA, and co-treatment. By 48 h there was a 2.1 and 10.6 fold decrease for t-RES 
and α-TEA and undetectable levels in the co-treatment.  Similar to the results seen for c-
FLIP, the co-treatment was the most effective at each time-point in decreasing survivin.  
At 12 h there was a 1.6 fold decrease in survivin in co-treated cells. At 48 hrs treatment, 
there was a 4.1 fold decrease by t-RES, a 2.3 fold decrease by α-TEA, and undetectable 
levels of survivin in the co-treated cells (Fig 3A).   
To determine if c-FLIPL and survivin are integral to t-RES and α-TEA treatment 
induced apoptosis, c-FLIPL and survivin were overexpressed in the MDA-MB-435 cells. 
Elevated levels of c-FLIPL and survivin in the transfected cells were confirmed by 
western blotting (Fig 3 B &C).  Cells expressing either vector control, survivin, or c-
FLIPL over-expression vectors were treated with α-TEA and t-RES alone or together and 
evaluated for apoptosis.  Levels of apoptosis were significantly reduced in the co-treated 
cells expressing c-FLIPL and survivin (P < 0.01 and P < 0.05) (Fig 3D).   Cells treated 
with α-TEA showed a 43 and 46% decrease for survivin and c-FLIPL over-expression, 
respectively, compared to α-TEA treated vector control cells, but this difference was not 
statistically significant (Fig 3D).   Over expression of c-FLIPL or survivin had no effect 
on t-RES induced apoptosis (Fig 3D).   
 125
Effects of siRNA to Fas, DR5, c-FLIPL and survivin on treatment-induced apoptosis.  
Western immunoblot analyses were used to verify that transfection of MDA-MB-
435 cells with siRNA to Fas, DR5, c-FLIPL, and survivin reduced levels of each protein, 
respectively (Fig 4A).   Next, cells transfected with siRNA to Fas, DR5, c-FLIPL and 
survivin were treated with VEH, t-RES, α-TEA, or co-treatment and then evaluated for 
apoptosis.  Knockdown of c-FLIPL and survivin significantly enhanced the ability of t-
RES to induce the cells to undergo apoptosis, (P< 0.0001 and P< 0.01).  Knockdown of 
DR5 and Fas had no significant effect on t-RES-induced apoptosis (Fig 4B).   
Knockdown of DR5 and Fas reduced α-TEA induced apoptosis by 46 and 36%, 
respectively, and knockdown of c-FLIPL and survivin significantly enhanced α-TEA 
induced apoptosis (P< 0.01, and P< 0.0001; Fig 4B).  For the co-treated cells, 
knockdown of Fas and DR5 significantly reduced treatment induced apoptosis (P< 0.01, 
and P< 0.01).  While there was an increase in apoptosis in the co-treated cells transfected 
with siRNA to c-FLIP (26 %) and survivin (31 %) the increase was not significantly 
different from the negative control transfected  or α-TEA treated cells (Fig 4B).    
t-RES and co-treatments induce low levels of autophagic vacuoles.  
The above data show that t-RES induces apoptosis as determined by PARP 
cleavage and DNA fragmentation, but apoptosis does not appear to be mediated by 
caspase activation. Next, based on studies showing t-RES to induce autophagocytosis in 
human ovarian cancer cells [54], treatment induced autophagocytosis was investigated in 
breast cancer cells. A2780 cisplatin sensitive ovarian cancer cells treated with cisplatin or 
t-RES were used as positive controls for apoptosis and autophagocytosis (Fig 5A and B).  
MDA-MB-435-F-L breast cancer cells were treated with VEH, t-RES, α-TEA or co-
treatment and then evaluated for the presence of autophagic vacuoles (AV) using TEM 
(Fig 5 C-G).  Cells treated with t-RES (Fig 6D) showed low levels of AV and no nuclear 
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condensation compared to control (Fig 5C).  In contrast, cells treated with α-TEA 
showed no AV but showed nuclear condensation and invaginations of the nuclear 
membrane compared to control (Fig 5F compared to Fig 5C).  Co-treated cells showed 
AV similar to that of t-RES (Fig 5E compared to Fig 5D) and apoptotic profile similar to 
α-TEA (Fig 5G compared to Fig 5F)).   
Autophagy proteins do not increase in response to t-RES in MDA-MB-435-F-L cells.  
Although AV were seen with t-RES treatments using TEM analyses, only low 
levels of AV were seen in individual cells.  Next, LAMP-1, Beclin-1, and MAP-LC3 
proteins known to be associated with autophagocytosis were examined using western 
blotting.  As a positive control, MCF-7 cells were treated with 0.15 µM camptothecin 
(CPT [132]) and t-RES. CPT treatment gave a time-dependent increase in LAMP-1 (2.2, 
3.3 and 2.2 fold), beclin-1 (1.6 and 1.9 fold), and MAP-LC3 (1.8 and 2.0 fold) (Fig 6A).  
In MCF-7 cells treated with t-RES there was an increase in beclin-1 and MAP-LC3 
proteins beginning at 6 h.  LAMP-1 protein levels were not significantly changed (Fig 
6A).  In MDA-MB-435-F-L breast cancer cells, t-RES treatment increased beclin-1 
protein levels at 6 (2.4 fold) and 12 h (1.6 fold), which decreased to basal levels at 24 h 
(Fig 6B).  LAMP-1 and MAP-LC3 protein levels were not significantly changed (Fig 
6B).   
 Mean red:green fluorescence does not increase after treatment with t-RES, α-TEA 
or co-treatment.  
In one final effort to quantitate AV, MDA-MB-435 cells were treated with 
acridine orange, a dye that localizes and accumulates in vacuoles, and is used an indictor 
for AV.  MCF-7 cells gamma-irradiated were used as a positive control.  Twenty-one 
percent of the MCF-7 gamma irradiated cells showed high red fluorescence The mean 
red:green ratio increased from 1.36 to 2.34 in these cells (Fig 7 A & B). Using these same 
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conditions, MDA-MB-435 cells were treated with VEH, t-RES, α-TEA or co-treatment.  
All treatments showed a decrease in the mean red:green ratio and a decrease in high red 
fluorescent cells from VEH treated cells (Fig 7 C-F).  Taken together, there is little 
support for t-RES -induced autophagy in MDA-MB-435 cells.    
DISCUSSION 
Combinations of t-RES and α-TEA synergize to produce increased levels of cell 
death by apoptosis in MDA-MB-435-F-L human breast cancer cells in vitro.   MDA-MB-
435 cells are insensitive to both Fas and DR5/TRAIL induced apoptosis, but pretreatment 
of the cells with α-TEA or α-TEA + t-RES sensitizes the cells to both Fas and DR5 
apoptotic signaling.  α-TEA alone and in combination with t-RES enhances levels of 
DR5, TRAIL and Fas, and all three treatments reduce Fas ligand protein levels.  t-RES 
alone induced increased levels of TRAIL at 48 hrs of treatment.  α-TEA alone and in 
combination with t-RES apoptotic signaling via these membrane receptors involves 
activation of caspases-8, -9, -3, and -2.  Treatment reduction of caspase-2 levels is 
indicative of activation of caspase-2.  t-RES alone induces the cells to undergo apoptosis 
in a Fas/DR5/caspase independent manner.  α-TEA and t-RES alone and in combination 
down-regulate pro-survival c-FLIPL and survivin. siRNA knockdown of c-FLIPL and 
survivin significantly enhances t-RES-induced apoptosis.  Decreased levels of c-FLIPL 
and survivin proteins are proposed as one mechanism for combination treatment induced 
synergistic apoptotic effects.  Autophagy was ruled out as a mechanism whereby t-RES 
induces apoptosis in a caspase-independent manner.  
One possible explanation for treatment-induced decreases in Fas is the 
translocation of FasL to the cell exterior, as reported by our lab following treatment with 
vitamin E succinate (VES), a vitamin E derivative [89].  Overall, the Fas/TRAIL/caspase 
data for α-TEA reported here are consistent with previous reports for VES and α-TEA 
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[88-89, 121, 124-125].  t-RES-induced enhanced levels of TRAIL is supported by data in 
the literature showing t-RES to sensitize neuroblastoma cells to TRAIL induced 
apoptosis [11], and to involve Fas and TRAIL induced apoptosis in colon cancer cells, 
without an increase in receptor levels [126].   While t-RES induced cleavage of pro-
caspase-2 and -9, neither caspase was required for cell death.  This is consistent with 
previous reports that t-RES induces caspase-independent apoptosis [55, 93, 127].     
Data show that both t-RES and α-TEA decrease cellular levels of survivin and c-
FLIP and that a combination of the two decreases the levels of these two proteins to 
undetectable levels.  Although both α-TEA and t-RES reduce c-FLIPL and survivin 
protein levels, overexpression of these two proteins decreased α-TEA and combination 
induced apoptosis, but did not affect levels of t-RES induced apoptosis suggesting that 
while the decrease in these proteins by t-RES plays a role in the synergy, t-RES alone 
does not require a decrease in c-FLIPL or survivin to induce cell death.   
To further evaluate whether DR5, Fas, c-FLIP and survivin are important to the 
synergy effect, levels of these proteins were knocked down using siRNA.  A statistical 
decrease in apoptosis was seen in co-treated cells where Fas and DR5 were knocked 
down and smaller but not significant decreases were seen in t-RES and α-TEA treated 
cells.  There was also a statistical increase in apoptosis in t-RES and α-TEA treated cells 
after survivin and c-FLIP siRNA transfections were done.   α-TEA has been shown to 
reduce levels of survivin and c-FLIP [125], and t-RES has been shown to reduce levels of 
survivin [11, 17, 128]. To our knowledge, there are no reports showing a decrease in c-
FLIP following t-RES treatment. 
In an effort to explore alternative death pathways to explain how t-RES induces 
cell death independent of Fas/DR5/caspases/c-FLIP and survivin, three different 
approaches were used to determine if autophagocytosis was involved in t-RES-induced 
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apoptosis in MDA-MB-435 cells.  Although TEM analyses showed low levels of t-RES-
induced autophagocytosis, this data was not confirmed by western immunoblotting of 
proteins known to be involved in autophagy, and acridine orange stained lysosomes.   
Based on the data generated by these three approaches, it was concluded that 
autophagocytosis is not a major player in t-RES-induced apoptosis in human MDA-MB-
435 breast cancer cells.   
As more types of cell death and overlap between types of cell death are 
discovered, it becomes increasingly evident that it is difficult to neatly categorize cell 
death induced by a particular agent.  An increasing amount of work suggests an 
interdependence between multiple signaling pathways and in some cases there appear to 
be multiple paths to the same end.  Exclusive definitions are difficult to make and 
probably do not represent the true nature of cell death due to the overlap and shared 
signaling pathways [48].  Based on the results reported here, we propose a signaling 
model where the synergy between α-TEA and t-RES is due to both classical apoptosis 
and caspase-independent events (Fig 8).  The ability of both t-RES and α-TEA to reduce 
c-FLIPL and survivin levels could contribute to combination treatment synergy.    
Secondly, we propose that t-RES kills cells via a caspase-independent cell death (CICD) 
pathway.  t-RES data presented here are consistent with cells undergoing CICD, i.e.   low 
levels of DNA condensation and fragmentation, absence of caspase activation, and no 
DISC formation [6].  Percent t-RES treated cells showing DNA condensation and 
fragmentation under TEM analyses and DAPI staining were low. While studies of DISC 
formation were not performed, siRNA knockdown of DR5 and Fas, and caspase 
inhibitors had little effect on t-RES induced apoptosis, suggesting that DISC formation 
and caspase activity are not required for cell death induced by t-RES.   
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Future studies will focus on caspase-independent death signaling mechanisms in 
t-RES treated cells and caspase-2 signaling in α-TEA treated cells since both of these 
signaling mechanisms are poorly understood and appear important to the synergy 
between t-RES and α-TEA.  One theory for CICD signaling is that TRADD and RIP are 
recruited to TNFα receptor to activate cathepsin B, which then interacts with the 
mitochondria to release AIF, SMAC/DIABLO, EndoG, and Omi/HtrA2.  These proteins 
can then either inhibit IAPs in the cytoplasm or enter the nucleus to induce DNA 
condensation and fragmentation.  One theory for caspase-2 signaling is that it is activated 
in a p53-dependent PIDDosome formation, though Vakifahmetoglu et al have reported 
PIDDosome formation in both p53 
(+/+) and p53 (-/-) cells [129].  PIDDosome formation is 
thought to occur when p53 recruits PIDD, RRAID and caspase-2 to Fas receptor, which 
activates caspase-2 [120, 129-130].  Active caspase-2 acts upstream of the mitochondria 
to cleave bid and induce bax translocation and cytochrome c release [130-131].  Clearly, 
more work needs to be done for a better understanding of CICD, the function of caspase-
2, and their roles in cell death.  In a recent paper, t-RES was shown to induce apoptosis in 
human estrogen responsive MCF-7 breast cancer cells in a caspase-independent manner 
[55].  Data suggest that t-RES-induced apoptosis in MCF-7 cells involves an oxidative, 
caspase-independent mechanism, whereby inhibition of P13K signaling converges to 
Bcl2 through NF-kappaB and calpain protease activity.  Future studies are needed to 
determine if PI3K/AKT, Bcl-2 and NF-kappaB are targets of t-RES induced apoptosis in 
estrogen non-responsive MDA-MB-435 breast cancer cells.  
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Figure 5.1.  α−TEA and t-RES induce apoptosis and sensitize cells to Fas and DR5 
mediated cell death.  A, Apoptosis induced following treatment with various 
concentrations of α−TEA, t-RES, and combinations.  Densitometry values indicate fold 
difference from VEH.  * indicates synergy (CI= 0.742). B, Treatments statistically 
increase apoptosis in sensitivity assay. * p < 0.05 compared to irrelevant control for that 
treatment. C, Western blot of DR5, Fas, TRAIL, and FasL protein levels after treatment. 
Densitometric analyses were performed, using GAPDH,  to quantitate protein increases 
or decreases.    A & B data are depicted as the mean ± S. D. of three independent 
experiments.  C data are representative of three independent experiments. 
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Figure 5.2.  Caspase activation.  A, Western blot analyses for cleavage of caspases-8, -9, -
3, -2. and PARP.  * indicates fold increase of co-treatment over α-TEA, ** indicates fold 
decrease from control,  ^ indicates fold increase of co-treatment over individual 
treatments, ^^ indicates fold increase of α-TEA treatment over co-treatment. Data are 
representative of three independent experiments.   B, Cells were pretreated with caspase 
inhibitors (2 µM) for 2 h before treatment with VEH, t-RES (88 µM), α-TEA (20.5 µM) 
or co-treatment for 2 days, DAPI stained and apoptosis determined.  Data are depicted as 
the mean ± S. D. of three independent experiments. * = significantly different from 
control, P < 0.05.   C, Western blot analyses showing caspase-2 knockdown after siRNA 
transfection. Data are representative of 3 independent experiments.   D, Cells were 
transfected with caspase-2 siRNA and then treated with VEH, t-RES (88 µM), α-TEA 
(20.5 µM) or co-treatment for 1 day. Cells were DAPI-stained and percentage apoptosis 
was determined. Data are depicted as the mean ± S. D. of three independent experiments.   
* p < 0.05 compared to negative siRNA control for each respective treatment. 
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Figure 5.3.  Importance of survivin and c-FLIP.  A, Western blot showing decrease in 
survivin and c-FLIP following treatment for 6, 12, 24 or 48 h with VEH, t-RES (88 µM), 
α-TEA (20.5 µM) or co-treatment. Densitometry values indicate fold decrease from 
VEH.  B-C, Western blots showing over-expression of survivin and c-FLIP. D, Apoptosis 
induced by VEH, t-RES (88 µM), α-TEA (20.5 µM) or co-treatment following 
overexpression of survivin and c-FLIP.  A, B, and C data are representative of three 
independent experiments.  D data are depicted as the mean ± S. D. of three independent 




Figure 5.4.  siRNA knockdown of Fas, DR5, c-FLIP, and survivin.  A, Western blot for 
proteins knocked down following siRNA transfection.  B, Apoptosis induced by VEH, t- 
t-RES (88 µM), α-TEA (20.5 µM), or combination in DR5, Fas, Survivin, and FLIP 
siRNA transfected cells.   A data are representative of three independent experiments.  B 
data are depicted as the mean ± S. D. of three independent experiments.   * p < 0.05 
compared to negative siRNA control for each respective treatment.   
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Figure 5.5.  TEM analysis of autophagic vacuoles.  A-B, A2780 cells were treated with 
cisplatin or t-RES as positive controls for apoptosis and autophagocytosis, respectively. 
C-G, MDA-MB-435 cells treated with VEH, t-RES (88 µM), α-TEA (20.5 µM), or co-
treatment to look for the presence of autophagic vacuoles (AV).    
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Figure 5.6.  Western immunoblotting for autophagy associated proteins. A, MCF-7 cells 
were treated with CPT or t-RES for 0, 6, 12 or 24 h and then analyzed by western blotting 
for LAMP-1, Beclin-1 or MAP-LC3.  Cells treated with CPT served as a positive control 
for autophagy.  B, MDA-MB-435-F-L cells were treated with t-RES for 6, 12, and 24 h, 
and western immunoblotting was conducted on cell lysates,   Densitometry values 
indicate fold increase from VEH (O h time point).  A and B data are representative of 




Figure 5.7.  Lysosomal activity measured by acridine orange.  Acridine orange in its free 
form is a weak base that becomes trapped inside of acidic vacuoles.  The accumulation of 
these molecules results in bright red fluorescence (>650 nm).  Increases in mean 
red:green fluorescence therefore reflects an increase in lysosomal volume.  Cells were 
analyzed using flow cytometry to look for an increase in bright red fluorescent cells and 
an increase in the mean red:green ratio.  A-B, MCF-7 cells were either untreated or 
gamma-irradiated and analyzed after 24 h as a positive control.  C-F, MDA-MB-435 cells 
were treated with VEH, t-RES (88 µM), α-TEA (20.5 µM), or co-treatment for 24 h.  
Percentage indicates cells that show bright red fluorescence. 
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Figure 5.8.  Proposed Signaling Mechanism for α-TEA and t-RES induced cell death. α-
TEA induces apoptosis via the Fas and DR5 death receptors, which leads to activation 
caspases-2, -3, -8, and -9.  t-RES activates cell death through the caspase-independent 
cell death (CICD) pathway.  Both α-TEA and t-RES decrease levels of survivin and c-
FLIP, increase TRAIL and Fas receptor, and decrease cellular FasL.  α-TEA also 
increases DR5 levels in cells. Future studies will focus on caspase-2 and CICD signaling 
and are represented by dashed arrows and question marks.  
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Chapter 6:  Summary and Future Directions 
SUMMARY 
Cancer is currently the most common cause of death in women under the age of 
85.  Breast cancer specifically will have the highest incidence of reported new cases in 
2006 (32%) and be responsible for about 15 percent of cancer deaths in women [1].  
More than 90% of these cancer deaths will be due to metastatic lesions that have arisen 
from aggressive tumor cells that have escaped and survived earlier attempts at treatment 
[87].  As we continue to understand more about the nature of tumor cells, signaling 
mechanisms, and the heterogeneity of tumors, it becomes increasingly clear that 
treatment with a single agent or method will not eliminate all of the cells of a tumor, and 
that perhaps a cocktail of treatments would be more effective.  The goal of these studies 
was to further the understanding of the molecular mechanisms of α-TEA and explore its 
potential in combination with two other natural based chemotherapeutic agents, 
MSC/MSA and t-RES, to induce cell death in cancer cells.  
α-TEA was first developed in our lab with the hope of finding a clinically useful 
vitamin E-based chemotherapeutic agent that could be administered in a clinically 
relevant manner.  It is structurally similar to natural vitamin E, RRR-α-tocopherol but 
contains a non-hydrolysable ether-linked acetic acid moiety at carbon 6 of the chroman 
head, allowing it to remain stable in vivo.  α-TEA has repeatedly been shown to induce 
human ovarian, cervical, breast, endometrial, prostate, lung, colon and lymphoid cells to 
undergo apoptosis without toxicity in normal PrEC and HMEC epithelial cells [38-39].  
Several recent reports have also shown it to be an effective inhibitor of tumor and 
metastatic growth in vivo [40-44].  The studies reported here provide evidence to support 
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the efficacy of α-TEA as a chemopreventive and chemotherapeutic agent in human breast 
cancer cells. 
Chapter 1 is an introductory chapter that introduces types of cancer cell death, 
specifically apoptosis and autophagocytosis.  It also provides background information on 
the function, structure and metabolism of α-TEA, t-RES, and MSC/MSA. Various animal 
models and the main cell line used in the investigations presented in this dissertation were 
also reviewed.   
Chapter 2 focuses on the initial studies that characterized how α-TEA, t-RES, and 
MSC/MSA inhibit proliferation and induce apoptosis in various breast and prostate 
cancer cell lines.  Specifically we investigated the ability of α-TEA alone and together 
with MSA and t-RES to prevent proliferation and induce apoptosis and differentiation in 
human MDA-MB-435-F-L breast cancer cells.  All three compounds induced apoptosis 
individually and synergistic apoptosis was seen in combinations.  Other human breast 
(MDA-MB-231, MCF7, and T47D) and human prostate (LnCaP, PC-3, and DU-145) 
cancer cell lines were also tested and similar enhancements were seen.  No apoptosis was 
seen in primary cultures of human mammary epithelial cells (HMECs).  Western 
immunoblotting confirmed that all three compounds individually and in combination 
induced poly(ADP-ribose) polymerase cleavage with more complete cleavage seen in the 
combination.  In studies of DNA synthesis arrest, clonegenic assay, and cell 
differentiation, all three compounds produced dose-dependent responses individually and 
enhanced responses in combinations. We concluded that the combination of α-TEA, 
MSA, and t-RES is more effective than single treatments for inhibiting cell proliferation, 
and inducing differentiation and apoptosis of human cancer cells in culture. 
Chapter 3 investigated the ability of α-TEA, alone and together with MSC and t-
RES, to reduce tumor burden, induce apoptosis, and prevent proliferation of MDA-MB-
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435-F-L cells, in vivo.  We showed that α-TEA and low doses of t-RES reduce tumor 
burden in athymic nude mice but that combinations of the three compounds are not as 
effective as α-TEA or t-RES alone.  Immunohistochemistry of tumors showed an 
increase in TUNEL positive cells and a decrease in Ki-67 positive cells after treatment.  
Additionally, treatments were effective at reducing macroscopic and microscopic 
metastatic lung and lymph node lesions.  This chapter also showed that the diet is 
important to the overall tumor growth because we found that the efficacy of t-RES 
administered at low (10 mg/kg bw) and high (100 mg/kg bw) concentrations was diet 
related.  We concluded that when α-TEA, MSC, and t-RES are administered together to 
MDA-MB-435-F-L cells in vivo, the combination was not as effective as the individual 
treatments at reducing tumor burden, but all treatments prevent metastases to the lungs 
and lymph nodes.  We also conclude that careful analysis of rodent diets should be made 
prior to any in vivo studies. 
Chapter 4 focuses on the effectiveness of several natural compounds, α-TEA, 
MSA and t-RES, to prevent the formation of DMBA-induced lesions in the MMOC 
model and to prevent MNU-induced lesions in a rat mammary carcinogenesis model.  In 
the MMOC model, α-TEA, MSA and t-RES were each effective at inhibiting the 
incidence and multiplicity of alveolar lesions and the multiplicity of ductal lesions.  Four 
combinations of co-treatments were also made and analyzed for increased efficacy over 
individual treatments.  A combination of α-TEA + t-RES was most effective against 
alveolar and ductal lesions.  Based on these results, α-TEA + t-RES were combined in 
the MNU-induced rat mammary carcinogenesis model.  Treatments lasted for 39 days at 
which time there were 45, 55 and 65% fewer tumors in the α-TEA, t-RES and Co-tx 
groups compared to the control.  Even though a statistical difference was not seen 
between Co-tx, α-TEA and t-RES, the co-treatment group had 36% fewer tumors than α-
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TEA and 22% fewer than t-RES.  Weight loss was also looked at in this study as a 
measure of toxicity.  Neither α-TEA nor t-RES caused significant weight loss, nor did α-
TEA cause significant loss in tissue weight for spleen, heart, ovaries/uterus, lungs or 
kidneys.  Together, these results suggest that α-TEA and t-RES may be an effective 
chemopreventive regimen. 
Chapter 5 reports studies showing how t-RES and α-TEA synergize to produce 
increased levels of cell death in MDA-MB-435-F-L human breast cancer cells in vitro.  
Here we attempt to elucidate some of the signaling events that may contribute to this 
event.  We found that pretreatment with t-RES, α-TEA or co-treatment can sensitize cells 
to Fas and TRAIL mediated apoptosis. Treatment with t-RES, α-TEA and co-treatment 
also increases levels of DR5, TRAIL, and Fas receptor and decreases FasL.  α-TEA and 
co-treatment induced cell death was dependent on activation of caspases-2, -3, -8, and -9 
while that for t-RES was not.  Both t-RES and α-TEA decreased survivin and c-FLIP 
levels and a combination of the two decreased the levels of these proteins to undetectable 
levels.  To further evaluate whether DR5, Fas, c-FLIP and survivin are important to the 
synergy effect, levels of these proteins were knocked down using siRNA.  A statistical 
decrease in apoptosis was seen in co-treated cells where Fas and DR5 were knocked 
down and a statistical increase in apoptosis in t-RES and α-TEA treated cells after 
survivin and c-FLIP were knocked down.  We also used TEM to evaluate the possible 
activation of autophagocytosis to explain the results seen for t-RES.  Using TEM we saw 
low levels of AV in cells treated with t-RES and the co-treatment but not in α-TEA 
treated cells.  Western-blot analyses showed t-RES to increase levels of beclin-1 but not 
LAMP-1 or MAP-LC3, but we were unable to confirm autophagy using flow cytometry.  
Based on the results reported here, we propose a signaling model (Fig 6.1) where the 
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synergy between α-TEA and t-RES is due to a combination of apoptosis and caspase-
independent cell death (CICD). 
FUTURE DIRECTIONS 
Taken together, these studies suggest that α-TEA, in combination with other pro-
cell death agents such as t-RES and MSC/MSA, can reduce human breast cancer growth 
in vitro and in vivo more effectively than any of the agents alone.  These studies add 
insight into the complex mechanisms that regulate cell death in human breast cancer cells 
and provide a basis for future breast cancer treatments and prevention regimens.  Future 
studies will focus on caspase-independent death signaling mechanisms in t-RES treated 
cells and caspase-2 signaling in α-TEA treated cells since both of these signaling 
mechanisms are poorly understood and appear important to the synergy between t-RES 
and α-TEA.  One theory for CICD signaling is that TRADD and RIP are recruited to 
TNFα receptor to activate cathepsin B, which then interacts with the mitochondria to 
release AIF, SMAC/DIABLO, EndoG, and Omi/HtrA2.  These proteins can then either 
inhibit IAPs in the cytoplasm or enter the nucleus to induce DNA condensation and 
fragmentation.  One theory for caspase-2 signaling is that it is activated in p53-dependent 
PIDDosome formation, though it has been reported in both p53 (+/+) and p53 (-/-) cells [129].  
PIDDosome formation is thought to occur when p53 recruits PIDD, RRAID and caspase-
2 to Fas receptor, which activates caspase-2 [120, 129-130].  Active caspase-2 acts 
upstream of the mitochondria to cleave bid and induce bax translocation and cytochrome 
c release [130-131]. Clearly, more work needs to be done on understanding CICD and the 
function of caspase-2 and how they may act to enhance cell death. 
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Figure 6.1.  Proposed Signaling Mechanism for α-TEA and t-RES induced cell death and 
Future Studies. α-TEA induces apoptosis via the Fas and DR5 death receptors, which 
leads to activation caspases-2, -3, -8, and -9.  t-RES activates cell death through the 
caspase-independent cell death (CICD) pathway.  Both α-TEA and t-RES decrease levels 
of survivin and c-FLIP, increase TRAIL and Fas receptor, and decrease cellular FasL.  α-
TEA also increases DR5 levels in cells. Future studies will focus on caspase-2 and CICD 
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